Ciclesonide    B-SteroidHormone114745635
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
aceponate    I-SteroidHormone114745635
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
buteprate    I-SteroidHormone114745635
,    O
hydrocortisone    B-SteroidHormone114745635
butyrate    I-SteroidHormone114745635
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-SteroidHormone114745635
,    O
and    O
tixocortol    B-SteroidHormone114745635
pivalate    I-SteroidHormone114745635
.    O

Beclometasone    O
,    O
betamethasone    B-SteroidHormone114745635
,    O
dexamethasone    O
,    O
fluocortolone    B-SteroidHormone114745635
,    O
halometasone    B-SteroidHormone114745635
,    O
and    O
mometasone    O
.    O

Mepitiostane    B-SteroidHormone114745635

i.e.    O
,    O
prostate    O
cancer    O
not    O
responding    O
to    O
androgen    B-SteroidHormone114745635
deprivation    I-SteroidHormone114745635
or    O
treatment    O
with    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonists    O
.    O

Androgen    B-SteroidHormone114745635
deprivation    I-SteroidHormone114745635
therapy    I-SteroidHormone114745635

As    O
an    O
example    O
,    O
one    O
condition    O
in    O
which    O
spironolactone    O
is    O
contraindicated    O
is    O
prostate    O
cancer    O
in    O
men    O
being    O
treated    O
with    O
androgen    B-SteroidHormone114745635
deprivation    I-SteroidHormone114745635
therapy    I-SteroidHormone114745635
,    O
as    O
spironolactone    O
has    O
been    O
shown    O
"    O
in    O
vitro    O
"    O
to    O
significantly    O
accelerate    O
carcinoma    O
growth    O
in    O
the    O
absence    O
of    O
any    O
other    O
androgens    O
.    O

Proligestone    B-SteroidHormone114745635

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivatives    O
gestonorone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
abbreviated    O
as    O
NOMAC    B-SteroidHormone114745635
,    O
is    O
a    O
progestin    O
,    O
or    O
a    O
synthetic    O
progestogen    O
,    O
which    O
was    O
first    O
introduced    O
in    O
the    O
mid-1980s    O
and    O
is    O
used    O
in    O
the    O
treatment    O
of    O
gynecological    O
disorders    O
,    O
in    O
hormone    O
replacement    O
therapy    O
(    O
HRT    O
)    O
for    O
menopausal    O
symptoms    O
,    O
and    O
in    O
hormonal    O
contraceptives    O
.    O

It    O
is    O
marketed    O
alone    O
under    O
the    O
brand    O
name    O
Lutenyl    B-SteroidHormone114745635
and    O
in    O
combination    O
with    O
estradiol    O
under    O
the    O
brand    O
names    O
Naemis    B-SteroidHormone114745635
and    O
Zoely    B-SteroidHormone114745635
.    O

Estrogen    O
insensitivity    O
syndrome    O
(    O
EIS    O
)    O
,    O
or    O
estrogen    O
resistance    O
,    O
is    O
a    O
form    O
of    O
congenital    O
estrogen    O
deficiency    O
or    O
hypoestrogenism    B-SteroidHormone114745635
which    O
is    O
caused    O
by    O
a    O
defective    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
–    O
specifically    O
,    O
the    O
estrogen    O
receptor    O
alpha    O
(    O
ERα    O
)    O
–    O
that    O
results    O
in    O
an    O
inability    O
of    O
estrogen    O
to    O
mediate    O
its    O
biological    O
effects    O
in    O
the    O
body    O
.    O
Congenital    O
estrogen    O
deficiency    O
can    O
alternatively    O
be    O
caused    O
by    O
a    O
defect    O
in    O
aromatase    O
,    O
the    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
estrogens    O
,    O
a    O
condition    O
which    O
is    O
referred    O
to    O
as    O
aromatase    B-SteroidHormone114745635
deficiency    I-SteroidHormone114745635
and    O
is    O
similar    O
in    O
symptomatology    O
to    O
EIS    O
.    O

Aromatase    B-SteroidHormone114745635
deficiency    I-SteroidHormone114745635
,    O
a    O
condition    O
in    O
which    O
aromatase    O
is    O
absent    O
and    O
androgens    O
can    O
not    O
be    O
converted    O
into    O
estrogens    O
.    O

Oral    O
contraceptive    O
produced    O
by    O
Jenapharm    O
containing    O
ethinylestradiol    O
and    O
dienogest    B-SteroidHormone114745635

It    O
is    O
said    O
to    O
be    O
a    O
weaker    O
antiandrogen    O
than    O
dienogest    B-SteroidHormone114745635
(    O
another    O
commonly    O
used    O
progestin    O
with    O
antiandrogen    O
activity    O
)    O
,    O
but    O
still    O
may    O
be    O
useful    O
in    O
alleviating    O
acne    O
,    O
seborrhea    O
,    O
and    O
other    O
androgen    O
-    O
dependent    O
symptoms    O
in    O
women    O
.    O

Dienogest    B-SteroidHormone114745635
,    O
which    O
is    O
antiandrogenic    O
,    O
features    O
extension    O
of    O
the    O
C17α    O
chain    O
in    O
the    O
form    O
of    O
a    O
cyanomethyl    O
group    O
at    O
the    O
C17α    O
position    O
.    O

In    O
contrast    O
,    O
dienogest    B-SteroidHormone114745635
,    O
the    O
17α-cyanomethyl    O
derivative    O
of    O
dienolone    O
,    O
is    O
a    O
potent    O
progestogen    O
and    O
antiandrogen    B-SteroidHormone114745635
.    O

17α-Dihydroequilenin    O
,    O
or    O
α-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
17α-estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.2%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

17β-Dihydroequilenin    O
,    O
or    O
β-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
0.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

8,9-Dehydroestrone    O
,    O
or    O
Δ8-estrone    O
,    O
also    O
known    O
as    O
estra-1,3,5(10),8-tetraen-3-ol-17-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estrone    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
3.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

Algestone    B-SteroidHormone114745635

File    O
:    O
Dydrogesterone    B-SteroidHormone114745635
(    O
progestin    O
)    O

Progesterone    O
and    O
non    O
-    O
androgenic    O
progestins    O
,    O
such    O
as    O
dydrogesterone    B-SteroidHormone114745635
,    O
do    O
not    O
affect    O
serum    O
IGF-1    O
levels    O
regardless    O
of    O
route    O
of    O
administration    O
.    O

Gynorest    B-SteroidHormone114745635

Endogenous    O
estrogens    O
(    O
e.g.    O
,    O
estradiol    O
,    O
estrone    O
,    O
estriol    O
,    O
estetrol    B-SteroidHormone114745635
)    O

During    O
pregnancy    O
,    O
DHEA    O
-    O
S    O
is    O
metabolized    O
into    O
the    O
sulfates    O
of    O
16α-hydroxy    O
-    O
DHEA    O
and    O
15α-hydroxy    O
-    O
DHEA    O
in    O
the    O
fetal    O
liver    O
as    O
intermediates    O
in    O
the    O
production    O
of    O
the    O
estrogens    O
estriol    O
and    O
estetrol    B-SteroidHormone114745635
,    O
respectively    O
.    O

Hydrocortisone-17-butyrate    O
,    O
hydrocortisone-17-valerate    O
,    O
alclometasone    O
dipropionate    O
,    O
betamethasone    O
valerate    O
,    O
betamethasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
,    O
prednicarbate    B-SteroidHormone114745635
,    O
clobetasone-17-butyrate    O
,    O
Clobetasol-17    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
fluocortolone    O
caproate    O
,    O
fluocortolone    O
pivalate    O
,    O
fluprednidene    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
mometasone    B-SteroidHormone114745635
furoate    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
mometasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635
.    O

NOMAC    O
is    O
the    O
C17α    O
acetate    O
ester    O
of    O
nomegestrol    B-SteroidHormone114745635
and    O
the    O
19-demethylated    O
(    O
or    O
19-nor    O
)    O
analogue    O
of    O
megestrol    O
acetate    O
,    O
and    O
can    O
also    O
be    O
referred    O
to    O
as    O
19-normegestrol    O
acetate    O
.    O

Flurandrenolide    B-SteroidHormone114745635
0.05%    O
(    O
Cordran    O
)    O

Chloroprednisone    B-SteroidHormone114745635

Between    O
1957    O
and    O
1962    O
Gerhard    O
Langbein    O
further    O
expanded    O
the    O
gamut    O
of    O
steroids    O
that    O
Jenapharm    O
produced    O
using    O
its    O
unique    O
process    O
to    O
include    O
testosterone    O
,    O
4-chlorotestosterone    B-SteroidHormone114745635
,    O
cortexolone    O
,    O
cortisone    O
,    O
cortisol    O
and    O
prednisone    O
.    O

Clostebol    B-SteroidHormone114745635

On    O
20    O
September    O
2013    O
the    O
UCI    O
announced    O
that    O
Agostini    O
was    O
provisionally    O
suspended    O
for    O
an    O
adverse    O
analytical    O
finding    O
for    O
0.7    O
nanogram    O
per    O
millilitre    O
clostebol    B-SteroidHormone114745635
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
test    O
taken    O
on    O
21    O
August    O
2013    O
.    O

4-OHT    O
has    O
moderate    O
anabolic    O
,    O
mild    O
androgenic    O
,    O
and    O
anti    O
-    O
aromatase    O
properties    O
and    O
is    O
similar    O
to    O
the    O
steroid    O
clostebol    B-SteroidHormone114745635
(    O
4-chlorotestosterone    O
)    O
.    O

Androstadienol    O
is    O
then    O
sequentially    O
converted    O
into    O
androstenol    O
by    O
3β-hydroxysteroid    O
dehydrogenase    O
(    O
androstadienol    O
to    O
androstadienone    B-SteroidHormone114745635
)    O
,    O
5α-reductase    O
(    O
androstadienone    O
to    O
androstenone    O
)    O
,    O
and    O
3α-hydroxysteroid    O
dehydrogenase    O
(    O
androstenone    O
to    O
androstenol    O
)    O
,    O
in    O
a    O
manner    O
analogous    O
to    O
the    O
biosynthesis    O
of    O
3α-androstanediol    O
from    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
.    O

Androstadienol    O
to    O
androstadienone    B-SteroidHormone114745635

In    O
the    O
same    O
study    O
,    O
spironolactone    O
was    O
administered    O
to    O
rats    O
and    O
found    O
to    O
produce    O
mixed    O
estrogenic    O
and    O
antiestrogenic    O
or    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM)-like    O
effects    O
that    O
were    O
described    O
as    O
very    O
similar    O
to    O
those    O
of    O
tamoxifen    O
.    O

In    O
postmenopausal    O
women    O
,    O
the    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
raloxifene    O
is    O
occasionally    O
administered    O
instead    O
of    O
bisphosphonates    O
.    O

Acolbifene    O
(    O
INN    O
)    O
(    O
developmental    O
code    O
names    O
EM-652    O
,    O
SCH-57068    O
)    O
is    O
a    O
nonsteroidal    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM    O
)    O
which    O
,    O
as    O
of    O
2015    O
,    O
is    O
in    O
phase    O
III    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
.    O

Enclomifene    O
(    O
tentative    O
brand    O
name    O
Androxal    O
)    O
,    O
or    O
enclomiphene    O
,    O
is    O
a    O
nonsteroidal    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM    O
)    O
of    O
the    O
triphenylethylene    O
group    O
that    O
is    O
under    O
development    O
for    O
the    O
treatment    O
of    O
male    O
hypogonadism    O
.    O

Zuclomifene    O
(    O
INN    O
)    O
,    O
or    O
zuclomiphene    O
(    O
USAN    O
)    O
,    O
is    O
a    O
nonsteroidal    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM    O
)    O
of    O
the    O
triphenylethylene    O
group    O
that    O
was    O
never    O
marketed    O
.    O

selective    B-SteroidHormone114745635
oestrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulators    I-SteroidHormone114745635
,    O
hormone    O
replacement    O
therapy    O
and    O
calcitonin    O
are    O
some    O
of    O
the    O
common    O
treatments    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    B-SteroidHormone114745635
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    B-SteroidHormone114745635
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
,    O
specifically    O
tamoxifen    O
,    O
have    O
been    O
found    O
to    O
reduce    O
breast    O
cancer    O
risk    O
in    O
women    O
with    O
"    O
BRCA    O
"    O
mutations    O
who    O
do    O
not    O
have    O
their    O
breast    O
removed    O
.    O

The    O
drug    O
can    O
both    O
mimic    O
the    O
action    O
of    O
estrogen    O
and    O
antagonize    O
estrogen    O
,    O
indicating    O
that    O
it    O
is    O
a    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM    O
)    O
or    O
partial    O
agonist    O
of    O
the    O
ER    O
.    O

Menerba    O
,    O
also    O
known    O
as    O
Menopause    O
Formula    O
101    O
(    O
MF-101    O
)    O
,    O
is    O
a    O
botanical    O
drug    O
candidate    O
that    O
acts    O
as    O
a    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM    O
)    O
which    O
is    O
being    O
studied    O
for    O
its    O
potential    O
to    O
relieve    O
hot    O
flashes    O
associated    O
with    O
menopause    O
.    O

Selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635

It    O
is    O
a    O
fixed    O
-    O
dose    O
combination    O
drug    O
containing    O
the    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
bazedoxifene    O
and    O
conjugated    O
estrogens    O
being    O
marketed    O
by    O
the    O
pharmaceutical    O
company    O
Pfizer    O
.    O

17β-Dihydroequilenin    O
has    O
unexpectedly    O
shown    O
a    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
-    O
like    O
profile    O
of    O
estrogenic    O
activity    O
in    O
studies    O
with    O
monkeys    O
,    O
in    O
which    O
beneficial    O
effects    O
on    O
bone    O
and    O
the    O
cardiovascular    O
system    O
were    O
noted    O
but    O
proliferative    O
responses    O
in    O
breast    O
or    O
endometrium    O
were    O
not    O
observed    O
.    O

The    O
steroid    O
is    O
only    O
very    O
weakly    O
estrogenic    O
,    O
and    O
is    O
able    O
to    O
antagonize    O
the    O
estrogenic    O
effects    O
of    O
estradiol    O
,    O
indicating    O
that    O
its    O
intrinsic    O
activity    O
at    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
is    O
less    O
than    O
that    O
of    O
estradiol    O
and    O
hence    O
that    O
it    O
possesses    O
the    O
profile    O
of    O
a    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
.    O

Lasofoxifene    O
(    O
INN    O
)    O
(    O
brand    O
name    O
Fablyn    O
)    O
is    O
a    O
nonsteroidal    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SERM    O
)    O
which    O
is    O
marketed    O
by    O
Pfizer    O
for    O
the    O
prevention    O
and    O
treatment    O
of    O
osteoporosis    O
and    O
for    O
the    O
treatment    O
of    O
vaginal    O
atrophy    O
,    O
and    O
the    O
result    O
of    O
an    O
exclusive    O
research    O
collaboration    O
with    O
Ligand    O
Pharmaceuticals    O
(    O
LGND    O
)    O
.    O

17β-Dihydroequilenin    O
,    O
or    O
β-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
0.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

8,9-Dehydroestrone    O
,    O
or    O
Δ8-estrone    O
,    O
also    O
known    O
as    O
estra-1,3,5(10),8-tetraen-3-ol-17-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estrone    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
3.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-SteroidHormone114745635
,    O
drospirenone    O
and    O
norethisterone    B-SteroidHormone114745635
compared    O
with    O
levonorgestrel    B-SteroidHormone114745635
.    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivative    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
norethisterone    O
enanthate    O
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivatives    O
gestonorone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Estradiol    O
undecylate    O
,    O
in    O
combination    O
with    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
at    O
doses    O
of    O
5    O
mg    O
and    O
50    O
mg    O
,    O
respectively    O
)    O
,    O
was    O
studied    O
as    O
a    O
combined    O
injectable    O
contraceptive    O
,    O
but    O
ultimately    O
was    O
not    O
marketed    O
for    O
this    O
purpose    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

Ultraspiracle    B-SteroidHormone114745635
protein    I-SteroidHormone114745635
,    O
a    O
part    O
of    O
the    O
ecdysone    O
receptor    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    B-SteroidHormone114745635
and    O
oxymetholone    B-SteroidHormone114745635
.    O

Oxymetholone    B-SteroidHormone114745635

Oxymetholone    B-SteroidHormone114745635

Prednylidene    B-SteroidHormone114745635
=    O
11β,17α,21-trihydroxy-16-methylenepregna-1,4-diene-3,20-dione    O

Progesterone    B-SteroidHormone114745635
Only    I-SteroidHormone114745635
Pill    I-SteroidHormone114745635

Dobson    O
and    O
Cutrer    O
view    O
progesterone-only    B-SteroidHormone114745635
birth    I-SteroidHormone114745635
control    I-SteroidHormone114745635
pills    I-SteroidHormone114745635
as    O
potentially    O
problematic    O
,    O
since    O
they    O
may    O
be    O
potentially    O
abortive    O
contraceptives    O
because    O
of    O
the    O
theoretical    O
possibility    O
that    O
they    O
may    O
have    O
a    O
slight    O
secondary    O
action    O
of    O
preventing    O
a    O
fertilized    O
embryo    O
from    O
implanting    O
within    O
the    O
uterine    O
wall    O
,    O
while    O
Alcorn    O
implicates    O
all    O
hormonal    O
contraceptives    O
as    O
problematic    O
in    O
these    O
regards    O
.    O

At    O
very    O
low    O
daily    O
dose    O
of    O
30    O
µg    O
,    O
levonorgestrel    O
is    O
used    O
in    O
some    O
progestogen    B-SteroidHormone114745635
only    I-SteroidHormone114745635
pill    I-SteroidHormone114745635

Cloprednol    B-SteroidHormone114745635
=    O
6-chloro-11β,17α,21-trihydroxypregna-1,4,6-triene-3,20-dione    O

Delalutin    B-SteroidHormone114745635

hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
(    O
INN    O
)    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivative    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
norethisterone    O
enanthate    O
.    O

The    O
first    O
progestogen    O
esters    O
were    O
not    O
introduced    O
until    O
the    O
mid-1950s    O
,    O
and    O
were    O
esters    O
of    O
17α-hydroxyprogesterone    O
(    O
which    O
,    O
unlike    O
progesterone    O
,    O
has    O
a    O
hydroxy    O
group    O
available    O
for    O
esterification    O
)    O
rather    O
than    O
of    O
progesterone    O
;    O
they    O
included    O
17α-hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
(    O
Delalutin    O
,    O
Proluton    O
)    O
and    O
17α-hydroxyprogesterone    O
acetate    O
(    O
Prodrox    O
)    O
.    O

Hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
(    O
Delalutin    O
,    O
Proluton    O
)    O
,    O
the    O
first    O
progestogen    O
ester    O
.    O

Hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635

Estradiol    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
(    O
BAN    O
,    O
JAN    O
)    O
(    O
brand    O
names    O
Agofollin    B-SteroidHormone114745635
,    O
Di-Ovocyclin    B-SteroidHormone114745635
,    O
Progynon    B-SteroidHormone114745635
DP    I-SteroidHormone114745635
,    O
others    O
)    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
that    O
is    O
or    O
has    O
been    O
marketed    O
in    O
the    O
United    O
States    O
and    O
Europe    O
.    O

Along    O
with    O
estradiol    B-SteroidHormone114745635
benzoate    I-SteroidHormone114745635
,    O
estradiol    O
dipropionate    O
was    O
one    O
of    O
the    O
first    O
estradiol    O
esters    O
to    O
be    O
developed    O
,    O
having    O
been    O
patented    O
in    O
1937    O
,    O
was    O
assessed    O
in    O
clinical    O
studies    O
by    O
1939    O
,    O
and    O
has    O
been    O
marketed    O
by    O
Schering    O
as    O
Progynon    B-SteroidHormone114745635
DP    I-SteroidHormone114745635
and    O
Ciba    O
Pharmaceutical    O
Products    O
as    O
Di-Ovocylin    B-SteroidHormone114745635
since    O
at    O
least    O
1940    O
.    O

Steroid    O
sulfatase    O
(    O
STS    O
)    O
inhibitors    O
such    O
as    O
estradiol    O
sulfamate    O
,    O
estrone    O
sulfamate    O
,    O
irosustat    O
,    O
and    O
danazol    B-SteroidHormone114745635
inhibit    O
the    O
conversion    O
of    O
steroid    O
sulfates    O
such    O
as    O
estrone    B-SteroidHormone114745635
sulfate    I-SteroidHormone114745635
and    O
DHEA    O
sulfate    O
into    O
their    O
hormonally    O
active    O
forms    O
.    O

Estrone    B-SteroidHormone114745635
sulfate    I-SteroidHormone114745635

E2S    O
can    O
also    O
be    O
metabolized    O
into    O
estrone    B-SteroidHormone114745635
sulfate    I-SteroidHormone114745635
(    O
E1S    O
)    O
,    O
which    O
in    O
turn    O
can    O
be    O
converted    O
into    O
estrone    O
and    O
estradiol    O
.    O

Like    O
many    O
other    O
progestogens    O
,    O
NOMAC    O
has    O
been    O
assessed    O
and    O
found    O
"    O
in    O
vitro    O
"    O
to    O
inhibit    O
the    O
conversion    O
of    O
estrone    B-SteroidHormone114745635
sulfate    I-SteroidHormone114745635
to    O
estrone    O
(    O
via    O
inhibition    O
of    O
steroid    O
sulfatase    O
)    O
and    O
estrone    O
to    O
estradiol    O
(    O
via    O
inhibition    O
of    O
)    O
at    O
high    O
concentrations    O
(    O
0.5–50    O
μM    O
)    O
and    O
to    O
stimulate    O
the    O
conversion    O
of    O
estrone    O
into    O
estrone    O
sulfate    O
(    O
via    O
activation    O
of    O
estrogen    O
sulfotransferase    O
activity    O
)    O
at    O
low    O
concentrations    O
(    O
0.05–0.5    O
μM    O
)    O
,    O
whilst    O
not    O
affecting    O
aromatase    O
activity    O
at    O
any    O
tested    O
concentration    O
(    O
up    O
to    O
10    O
μM    O
)    O
.    O

It    O
produces    O
8,9-dehydroestradiol    O
as    O
an    O
important    O
active    O
metabolite    O
,    O
analogously    O
to    O
conversion    O
of    O
estrone    O
or    O
estrone    B-SteroidHormone114745635
sulfate    I-SteroidHormone114745635
into    O
estradiol    O
.    O

Trenbolone    B-SteroidHormone114745635
(    O
δ9,11    O
-    O
19-NT    O
)    O

Trenbolone    B-SteroidHormone114745635

Other    O
steroids    O
stacked    O
with    O
metandienone    O
are    O
primarily    O
,    O
if    O
not    O
always    O
,    O
injectable    O
compounds    O
such    O
as    O
testosterone    O
,    O
trenbolone    B-SteroidHormone114745635
and    O
nandrolone    O
.    O

Trenbolone    B-SteroidHormone114745635
(    O
trienolone    O
)    O

The    O
infamous    O
"    O
duchess    O
"    O
cocktail    O
administered    O
to    O
Russian    O
athletes    O
at    O
the    O
Sochi    O
Winter    O
Olympics    O
consisted    O
of    O
oxandrolone    B-SteroidHormone114745635
,    O
metenolone    O
,    O
and    O
trenbolone    B-SteroidHormone114745635
.    O

However    O
,    O
Park    O
Jong    O
-    O
sei    O
of    O
the    O
Olympic    O
Doping    O
Control    O
Center    O
found    O
that    O
Johnson    O
's    O
blood    O
and    O
urine    O
samples    O
contained    O
stanozolol    B-SteroidHormone114745635
,    O
and    O
he    O
was    O
disqualified    O
three    O
days    O
later    O
.    O

In    O
July    O
2006    O
,    O
Zakari    O
was    O
reported    O
to    O
have    O
failed    O
a    O
drugs    O
test    O
for    O
the    O
banned    O
substance    O
stanozolol    B-SteroidHormone114745635
.    O

Jenrry    O
Mejia    O
,    O
formerly    O
of    O
the    O
New    O
York    O
Mets    O
,    O
was    O
suspended    O
in    O
July    O
2015    O
when    O
he    O
tested    O
positive    O
for    O
boldenone    O
and    O
stanozolol    B-SteroidHormone114745635
,    O
and    O
in    O
February    O
2016    O
he    O
again    O
tested    O
positive    O
for    O
boldenone    O
;    O
this    O
marked    O
Mejia    O
's    O
third    O
positive    O
test    O
for    O
a    O
performance    O
-    O
enhancing    O
drug    O
,    O
for    O
which    O
he    O
received    O
the    O
first    O
PED    O
-    O
related    O
lifetime    O
ban    O
in    O
MLB    O
history    O
.    O

Following    O
the    O
Strikeforce    O
card    O
on    O
June    O
22    O
,    O
2007    O
former    O
PRIDE    O
and    O
UFC    O
fighter    O
Phil    O
Baroni    O
tested    O
positive    O
for    O
boldenone    O
,    O
as    O
well    O
as    O
stanozolol    B-SteroidHormone114745635
.    O

Liliya    O
Nurutdinova    O
(    O
Russia    O
)    O
was    O
disqualified    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-SteroidHormone114745635
.    O

The    O
original    O
bronze    O
medalist    O
Dmitriy    O
Polyunin    O
(    O
Uzbekistan    O
)    O
was    O
disqualifed    O
for    O
doping    O
after    O
his    O
sample    O
was    O
found    O
positive    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-SteroidHormone114745635
,    O
and    O
the    O
medal    O
was    O
instead    O
awarded    O
Mick    O
Hill    O
(    O
Great    O
Britain    O
)    O
.    O

Burkman    O
was    O
originally    O
chosen    O
to    O
be    O
on    O
the    O
inaugural    O
season    O
of    O
"    O
The    O
Ultimate    O
Fighter    O
"    O
,    O
but    O
he    O
failed    O
pre    O
-    O
show    O
drug    O
test    O
failure    O
and    O
admitted    O
to    O
taking    O
Winstrol    B-SteroidHormone114745635
.    O

The    O
management    O
of    O
lipodermatosclerosis    O
may    O
include    O
treating    O
venous    O
insufficiency    O
with    O
leg    O
elevation    O
and    O
elastic    O
compression    O
stockings    O
;    O
in    O
some    O
difficult    O
cases    O
,    O
the    O
condition    O
may    O
be    O
improved    O
with    O
the    O
additional    O
use    O
of    O
the    O
fibrinolytic    O
agent    O
,    O
stanozol    B-SteroidHormone114745635
.    O

Copeland    O
was    O
said    O
to    O
have    O
received    O
somatropin    O
,    O
genotropin    O
,    O
and    O
stanozolol    B-SteroidHormone114745635
between    O
September    O
2004    O
and    O
February    O
2007    O
.    O

This    O
article    O
mentioned    O
several    O
current    O
and    O
former    O
WWE    O
wrestlers    O
,    O
including    O
Guerrero    O
,    O
who    O
was    O
alleged    O
to    O
have    O
obtained    O
hCG    O
and    O
the    O
steroid    O
stanozolol    B-SteroidHormone114745635
in    O
early    O
2005    O
.    O

On    O
August    O
23    O
,    O
2004    O
,    O
Russian    O
shot    O
putter    O
Irina    O
Korzhanenko    O
was    O
stripped    O
of    O
her    O
gold    O
medal    O
and    O
thereby    O
received    O
a    O
lifetime    O
ban    O
by    O
the    O
International    O
Olympic    O
Committee    O
after    O
she    O
tested    O
positive    O
for    O
the    O
steroid    O
stanozolol    B-SteroidHormone114745635
.    O

She    O
competed    O
at    O
the    O
2013    O
World    O
Championships    O
in    O
the    O
Women    O
's    O
+    O
75    O
kg    O
,    O
winning    O
the    O
Bronze    O
medal    O
but    O
later    O
lost    O
medal    O
and    O
was    O
banned    O
from    O
international    O
competition    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
for    O
use    O
of    O
anabolic    O
steroid    O
Stanozolol    B-SteroidHormone114745635
.    O

He    O
tested    O
positive    O
for    O
banned    O
substance    O
stanozolol    B-SteroidHormone114745635
,    O
an    O
anabolic    O
steroid    O
.    O

One    O
positive    O
test    O
for    O
the    O
anabolic    O
steroid    O
stanozolol    B-SteroidHormone114745635
at    O
the    O
GP    O
Carnevale    O
Europa    O
and    O
twice    O
for    O
the    O
hormone    O
testosterone    O
at    O
the    O
Giro    O
di    O
San    O
Marino    O
and    O
Sparkassen    O
Giro    O
Bochum    O
.    O

However    O
,    O
the    O
validity    O
of    O
her    O
record    O
and    O
title    O
was    O
called    O
into    O
question    O
by    O
a    O
positive    O
blood    O
test    O
result    O
for    O
the    O
banned    O
steroids    O
oxandrolone    B-SteroidHormone114745635
and    O
stanozolol    B-SteroidHormone114745635
,    O
and    O
she    O
was    O
"    O
provisionally    O
suspended    O
"    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
.    O

In    O
June    O
2016    O
,    O
IWF    O
announced    O
that    O
retests    O
of    O
the    O
samples    O
taken    O
from    O
the    O
2012    O
Olympics    O
indicated    O
that    O
Zulfiya    O
Chinshanlo    O
had    O
tested    O
positive    O
for    O
prohibited    O
substances    O
,    O
namely    O
Oxandrolone    B-SteroidHormone114745635
and    O
Stanazolol    B-SteroidHormone114745635
.    O

Already    O
in    O
retirement    O
,    O
Antonova    O
was    O
suspended    O
from    O
competition    O
for    O
two    O
years    O
in    O
July    O
2013    O
,    O
after    O
a    O
re    O
-    O
tested    O
doping    O
sample    O
from    O
the    O
2009    O
world    O
championships    O
proved    O
positive    O
for    O
stanozolol    B-SteroidHormone114745635
.    O

The    O
IAAF    O
reported    O
in    O
December    O
2015    O
that    O
Andrianova    O
would    O
be    O
retroactively    O
suspended    O
for    O
testing    O
positive    O
for    O
the    O
performance    O
-    O
enhancing    O
drug    O
stanozolol    B-SteroidHormone114745635
.    O

On    O
April    O
3    O
,    O
MLB    O
announced    O
that    O
Santana    O
would    O
be    O
suspended    O
for    O
80    O
games    O
after    O
testing    O
positive    O
for    O
Stanozolol    B-SteroidHormone114745635
,    O
a    O
performance    O
-    O
enhancing    O
drug    O
.    O

Stanozolol    B-SteroidHormone114745635

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-SteroidHormone114745635
during    O
a    O
drug    O
test    O
.    O

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-SteroidHormone114745635
during    O
a    O
drug    O
test    O
.    O

He    O
was    O
due    O
to    O
compete    O
at    O
the    O
2012    O
Olympic    O
Games    O
but    O
was    O
withdrawn    O
after    O
his    O
A    O
-    O
sample    O
tested    O
positive    O
for    O
hydroxystanozolol    B-SteroidHormone114745635
during    O
a    O
drug    O
test    O
.    O

Stanozolol    B-SteroidHormone114745635
,    O
an    O
anabolic    O
steroid    O
.    O

After    O
the    O
fight    O
he    O
tested    O
positive    O
for    O
the    O
banned    O
substance    O
stanozolol    B-SteroidHormone114745635
.    O

In    O
the    O
report    O
,    O
Kirk    O
Radomski    O
claimed    O
he    O
sold    O
Deca    O
-    O
Durabolin    O
and    O
Winstrol    B-SteroidHormone114745635
to    O
Zaun    O
in    O
2001    O
,    O
after    O
a    O
referral    O
from    O
Jason    O
Grimsley    O
.    O

Stanozolol    B-SteroidHormone114745635

In    O
September    O
2005    O
Baggaley    O
tested    O
positive    O
for    O
banned    O
steroids    O
(    O
stanozolol    B-SteroidHormone114745635
and    O
methandienone    B-SteroidHormone114745635
)    O
.    O

He    O
received    O
a    O
doping    O
ban    O
for    O
two    O
years    O
in    O
2001    O
,    O
after    O
testing    O
positive    O
for    O
stanozolol    B-SteroidHormone114745635
at    O
the    O
Jamaican    O
Championships    O
.    O

He    O
finished    O
second    O
at    O
the    O
Jamaican    O
National    O
Championships    O
that    O
year    O
but    O
his    O
doping    O
test    O
from    O
the    O
competition    O
was    O
positive    O
for    O
the    O
banned    O
steroid    O
stanozolol    B-SteroidHormone114745635
.    O

It    O
is    O
the    O
C17β    O
ester    O
metenolone    B-SteroidHormone114745635
,    O
which    O
itself    O
is    O
1-methyl-δ1    O
-    O
4,5α-dihydrotestosterone    O
(    O
1-methyl-δ1-DHT    O
)    O
or    O
1-methyl-5α-androst-1-en-17β-ol-3-one    O
.    O

In    O
2005    O
,    O
she    O
received    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
track    O
due    O
to    O
positive    O
testing    O
for    O
illegal    O
substance    O
Metenolone    B-SteroidHormone114745635
.    O

On    O
13    O
August    O
2012    O
,    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
of    O
her    O
gold    O
medal    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
metenolone    B-SteroidHormone114745635
,    O
and    O
the    O
gold    O
medal    O
was    O
subsequently    O
awarded    O
to    O
silver    O
medalist    O
Valerie    O
Adams    O
from    O
New    O
Zealand    O
.    O

On    O
August    O
13    O
,    O
International    O
Olympic    O
Committee    O
decided    O
the    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
,    O
the    O
nation    O
's    O
only    O
track    O
and    O
field    O
medalist    O
,    O
to    O
strip    O
off    O
her    O
gold    O
medal    O
at    O
the    O
London    O
games    O
after    O
she    O
was    O
tested    O
positive    O
for    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
metenolone    B-SteroidHormone114745635
.    O

Methenolone    B-SteroidHormone114745635

Metenolone    B-SteroidHormone114745635
,    O
or    O
methenolone    B-SteroidHormone114745635
,    O
also    O
known    O
as    O
methylandrostenolone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

No    O
statistically    O
significant    O
increase    O
in    O
risk    O
was    O
associated    O
with    O
the    O
other    O
formulations    O
of    O
oral    O
contraceptive    O
(    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
norgestrel    O
and    O
norgestimate    B-SteroidHormone114745635
)    O
.    O

The    O
results    O
came    O
in    O
on    O
the    O
day    O
of    O
the    O
announcement    O
and    O
revealed    O
Silva    O
tested    O
positive    O
for    O
drostanolone    B-SteroidHormone114745635
metabolites    O
,    O
which    O
is    O
an    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

However    O
,    O
Casey    O
later    O
failed    O
a    O
post    O
-    O
fight    O
drug    O
test    O
for    O
drostanolone    B-SteroidHormone114745635
,    O
a    O
form    O
of    O
anabolic    O
steroid    O
.    O

Drostanolone    B-SteroidHormone114745635

However    O
,    O
Lawal    O
tested    O
positive    O
for    O
anabolic    O
steroids    O
(    O
Drostanolone    B-SteroidHormone114745635
)    O
and    O
as    O
a    O
result    O
of    O
the    O
banned    O
substance    O
,    O
the    O
fight    O
's    O
result    O
has    O
been    O
changed    O
to    O
a    O
no    O
contest    O
while    O
Lawal    O
will    O
have    O
his    O
license    O
suspended    O
for    O
one    O
year    O
.    O

Balykina    O
tested    O
positive    O
for    O
drostanolone    B-SteroidHormone114745635
in    O
an    O
out    O
-    O
of    O
-    O
competition    O
doping    O
test    O
in    O
June    O
2013    O
and    O
was    O
banned    O
from    O
competitive    O
athletics    O
for    O
two    O
years    O
.    O

She    O
tested    O
positive    O
for    O
the    O
banned    O
steroid    O
drostanolone    B-SteroidHormone114745635
right    O
after    O
winning    O
the    O
60    O
metres    O
event    O
at    O
the    O
2013    O
European    O
Athletics    O
Indoor    O
Championships    O
held    O
in    O
Gothenburg    O
in    O
March    O
.    O

Isolated    B-SteroidHormone114745635
17,20-lyase    I-SteroidHormone114745635
deficiency    I-SteroidHormone114745635
;    O
;    O
CYP17A1    O

Mutations    O
in    O
this    O
gene    O
are    O
associated    O
with    O
rare    O
forms    O
of    O
congenital    O
adrenal    O
hyperplasia    O
,    O
specifically    O
17α-hydroxylase    O
deficiency/17,20-lyase    O
deficiency    O
and    O
isolated    B-SteroidHormone114745635
17,20-lyase    I-SteroidHormone114745635
deficiency    I-SteroidHormone114745635
.    O

Hydroxycorticosteroids    B-SteroidHormone114745635
(    O
OHCSs    B-SteroidHormone114745635
)    O
are    O
corticosteroids    O
that    O
have    O
an    O
additional    O
hydroxy    O
(    O
-OH    O
)    O
group    O
.    O

Telapristone    B-SteroidHormone114745635
(    O
INN    O
)    O
,    O
as    O
telapristone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
proposed    O
brand    O
names    O
Proellex    B-SteroidHormone114745635
,    O
Progenta    B-SteroidHormone114745635
;    O
former    O
code    O
name    O
CDB-4124    B-SteroidHormone114745635
)    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
selective    B-SteroidHormone114745635
progesterone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SPRM    O
)    O
related    O
to    O
mifepristone    O
which    O
is    O
under    O
development    O
by    O
Repros    O
Therapeutics    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
endometriosis    O
,    O
and    O
uterine    O
fibroids    O
.    O

telapristone    B-SteroidHormone114745635
(    O
USAN    O
,    O
INN    O
)    O

A    O
pregnenedione    B-SteroidHormone114745635
is    O
an    O
unsaturated    O
diketone    O
derivative    O
of    O
a    O
pregnane    B-SteroidHormone114745635
.    O

In    O
contrast    O
to    O
however    O
,    O
they    O
are    O
non    O
-    O
selective    O
,    O
also    O
binding    O
to    O
other    O
steroid    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
exhibit    O
a    O
variety    O
of    O
other    O
activities    O
including    O
progestogenic    O
,    O
antigonadotropic    O
,    O
glucocorticoid    O
,    O
and/or    O
antimineralocorticoid    O
.    O

Additionally    O
,    O
one    O
study    O
found    O
that    O
soldiers    O
whose    O
leukocytes    O
had    O
greater    O
numbers    O
of    O
glucocorticoid    B-SteroidHormone114745635
receptors    I-SteroidHormone114745635
were    O
more    O
prone    O
to    O
developing    O
PTSD    O
after    O
experiencing    O
trauma    O
.    O

Steroid    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635

For    O
example    O
,    O
a    O
recent    O
report    O
indicated    O
that    O
T    O
cells    O
could    O
be    O
modified    O
to    O
inactivate    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
;    O
the    O
resulting    O
immune    O
cells    O
are    O
fully    O
functional    O
but    O
resistant    O
to    O
the    O
effects    O
of    O
commonly    O
used    O
corticosteroids    O
.    O

Guggulsterone    O
is    O
a    O
broad    O
-    O
spectrum    O
ligand    O
of    O
steroid    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
is    O
known    O
to    O
possess    O
the    O
following    O
activities    O
:    O

Although    O
inactive    O
at    O
steroid    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
E2S    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
potent    O
inhibitor    O
of    O
glutathione    O
S    O
-    O
transferase    O
,    O
an    O
enzyme    O
that    O
contributes    O
to    O
the    O
inactivation    O
of    O
estradiol    O
via    O
conversion    O
of    O
it    O
into    O
an    O
estradiol    O
-    O
glutathione    O
conjugate    O
.    O

Steroid    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635

It    O
can    O
also    O
associate    O
with    O
two    O
heat    O
shock    O
proteins    O
(    O
hsp90    O
and    O
hsp70    O
)    O
and    O
thus    O
may    O
play    O
a    O
role    O
in    O
the    O
intracellular    O
trafficking    O
of    O
hetero    O
-    O
oligomeric    O
forms    O
of    O
the    O
steroid    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

"The    B-SteroidHormone114745635
cream"    I-SteroidHormone114745635
is    O
a    O
testosterone    O
-    O
based    O
ointment    O
that    O
is    O
used    O
in    O
conjunction    O
with    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
such    O
as    O
tetrahydrogestrinone    B-SteroidHormone114745635
(    O
THG    O
,    O
also    O
known    O
as    O
"    O
the    O
clear    O
"    O
)    O
in    O
order    O
to    O
mask    O
doping    O
in    O
professional    O
athletes    O
.    O

Records    O
seized    O
by    O
the    O
government    O
belonging    O
to    O
the    O
Bay    O
Area    O
Laboratory    O
Co    O
-    O
operative    O
,    O
later    O
discovered    O
to    O
be    O
the    O
source    O
of    O
a    O
designer    O
steroid    O
,    O
indicate    O
that    O
he    O
had    O
used    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
"    O
The    B-SteroidHormone114745635
Clear    I-SteroidHormone114745635
"    O
and    O
synthetic    O
testosterone    O
ointment    O
"    O
The    B-SteroidHormone114745635
Cream    I-SteroidHormone114745635
"    O
provided    O
by    O
BALCO    O
since    O
2003    O
.    O

FS    B-SteroidHormone114745635
Shampoo    I-SteroidHormone114745635

This    O
term    O
has    O
traditionally    O
been    O
applied    O
to    O
semisolids    O
that    O
possess    O
a    O
relatively    O
fluid    O
consistency    O
formulated    O
as    O
either    O
water    O
-    O
in    O
-    O
oil    O
(    O
e.g.    O
,    O
cold    O
cream    O
)    O
or    O
oil    O
-    O
in    O
-    O
water    O
(    O
e.g.    O
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
cream    O
)    O
emulsions    O
.    O

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

3α,5α-Tetrahydrocorticosterone    B-SteroidHormone114745635
(    O
3α,5α-THB    B-SteroidHormone114745635
)    O
,    O
or    O
simply    O
tetrahydrocorticosterone    B-SteroidHormone114745635
(    O
THB    B-SteroidHormone114745635
or    O
THCC    B-SteroidHormone114745635
)    O
,    O
is    O
an    O
endogenous    O
glucocorticoid    O
hormone    O
.    O

Estradiol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
and    O
estradiol    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Estradiol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

Estrogen    O
insensitivity    O
syndrome    O
(    O
EIS    O
)    O
,    O
or    O
estrogen    O
resistance    O
,    O
is    O
a    O
form    O
of    O
congenital    O
estrogen    O
deficiency    O
or    O
hypoestrogenism    B-SteroidHormone114745635
which    O
is    O
caused    O
by    O
a    O
defective    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
–    O
specifically    O
,    O
the    O
estrogen    O
receptor    O
alpha    O
(    O
ERα    O
)    O
–    O
that    O
results    O
in    O
an    O
inability    O
of    O
estrogen    O
to    O
mediate    O
its    O
biological    O
effects    O
in    O
the    O
body    O
.    O
Congenital    O
estrogen    O
deficiency    O
can    O
alternatively    O
be    O
caused    O
by    O
a    O
defect    O
in    O
aromatase    O
,    O
the    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
estrogens    O
,    O
a    O
condition    O
which    O
is    O
referred    O
to    O
as    O
aromatase    B-SteroidHormone114745635
deficiency    I-SteroidHormone114745635
and    O
is    O
similar    O
in    O
symptomatology    O
to    O
EIS    O
.    O

Treatment    O
with    O
up    O
to    O
extremely    O
high    O
doses    O
of    O
ethinylestradiol    O
(    O
fourteen    O
100-µg    O
patches    O
per    O
week    O
)    O
had    O
no    O
effect    O
on    O
any    O
of    O
his    O
symptoms    O
of    O
hypoestrogenism    B-SteroidHormone114745635
,    O
did    O
not    O
produce    O
any    O
estrogenic    O
effects    O
such    O
as    O
gynecomastia    O
,    O
and    O
had    O
no    O
effect    O
on    O
any    O
of    O
his    O
physiological    O
parameters    O
(    O
e.g.    O
,    O
hormone    O
levels    O
or    O
bone    O
parameters    O
)    O
,    O
suggesting    O
a    O
profile    O
of    O
complete    O
estrogen    O
insensitivity    O
syndrome    O
.    O

Congenital    O
estrogen    O
deficiency    O
is    O
a    O
congenital    O
form    O
of    O
hypoestrogenism    B-SteroidHormone114745635
in    O
which    O
the    O
body    O
is    O
unable    O
to    O
produce    O
or    O
use    O
estrogens    O
.    O

Hyperprolactinaemia    O
,    O
or    O
excess    O
serum    O
prolactin    O
,    O
is    O
associated    O
with    O
hypoestrogenism    B-SteroidHormone114745635
,    O
anovulatory    O
infertility    O
,    O
oligomenorrhoea    O
,    O
amenorrhoea    O
,    O
unexpected    O
lactation    O
and    O
loss    O
of    O
libido    O
in    O
women    O
and    O
erectile    O
dysfunction    O
and    O
loss    O
of    O
libido    O
in    O
men    O
.    O

Generally    O
,    O
side    O
effects    O
include    O
signs    O
and    O
symptoms    O
of    O
hypoestrogenism    B-SteroidHormone114745635
.    O

Ciclesonide    B-SteroidHormone114745635

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-SteroidHormone114745635
,    O
fluticasone    B-SteroidHormone114745635
,    O
mometasone    O
and    O
ciclesonide    B-SteroidHormone114745635
.    O

any    O
compound    O
(    O
not    O
being    O
Trilostane    B-SteroidHormone114745635
or    O
a    O
compound    O
for    O
the    O
time    O
being    O
specified    O
in    O
sub    O
-    O
paragraph    O
(    O
b    O
)    O
above    O
)    O
structurally    O
derived    O
from    O
17-hydroxyandrostan-3-one    O
or    O
from    O
17-hydroxyestran-3-one    O
by    O
modification    O
in    O
any    O
of    O
the    O
following    O
ways    O
,    O
that    O
is    O
to    O
say    O
,    O

3β-HSD    O
is    O
potently    O
inhibited    O
by    O
azastene    O
,    O
cyanoketone    O
,    O
epostane    O
,    O
and    O
trilostane    B-SteroidHormone114745635
.    O

Mestanolone    B-SteroidHormone114745635

Mestanolone    B-SteroidHormone114745635
(methylandrostanolone)    I-SteroidHormone114745635

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    B-SteroidHormone114745635
,    O
as    O
in    O
topterone    O
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-SteroidHormone114745635
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    B-SteroidHormone114745635
)    O
.    O

Ethylestrenol    B-SteroidHormone114745635
(ethylnandrol)    I-SteroidHormone114745635

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-SteroidHormone114745635
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-SteroidHormone114745635
,    O
bolenol    B-SteroidHormone114745635
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-SteroidHormone114745635
.    O

Quingestanol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivatives    O
gestonorone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Androisoxazole    B-SteroidHormone114745635

Proellex    O
is    O
a    O
very    O
similar    O
drug    O
to    O
asoprisnil    B-SteroidHormone114745635
.    O

In    O
men    O
,    O
due    O
to    O
androgen    B-SteroidHormone114745635
deprivation    I-SteroidHormone114745635
,    O
a    O
variety    O
of    O
side    O
effects    O
of    O
varying    O
severity    O
may    O
occur    O
during    O
bicalutamide    O
treatment    O
,    O
with    O
breast    O
pain    O
/    O
tenderness    O
and    O
gynecomastia    O
(    O
breast    O
development    O
/    O
enlargement    O
)    O
being    O
the    O
most    O
common    O
.    O

Depressed    O
mood    O
can    O
be    O
the    O
result    O
of    O
a    O
number    O
of    O
infectious    O
diseases    O
,    O
nutritional    O
deficiencies    O
,    O
neurological    O
conditions    O
and    O
physiological    O
problems    O
,    O
including    O
hypoandrogenism    B-SteroidHormone114745635
(    O
in    O
men    O
)    O
,    O
Addison    O
's    O
disease    O
,    O
Cushing    O
's    O
syndrome    O
,    O
hypothyroidism    O
,    O
Lyme    O
disease    O
,    O
multiple    O
sclerosis    O
,    O
Parkinson    O
's    O
disease    O
,    O
chronic    O
pain    O
,    O
stroke    O
,    O
diabetes    O
,    O
and    O
cancer    O
.    O

Hypoprolactinemia    O
,    O
or    O
serum    O
prolactin    O
deficiency    O
,    O
is    O
associated    O
with    O
ovarian    O
dysfunction    O
in    O
women    O
,    O
and    O
arteriogenic    O
erectile    O
dysfunction    O
,    O
premature    O
ejaculation    O
,    O
oligozoospermia    O
,    O
asthenospermia    O
,    O
hypofunction    O
of    O
seminal    O
vesicles    O
and    O
hypoandrogenism    B-SteroidHormone114745635
in    O
men    O
.    O

Screening    O
is    O
done    O
by    O
use    O
of    O
"    O
in    O
vitro    O
"    O
test    O
systems    O
(    O
by    O
examining    O
,    O
for    O
instance    O
,    O
if    O
an    O
agent    O
interacts    O
with    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
or    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
)    O
and    O
via    O
the    O
use    O
of    O
in    O
animal    O
models    O
,    O
such    O
as    O
development    O
of    O
tadpoles    O
and    O
uterine    O
growth    O
in    O
prepubertal    O
rodents    O
.    O

This    O
is    O
because    O
nandrolone    O
is    O
metabolized    O
by    O
5α-reductase    O
to    O
the    O
much    O
weaker    O
androgen    O
5α-dihydronandrolone    O
(    O
DHN    O
)    O
,    O
which    O
has    O
both    O
reduced    O
affinity    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
relative    O
to    O
nandrolone    O
"    O
in    O
vitro    O
"    O
and    O
weaker    O
androgenic    O
activity    O
"    O
in    O
vivo    O
"    O
.    O

Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
antagonist    O
/    O
very    O
weak    O
partial    O
agonist    O

It    O
was    O
a    O
successor    O
of    O
EPI-001    O
and    O
targets    O
the    O
N    O
-    O
terminal    O
domain    O
(    O
NTD    O
)    O
of    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
.    O

Unlike    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
CPA    O
)    O
,    O
it    O
is    O
not    O
also    O
a    O
progestogen    O
,    O
instead    O
acting    O
as    O
a    O
selective    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonist    O
similarly    O
to    O
nonsteroidal    O
antiandrogens    O
such    O
as    O
bicalutamide    O
.    O

It    O
is    O
reported    O
to    O
possess    O
an    O
IC50    O
of    O
700    O
nM    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
,    O
about    O
4-fold    O
less    O
than    O
that    O
of    O
bicalutamide    O
.    O

It    O
binds    O
to    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
(    O
Ki    O
=    O
320    O
nM    O
)    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
Ki    O
=    O
20    O
nM    O
)    O
and    O
acts    O
as    O
a    O
weak    O
but    O
clinically    O
relevant    O
inhibitor    O
of    O
5α-reductase    O
(    O
IC50    O
=    O
1.4    O
μM    O
)    O
.    O

It    O
is    O
an    O
antagonist    O
of    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
Ki    O
=    O
2.2    O
μM    O
)    O
,    O
and    O
with    O
the    O
exception    O
of    O
antiprogestogen    O
activity    O
in    O
rat    O
and    O
rabbit    O
models    O
,    O
is    O
devoid    O
of    O
other    O
hormonal    O
activities    O
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonist    O
(    O
Ki    O
=    O
240    O
nM    O
)    O

Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O

EIS    O
is    O
analogous    O
to    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
is    O
defective    O
and    O
insensitive    O
to    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

This    O
is    O
a    O
critical    O
residue    O
that    O
is    O
completely    O
conserved    O
among    O
species    O
and    O
in    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
and    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
MR    O
)    O
.    O

In    O
contrast    O
to    O
EIS    O
,    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
is    O
defective    O
,    O
is    O
relatively    O
common    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    B-SteroidHormone114745635
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    B-SteroidHormone114745635
and    O
antiprogestogen    O
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

Spinal    O
and    O
bulbar    O
muscular    O
atrophy    O
(    O
SBMA    O
)    O
,    O
also    O
known    O
as    O
Kennedy    O
's    O
disease    O
,    O
is    O
a    O
severe    O
neurodegenerative    O
syndrome    O
that    O
is    O
associated    O
with    O
a    O
particular    O
mutation    O
of    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
's    O
polyglutamine    O
tract    O
called    O
a    O
trinucleotide    O
repeat    O
expansion    O
.    O

The    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
gene    O
contains    O
two    O
polymorphic    O
trinucleotide    O
microsatellites    O
in    O
exon    O
1    O
.    O

MAIS    O
has    O
a    O
mild    O
presentation    O
that    O
often    O
goes    O
unnoticed    O
and    O
untreated    O
;    O
even    O
with    O
semenological    O
,    O
clinical    O
and    O
laboratory    O
data    O
,    O
it    O
can    O
be    O
difficult    O
to    O
distinguish    O
between    O
men    O
with    O
and    O
without    O
MAIS    O
,    O
and    O
thus    O
a    O
diagnosis    O
of    O
MAIS    O
is    O
not    O
usually    O
made    O
without    O
confirmation    O
of    O
an    O
AR    B-SteroidHormone114745635
gene    I-SteroidHormone114745635
mutation    O
.    O

Management    O
of    O
MAIS    O
is    O
currently    O
limited    O
to    O
symptomatic    O
management    O
;    O
methods    O
to    O
correct    O
a    O
malfunctioning    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
protein    O
that    O
result    O
from    O
an    O
AR    O
gene    O
mutation    O
are    O
not    O
currently    O
available    O
.    O

It    O
is    O
a    O
known    O
endocrine    O
disruptor    O
(    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonist    O
)    O
and    O
to    O
interfere    O
with    O
the    O
sexual    O
differention    O
of    O
male    O
rats    O
.    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogen    B-SteroidHormone114745635
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
)    O
.    O

Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O

At    O
high    O
concentrations    O
,    O
BPA    O
also    O
binds    O
to    O
and    O
acts    O
as    O
an    O
antagonist    O
of    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
.    O

AR    B-SteroidHormone114745635
,    O

Digit    O
ratio    O
in    O
men    O
correlates    O
with    O
genetic    O
variation    O
in    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
gene    O
.    O

The    O
condition    O
is    O
associated    O
with    O
mutation    O
of    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
"    O
AR    O
"    O
)    O
gene    O
and    O
is    O
inherited    O
in    O
an    O
X    O
-    O
linked    O
recessive    O
manner    O
.    O

The    O
genetics    O
of    O
spinal    O
and    O
bulbar    O
muscular    O
atrophy    O
have    O
to    O
do    O
with    O
the    O
mutated    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
gene    O
located    O
on    O
the    O
X    O
chromosome    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
and    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Metandienone    O
binds    O
to    O
and    O
activates    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
in    O
order    O
to    O
exert    O
its    O
effects    O
.    O

M    O
,    O
C4    O
,    O
C5    O
and    O
C4    O
-    O
2    O
also    O
expressed    O
reduced    O
human    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
mRNA    O
as    O
expected    O
in    O
AI    O
cells    O
.    O

LN95    O
cells    O
differ    O
from    O
parental    O
LNCaP    O
cells    O
morphologically    O
,    O
with    O
pronounced    O
dendritic    O
extensions    O
,    O
and    O
molecularly    O
,    O
with    O
Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
variant    O
expression    O
similar    O
to    O
that    O
of    O
AR    O
-    O
V7High    O
VCaP    O
cells    O
.    O

While    O
LNCaP    O
-    O
AI    O
are    O
wholly    O
androgen    O
independent    O
,    O
they    O
retain    O
high    O
expression    O
of    O
Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
low    O
expression    O
of    O
AR    O
-    O
V7    O
,    O
and    O
remain    O
androgen    O
responsive    O
..    O

It    O
has    O
been    O
found    O
to    O
possess    O
slightly    O
lower    O
affinity    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
relative    O
to    O
nandrolone    O
in    O
rat    O
and    O
rabbit    O
tissue    O
bioassays    O
,    O
whereas    O
trenbolone    O
was    O
found    O
to    O
possess    O
the    O
same    O
affinity    O
for    O
the    O
AR    O
as    O
dienolone    O
but    O
several    O
-    O
fold    O
increased    O
affinity    O
for    O
the    O
PR    O
.    O

Mutations    O
in    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
genes    O
are    O
highly    O
implicated    O
,    O
as    O
these    O
are    O
involved    O
in    O
penile    O
development    O
,    O
testes    O
descent    O
,    O
and    O
testes    O
development    O
.    O

It    O
contains    O
10    O
NR    O
-    O
interacting    O
boxes    O
(    O
LXXLL    O
motifs    O
)    O
and    O
functions    O
as    O
a    O
coregulator    O
of    O
several    O
nuclear    O
receptors    O
via    O
its    O
LXXLL    O
motifs    O
including    O
ESR1    O
,    O
ESR2    O
,    O
ERR    O
-    O
alpha    O
,    O
PR    B-SteroidHormone114745635
,    O
GR    B-SteroidHormone114745635
,    O
AR    B-SteroidHormone114745635
,    O
and    O
RXR    O
.    O

It    O
acts    O
as    O
a    O
partial    O
agonist    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
with    O
a    O
Ki    O
of    O
5nM    O
,    O
and    O
no    O
significant    O
affinity    O
for    O
any    O
other    O
receptors    O
tested    O
.    O

It    O
binds    O
to    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
more    O
strongly    O
than    O
older    O
drugs    O
such    O
as    O
andarine    O
with    O
a    O
Ki    O
of    O
1.7    O
nM    O
,    O
and    O
in    O
animal    O
studies    O
it    O
showed    O
both    O
a    O
good    O
ratio    O
of    O
anabolic    O
to    O
androgenic    O
effects    O
,    O
and    O
dose    O
-    O
dependent    O
suppression    O
of    O
spermatogenesis    O
with    O
spontaneous    O
recovery    O
after    O
cessation    O
of    O
treatment    O
.    O

Other    O
receptors    O
also    O
show    O
this    O
functional    O
profile    O
,    O
including    O
p75NTR    O
,    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
RET    O
,    O
several    O
integrins    O
and    O
Patched    O
.    O

Androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O

Promestriene    B-SteroidHormone114745635
(    O
Colpotrofin    O
,    O
Colpotrophine    O
,    O
Delipoderm    O
)    O
–    O
the    O
3-propyl    O
and    O
17β-methyl    O
diether    O
of    O
estradiol    O

For    O
instance    O
,    O
19-norsteroids    O
(    O
e.g.    O
,    O
19-norprogesterone    B-SteroidHormone114745635
)    O
constitute    O
an    O
important    O
class    O
of    O
natural    O
and    O
synthetic    O
steroids    O
derived    O
by    O
removal    O
of    O
the    O
methyl    O
group    O
of    O
the    O
natural    O
product    O
progesterone    O
;    O
the    O
equivalent    O
change    O
between    O
testosterone    O
and    O
19-nortestosterone    O
(    O
nandrolone    O
)    O
is    O
illustrated    O
below    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

The    O
elaboration    O
of    O
a    O
method    O
for    O
the    O
reduction    O
of    O
aromatic    O
rings    O
to    O
the    O
corresponding    O
dihydrobenzenes    O
under    O
controlled    O
conditions    O
by    O
A.    O
J.    O
Birch    O
opened    O
a    O
convenient    O
route    O
to    O
compounds    O
related    O
to    O
the    O
putative    O
19-norprogesterone    B-SteroidHormone114745635
.    O

NOMAC    O
is    O
a    O
norpregnane    O
steroid    O
and    O
a    O
derivative    O
of    O
progesterone    O
belonging    O
to    O
the    O
19-norprogesterone    B-SteroidHormone114745635
and    O
17α-hydroxyprogesterone    O
groups    O
.    O

Norelgestromin    B-SteroidHormone114745635

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

Nidoflor    O
(    O
cream    O
,    O
combined    O
with    O
neomycin    O
sulfate    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
)    O

Animax    O
(    O
veterinary    O
topical    O
ointment    O
or    O
cream    O
;    O
combined    O
with    O
neomycin    O
sulfate    O
,    O
thiostrepton    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
)    O

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

Triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635

It    O
is    O
injected    O
into    O
the    O
heel    O
when    O
treating    O
plantar    O
fasciitis    O
,    O
sometimes    O
in    O
conjunction    O
with    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

Additionally    O
,    O
intralesional    O
injection    O
with    O
a    O
corticosteroid    O
such    O
as    O
Kenalog    B-SteroidHormone114745635
does    O
appear    O
to    O
aid    O
in    O
the    O
reduction    O
of    O
inflammation    O
and    O
pruritus    O
.    O

It    O
is    O
an    O
isomer    O
of    O
the    O
related    O
19-nortestosterone    O
derivative    O
progestins    O
lynestrenol    B-SteroidHormone114745635
and    O
cingestol    O
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-SteroidHormone114745635
,    O
Ethisterone    B-SteroidHormone114745635
,    O
and    O
Lynestrenol    B-SteroidHormone114745635
.    O

Bolenol    B-SteroidHormone114745635
(ethylnorandrostenol)    I-SteroidHormone114745635

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-SteroidHormone114745635
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-SteroidHormone114745635
,    O
bolenol    B-SteroidHormone114745635
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-SteroidHormone114745635
.    O

Delmadinone    B-SteroidHormone114745635

Oxabolone    B-SteroidHormone114745635
(    O
4-hydroxy-19-NT    O
)    O

Oxabolone    B-SteroidHormone114745635

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

The    O
company    O
's    O
products    O
include    O
Botox    O
,    O
Namenda    O
,    O
Restasis    O
,    O
Linzess    O
,    O
Bystolic    O
,    O
Juvederm    O
,    O
Latisse    O
,    O
Lo    O
Loestrin    O
Fe    O
,    O
Estrace    O
,    O
Teflaro    O
,    O
Dalvance    O
,    O
Ozurdex    O
,    O
Optive    O
,    O
Natrelle    O
,    O
Viibryd    O
,    O
Liletta    B-SteroidHormone114745635
,    O
Saphris    O
,    O
Enablex    O
,    O
Actonel    O
,    O
Androderm    O
,    O
Gelnique    O
and    O
others    O
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

The    O
Yuzpe    O
Regimen    O
is    O
a    O
method    O
of    O
emergency    O
contraception    O
using    O
a    O
combination    O
of    O
estrogen    O
and    O
progestogen    O
hormones    O
(    O
100    O
μg    O
ethinylestradiol    O
and    O
0.5    O
mg    O
of    O
levonorgestrel    B-SteroidHormone114745635
as    O
soon    O
as    O
possible    O
and    O
again    O
in    O
12    O
hrs    O
)    O
and    O
started    O
within    O
72    O
hours    O
of    O
sexual    O
intercourse    O
.    O

In    O
April    O
2005    O
,    O
Governor    O
Rod    O
Blagojevich    O
by    O
emergency    O
executive    O
order    O
required    O
all    O
pharmacists    O
to    O
provide    O
Plan    O
B    O
levonorgestrel    B-SteroidHormone114745635
.    O

Other    O
-    O
hemodialysis    O
,    O
excessive    O
UV    O
-    O
A    O
,    O
cola    O
,    O
oral    O
contraceptive    O
pills    O
(    O
levonorgestrel    B-SteroidHormone114745635
and    O
ethinylestradiol    O
)    O
,    O
narrowband    O
UV    O
-    O
B    O
phototherapy    O
(    O
rarely    O
)    O

Levonorgestrel    O
-    O
releasing    O
implant    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Jadelle    O
among    O
others    O
,    O
is    O
a    O
device    O
made    O
up    O
of    O
a    O
two    O
rods    O
of    O
levonorgestrel    B-SteroidHormone114745635
used    O
for    O
birth    O
control    O
.    O

The    O
original    O
Norplant    O
consisted    O
of    O
a    O
set    O
of    O
six    O
small    O
(    O
2.4    O
mm    O
×    O
34    O
mm    O
)    O
silicone    O
capsules    O
,    O
each    O
filled    O
with    O
36    O
mg    O
of    O
levonorgestrel    B-SteroidHormone114745635
implanted    O
under    O
the    O
skin    O
in    O
the    O
upper    O
arm    O
and    O
effective    O
for    O
five    O
years    O
.    O

It    O
has    O
been    O
shown    O
to    O
prevent    O
about    O
62–85%    O
of    O
expected    O
pregnancies    O
,    O
and    O
prevents    O
more    O
pregnancies    O
than    O
emergency    O
contraception    O
with    O
levonorgestrel    B-SteroidHormone114745635
.    O

It    O
might    O
also    O
interact    O
with    O
hormonal    O
contraceptives    O
and    O
progestogens    O
such    O
as    O
levonorgestrel    B-SteroidHormone114745635
and    O
other    O
substrates    O
of    O
the    O
progesterone    O
receptor    O
,    O
as    O
well    O
as    O
with    O
glucocorticoids    O
.    O

Ethinylestradiol    O
/    O
levonorgestrel    O
(    O
also    O
ethinyl    O
estradiol    O
/    O
levonorgestrel    O
)    O
is    O
a    O
combined    B-SteroidHormone114745635
birth    I-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
made    O
up    O
of    O
ethinylestradiol    O
,    O
an    O
estrogen    O
and    O
levonorgestrel    B-SteroidHormone114745635
a    O
progestin    O
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-SteroidHormone114745635
,    O
drospirenone    O
and    O
norethisterone    B-SteroidHormone114745635
compared    O
with    O
levonorgestrel    B-SteroidHormone114745635
.    O

In    O
early    O
February    O
2006    O
,    O
Stephens    O
challenged    O
Blagojevich    O
in    O
an    O
appearance    O
on    O
"    O
The    O
Daily    O
Show    O
"    O
to    O
discuss    O
the    O
Governor    O
's    O
executive    O
order    O
that    O
pharmacists    O
must    O
dispense    O
any    O
drugs    O
for    O
which    O
a    O
customer    O
had    O
a    O
valid    O
prescription    O
,    O
including    O
birth    O
control    O
pills    O
and    O
Plan    B-SteroidHormone114745635
B    I-SteroidHormone114745635
Blagojevich    O
was    O
interviewed    O
by    O
Jason    O
Jones    O
,    O
who    O
repeatedly    O
pretended    O
to    O
be    O
unable    O
to    O
pronounce    O
Blagojevich    O
and    O
simply    O
called    O
him    O
"    O
Governor    O
Smith    O
"    O
.    O

Normethandrone    B-SteroidHormone114745635
(    O
methylestrenolone    O
;    O
17α-methyl-19-NT    O
)    O

Normethandrone    B-SteroidHormone114745635
(methylestrenolone,    I-SteroidHormone114745635
normethisterone)    I-SteroidHormone114745635

Phytoecdysteroids    O
are    O
plant    O
-    O
derived    O
ecdysteroid    B-SteroidHormone114745635
.    O

Various    O
species    O
contain    O
apigenin    O
,    O
luteolin    O
,    O
quercetin    O
,    O
other    O
flavonoids    O
and    O
ecdysteroid    B-SteroidHormone114745635
.    O

These    O
glands    O
secrete    O
an    O
ecdysteroid    B-SteroidHormone114745635
called    O
ecdysone    B-SteroidHormone114745635
,    O
or    O
the    O
moulting    O
hormone    O
,    O
which    O
initiates    O
the    O
epidermal    O
moulting    O
process    O
.    O

18-Hydroxycorticosterone    B-SteroidHormone114745635
is    O
a    O
derivative    O
of    O
corticosterone    O
.    O

According    O
to    O
the    O
report    O
,    O
Bigbie    O
admitted    O
to    O
purchasing    O
and    O
using    O
a    O
variety    O
of    O
performance    O
-    O
enhancing    O
substances    O
from    O
Kirk    O
Radomski    O
from    O
2001    O
to    O
2005    O
,    O
including    O
human    O
growth    O
hormone    O
,    O
Deca    O
-    O
Durabolin    O
,    O
Sustanon    B-SteroidHormone114745635
,    O
testosterone    O
,    O
and    O
anti    O
-    O
estrogen    O
drugs    O
.    O

Products    O
include    O
:    O
Bridion    O
,    O
Esmirtazapine    O
,    O
Remeron    O
,    O
Remeron    O
SolTab    O
,    O
Sustanon    B-SteroidHormone114745635
,    O
Deca    O
-    O
Durabolin    O
,    O
Pregnyl    O
,    O
Implanon    O
,    O
NuvaRing    O
,    O
Marvelon    O
,    O
Desolett    O
and    O
a    O
variety    O
of    O
other    O
contraceptive    O
products    O
.    O

formocortal    B-SteroidHormone114745635
(    O
INN    O
)    O

Otobiotic    B-SteroidHormone114745635
Otic    I-SteroidHormone114745635
is    O
a    O
liquid    O
antibiotic    O
solution    O
used    O
to    O
treat    O
bacterial    O
infections    O
of    O
the    O
ear    O
.    O

In    O
addition    O
,    O
though    O
17α-MP    O
itself    O
was    O
never    O
introduced    O
for    O
medical    O
use    O
,    O
progestogen    O
derivatives    O
of    O
the    O
compound    O
,    O
including    O
medrogestone    B-SteroidHormone114745635
(    O
1966    O
)    O
and    O
the    O
19-norprogesterone    O
derivatives    O
demegestone    O
(    O
1974    O
)    O
,    O
promegestone    O
(    O
1983    O
)    O
,    O
and    O
trimegestone    B-SteroidHormone114745635
(    O
2001    O
)    O
,    O
have    O
been    O
marketed    O
.    O

Trimegestone    B-SteroidHormone114745635

Lidex    B-SteroidHormone114745635

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

Ointment    O
and    O
creams    O
containing    O
coal    O
tar    O
,    O
dithranol    O
,    O
corticosteroids    O
(    O
i.e.    O
desoximetasone    B-SteroidHormone114745635
)    O
,    O
fluocinonide    B-SteroidHormone114745635
,    O
vitamin    O
D3    O
analogs    O
(    O
for    O
example    O
,    O
calcipotriol    O
)    O
,    O
and    O
retinoids    O
are    O
routinely    O
used    O
.    O

Calorie    O
restriction    O
has    O
been    O
shown    O
to    O
increase    O
DHEA    B-SteroidHormone114745635
in    O
primates    O
,    O
but    O
it    O
has    O
not    O
been    O
shown    O
to    O
increase    O
DHEA    B-SteroidHormone114745635
in    O
post    O
-    O
pubescent    O
primates    O
.    O

By    O
inhibiting    O
3β-HSD    O
,    O
epostane    O
blocks    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-SteroidHormone114745635
(    O
and    O
also    O
the    O
conversion    O
of    O
dehydroepiandrosterone    B-SteroidHormone114745635
to    O
androstenedione    B-SteroidHormone114745635
)    O
,    O
thereby    O
functioning    O
as    O
an    O
antiprogestogen    O
and    O
terminating    O
pregnancy    O
.    O

A    O
Δ5    O
-    O
3-ketosteroid    O
isomerase    O
-    O
disrupted    O
mutant    O
of    O
strain    O
TA441    O
can    O
grow    O
on    O
dehydroepiandrosterone    B-SteroidHormone114745635
,    O
which    O
has    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
but    O
can    O
not    O
grow    O
on    O
epiandrosterone    B-SteroidHormone114745635
,    O
which    O
lacks    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
indicating    O
that    O
"    O
C.    O
testosteroni    O
"    O
KSI    O
is    O
responsible    O
for    O
transfer    O
of    O
the    O
double    O
bond    O
from    O
Δ5    O
to    O
Δ4    O
and    O
transfer    O
of    O
the    O
double    O
bond    O
by    O
hydrogenation    O
at    O
Δ5    O
and    O
following    O
dehydrogenation    O
at    O
Δ4    O
is    O
not    O
possible    O
.    O

In    O
vitro    O
"    O
cell    O
proliferation    O
assay    O
indicates    O
that    O
G6PD    O
inhibitors    O
,    O
DHEA    B-SteroidHormone114745635
(    O
dehydroepiandrosterone    O
)    O
and    O
ANAD    O
(    O
6-aminonicotinamide    O
)    O
,    O
effectively    O
decrease    O
the    O
growth    O
of    O
AML    O
cell    O
lines    O
.    O

In    O
December    O
2009    O
,    O
a    O
urine    O
test    O
taken    O
at    O
the    O
2009    O
USPRO    O
Time    O
Trial    O
Championships    O
the    O
previous    O
August    O
,    O
in    O
which    O
Zirbel    O
came    O
second    O
,    O
tested    O
positive    O
for    O
DHEA    B-SteroidHormone114745635
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-SteroidHormone114745635
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    O
,    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

It    O
has    O
been    O
demonstrated    O
that    O
,    O
after    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
larger    O
quantities    O
of    O
DHEA    B-SteroidHormone114745635
and    O
DHEA    O
-    O
S    O
tended    O
to    O
be    O
linked    O
to    O
larger    O
pituitary    O
volume    O
.    O

Again    O
controlling    O
for    O
age    O
,    O
sex    O
,    O
and    O
BMI    O
,    O
DHEA    B-SteroidHormone114745635
and    O
DHEA    O
-    O
S    O
have    O
been    O
found    O
to    O
be    O
predictive    O
of    O
larger    O
pituitary    O
gland    O
volume    O
,    O
which    O
was    O
also    O
associated    O
with    O
increased    O
ratings    O
of    O
social    O
anxiety    O
.    O

Dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
is    O
the    O
most    O
abundant    O
circulating    O
androgen    O
hormone    O
and    O
can    O
be    O
rapidly    O
metabolized    O
within    O
target    O
tissues    O
into    O
potent    O
androgens    O
and    O
estrogens    O
.    O

A    O
small    O
human    O
study    O
in    O
2011    O
found    O
that    O
monitoring    O
blood    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
variations    O
in    O
response    O
to    O
an    O
oxidative    O
stress    O
could    O
be    O
a    O
useful    O
proxy    O
test    O
:    O
the    O
subjects    O
with    O
MCI    O
did    O
not    O
have    O
a    O
DHEA    O
variation    O
,    O
while    O
the    O
healthy    O
controls    O
did    O
.    O

The    O
17α-hydroxylase    O
activity    O
of    O
CYP17A1    O
is    O
required    O
for    O
the    O
generation    O
of    O
glucocorticoids    O
such    O
as    O
cortisol    O
,    O
but    O
both    O
the    O
hydroxylase    O
and    O
17,20-lyase    O
activities    O
of    O
CYP17A1    O
are    O
required    O
for    O
the    O
production    O
of    O
androgenic    O
and    O
oestrogenic    O
sex    O
steroids    O
by    O
converting    O
17α-hydroxypregnenolone    O
to    O
dehydroepiandrosterone    B-SteroidHormone114745635
(DHEA)    I-SteroidHormone114745635
.    O

Other    O
androgens    O
,    O
however    O
,    O
such    O
as    O
DHEA    B-SteroidHormone114745635
,    O
increase    O
immune    O
response    O
.    O

It    O
produces    O
androgens    O
,    O
mainly    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
,    O
DHEA    O
sulfate    O
(    O
DHEA    O
-    O
S    O
)    O
,    O
and    O
androstenedione    B-SteroidHormone114745635
(    O
the    O
precursor    O
to    O
testosterone    O
)    O
in    O
humans    O
.    O

Cells    O
in    O
zona    O
reticularis    O
of    O
the    O
adrenal    O
glands    O
produce    O
male    O
sex    O
hormones    O
,    O
or    O
androgens    O
,    O
the    O
most    O
important    O
of    O
which    O
is    O
DHEA    B-SteroidHormone114745635
.    O

During    O
early    O
childhood    O
androgen    O
synthesis    O
and    O
secretion    O
remain    O
low    O
,    O
but    O
several    O
years    O
before    O
puberty    O
(    O
from    O
6–8    O
years    O
of    O
age    O
)    O
changes    O
occur    O
in    O
both    O
anatomical    O
and    O
functional    O
aspects    O
of    O
cortical    O
androgen    O
production    O
that    O
lead    O
to    O
increased    O
secretion    O
of    O
the    O
steroids    O
DHEA    B-SteroidHormone114745635
and    O
DHEA    O
-    O
S.    O
These    O
changes    O
are    O
part    O
of    O
a    O
process    O
called    O
adrenarche    O
,    O
which    O
has    O
only    O
been    O
described    O
in    O
humans    O
and    O
some    O
other    O
primates    O
.    O

This    O
includes    O
interconversion    O
of    O
DHEA    B-SteroidHormone114745635
and    O
androstenediol    O
,    O
androstenedione    B-SteroidHormone114745635
and    O
testosterone    O
,    O
and    O
estrone    O
and    O
estradiol    O
.    O

The    O
endogenous    O
steroids    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
and    O
its    O
sulfate    O
ester    O
,    O
DHEA    O
sulfate    O
(    O
DHEA    O
-    O
S    O
)    O
,    O
have    O
been    O
identified    O
as    O
small    O
-    O
molecule    O
agonists    O
of    O
the    O
TrkA    O
and    O
p75NTR    O
with    O
high    O
affinity    O
(    O
around    O
5    O
nM    O
)    O
,    O
and    O
hence    O
as    O
so    O
-    O
called    O
"    O
microneurotrophins    O
"    O
.    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-SteroidHormone114745635
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    B-SteroidHormone114745635
from    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

DHEA    B-SteroidHormone114745635
to    O
androstenedione    B-SteroidHormone114745635

Oxabolone    B-SteroidHormone114745635
cipionate    I-SteroidHormone114745635
(    O
Steranabol    O
Depo    O
,    O
Steranabol    O
Ritardo    O
)    O

Examples    O
include    O
testosterone    O
cypionate    O
,    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
,    O
hydrocortisone    O
cypionate    O
,    O
and    O
oxabolone    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
.    O

Magnacort    B-SteroidHormone114745635

The    O
chlorination    O
prevents    O
conversion    O
to    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
while    O
also    O
rendering    O
the    O
chemical    O
incapable    O
of    O
conversion    O
to    O
estrogen    O
.    O

Erectile    O
dysfunction    O
is    O
attributed    O
to    O
the    O
weaker    O
action    O
of    O
DHN    O
in    O
the    O
penis    O
since    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
is    O
a    O
known    O
sexual    O
modulator    O
.    O

This    O
is    O
attributed    O
to    O
the    O
fact    O
that    O
,    O
whereas    O
testosterone    O
is    O
potentiated    O
via    O
conversion    O
into    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
in    O
androgenic    O
tissues    O
,    O
the    O
opposite    O
is    O
true    O
with    O
nandrolone    O
and    O
similar    O
AAS    O
(    O
i.e.    O
,    O
other    O
19-nortestosterone    O
derivatives    O
)    O
.    O

Due    O
to    O
the    O
antiandrogenic    O
effects    O
that    O
result    O
from    O
these    O
actions    O
,    O
it    O
is    O
frequently    O
used    O
off    O
-    O
label    O
to    O
treat    O
a    O
variety    O
of    O
dermatological    O
conditions    O
in    O
which    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
,    O
play    O
a    O
role    O
.    O

Metenolone    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
(    O
brand    O
names    O
Nibal    B-SteroidHormone114745635
Injection    I-SteroidHormone114745635
,    O
Primobolan    B-SteroidHormone114745635
Depot    I-SteroidHormone114745635
)    O
,    O
or    O
methenolone    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
,    O
is    O
an    O
injected    O
anabolic–androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
of    O
the    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
group    O
.    O

The    O
testes    O
begin    O
to    O
secrete    O
three    O
hormones    O
that    O
influence    O
the    O
male    O
internal    O
and    O
external    O
genitalia    O
:    O
they    O
secrete    O
anti    O
-    O
müllerian    O
hormone    O
(    O
AMH    O
)    O
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

The    O
most    O
potent    O
is    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
,    O
generated    O
from    O
testosterone    O
in    O
skin    O
and    O
genital    O
tissue    O
by    O
the    O
action    O
of    O
5α-reductase    O
.    O

This    O
is    O
because    O
testosterone    O
is    O
converted    O
to    O
the    O
more    O
potent    O
DHT    B-SteroidHormone114745635
by    O
5-alpha    O
reductase    O
.    O

EIS    O
is    O
analogous    O
to    O
androgen    O
insensitivity    O
syndrome    O
(    O
AIS    O
)    O
,    O
a    O
condition    O
in    O
which    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
is    O
defective    O
and    O
insensitive    O
to    O
androgens    O
,    O
such    O
as    O
testosterone    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-SteroidHormone114745635
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    O
,    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

Testosterone    O
can    O
be    O
metabolized    O
to    O
17b    O
-    O
estradiol    O
by    O
the    O
enzyme    O
aromatase    O
,    O
or    O
to    O
5-alpha    O
-    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
by    O
5a    O
-    O
reductase    O
.    O

Image    O
:    O
Dihydrotestosterone    B-SteroidHormone114745635

Conversion    O
of    O
testosterone    O
(    O
T    O
)    O
to    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
may    O
be    O
impaired    O
,    O
although    O
to    O
a    O
lesser    O
extent    O
than    O
is    O
seen    O
in    O
5α-reductase    O
deficiency    O
.    O

DHT    B-SteroidHormone114745635
(dihydrotestosterone)    I-SteroidHormone114745635

Dihydrotestosterone    B-SteroidHormone114745635
(DHT)    I-SteroidHormone114745635

Beard    O
growth    O
is    O
linked    O
to    O
stimulation    O
of    O
hair    O
follicles    O
in    O
the    O
area    O
by    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
,    O
which    O
continues    O
to    O
affect    O
beard    O
growth    O
after    O
puberty    O
.    O

Finasteride    O
and    O
dutasteride    O
,    O
which    O
are    O
5α-reductase    O
inhibitors    O
and    O
inhibit    O
the    O
production    O
of    O
the    O
potent    O
androgen    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

|    O
|    O
Dihydrotestosterone    B-SteroidHormone114745635

All    O
sublines    O
were    O
treated    O
with    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
,    O
a    O
high    O
-    O
affinity    O
ligand    O
for    O
AR    O
.    O

In    O
addition    O
,    O
some    O
have    O
a    O
high    O
risk    O
of    O
gynecomastia    O
due    O
to    O
uniquely    O
high    O
estrogenic    O
activity    O
,    O
although    O
this    O
does    O
not    O
apply    O
to    O
17α-alkylated    O
AAS    O
that    O
are    O
also    O
4,5α-reduced    O
or    O
19-demethylated    O
(    O
i.e.    O
,    O
that    O
are    O
also    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
or    O
nandrolone    O
derivatives    O
,    O
respectively    O
)    O
.    O

In    O
general    O
,    O
these    O
hormones    O
do    O
not    O
have    O
an    O
overall    O
effect    O
in    O
the    O
male    O
body    O
,    O
and    O
are    O
converted    O
to    O
more    O
potent    O
androgens    O
such    O
as    O
testosterone    O
and    O
DHT    B-SteroidHormone114745635
or    O
to    O
estrogens    O
(    O
female    O
sex    O
hormones    O
)    O
in    O
the    O
gonads    O
,    O
acting    O
in    O
this    O
way    O
as    O
a    O
metabolic    O
intermediate    O
.    O

Metenolone    B-SteroidHormone114745635
,    O
or    O
methenolone    B-SteroidHormone114745635
,    O
also    O
known    O
as    O
methylandrostenolone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

Metenolone    O
,    O
also    O
known    O
as    O
1-methyl-4,5α-dihydro-δ1-testosterone    O
(    O
1-methyl-δ1-DHT    O
)    O
or    O
as    O
1-methyl-5α-androst-1-en-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
androstane    O
steroid    O
and    O
derivative    O
of    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

Dihydrotestosterone    B-SteroidHormone114745635
↔    O
5α-Androstanedione    O
/    O
3α-Androstanediol    O
/    O
3β-Androstanediol    O

Halobetasol    B-SteroidHormone114745635
propionate    O
0.05%    O
(    O
Ultravate    O
,    O
Halox    O
)    O

The    O
antihistamine    O
azelastine    O
,    O
applied    O
as    O
a    O
nasal    O
spray    O
,    O
may    O
be    O
effective    O
for    O
vasomotor    O
rhinitis    O
.    O
Fluticasone    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
or    O
budesonide    B-SteroidHormone114745635
(    O
both    O
are    O
steroids    O
)    O
in    O
nostril    O
spray    O
form    O

Fluticasone    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
C25H31F3O5S    O

A    O
variety    O
of    O
steroid    O
medications    O
,    O
from    O
anti    O
-    O
allergy    O
nasal    O
sprays    O
(    O
Nasonex    B-SteroidHormone114745635
,    O
Flonase    B-SteroidHormone114745635
)    O
to    O
topical    O
skin    O
creams    O
,    O
to    O
eye    O
drops    O
(    O
Tobradex    O
)    O
,    O
to    O
prednisone    O
have    O
been    O
implicated    O
in    O
the    O
development    O
of    O
CSR    O
.    O

Fluticasone    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635

A    O
brand    O
name    O
of    O
co-cyprindiol    B-SteroidHormone114745635
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O
,    O
an    O
oral    O
contraceptive    O

Cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

A    O
phase    O
III    O
clinical    O
trial    O
comparing    O
high    O
-    O
dose    O
intramuscular    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
300    O
mg    O
/    O
week    O
)    O
and    O
high    O
-    O
dose    O
intramuscular    O
estradiol    O
undecylate    O
(    O
100    O
mg    O
/    O
month    O
)    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
found    O
that    O
estradiol    O
undecylate    O
suppressed    O
testosterone    O
levels    O
into    O
the    O
castrate    O
range    O
(    O
<    O
50    O
ng    O
/    O
dL    O
)    O
within    O
at    O
least    O
3    O
months    O
whereas    O
testosterone    O
levels    O
with    O
cyproterone    O
acetate    O
were    O
significantly    O
higher    O
and    O
above    O
the    O
castrate    O
range    O
even    O
after    O
6    O
months    O
of    O
treatment    O
.    O

Spironolactone    O
is    O
frequently    O
used    O
as    O
a    O
component    O
of    O
hormone    O
replacement    O
therapy    O
in    O
transgender    O
women    O
,    O
especially    O
in    O
the    O
United    O
States    O
(    O
where    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
is    O
not    O
available    O
)    O
,    O
usually    O
in    O
addition    O
to    O
an    O
estrogen    O
.    O

Spironolactone    O
,    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
flutamide    O
are    O
some    O
of    O
the    O
most    O
well    O
-    O
known    O
and    O
widely    O
used    O
drugs    O
.    O

Spironolactone    O
,    O
similarly    O
to    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
is    O
actually    O
not    O
a    O
pure    O
,    O
or    O
"    O
silent    O
"    O
,    O
antagonist    O
of    O
the    O
AR    O
,    O
but    O
rather    O
is    O
a    O
weak    O
partial    O
agonist    O
with    O
the    O
capacity    O
for    O
both    O
antagonistic    O
and    O
agonistic    O
effects    O
.    O

Unlike    O
other    O
steroidal    O
antiandrogens    O
such    O
as    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
CPA    O
)    O
,    O
it    O
is    O
not    O
also    O
a    O
progestogen    O
,    O
instead    O
acting    O
as    O
a    O
selective    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonist    O
similarly    O
to    O
nonsteroidal    O
antiandrogens    O
such    O
as    O
bicalutamide    O
.    O

The    O
binding    O
affinity    O
of    O
oxendolone    O
for    O
the    O
AR    O
is    O
far    O
lower    O
than    O
that    O
of    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

A    O
brand    O
name    O
of    O
the    O
oral    O
contraceptive    O
co-cyprindiol    B-SteroidHormone114745635
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogen    B-SteroidHormone114745635
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
)    O
.    O

Cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
:    O
A    O
dual    O
antiandrogen    O
and    O
progestogen    O
.    O

A    O
brand    O
name    O
of    O
co-cyprindiol    B-SteroidHormone114745635
(    O
cyproterone    O
acetate    O
/    O
ethinylestradiol    O
)    O
,    O
an    O
oral    O
contraceptive    O

Dimethisterone    O
(    O
INN    O
,    O
USAN    O
,    O
BAN    O
)    O
(    O
brand    O
names    O
Lutagan    O
,    O
Secrosteron    O
)    O
,    O
also    O
known    O
as    O
6α,21-dimethylethisterone    O
,    O
is    O
a    O
steroidal    O
progestin    O
related    O
to    O
ethisterone    B-SteroidHormone114745635
(    O
17α-ethinyltestosterone    O
)    O
.    O

ethisterone    B-SteroidHormone114745635
(    O
INN    O
)    O

Nandrolone    O
,    O
together    O
with    O
ethisterone    B-SteroidHormone114745635
(    O
17α-ethynyltestosterone    O
)    O
,    O
is    O
also    O
the    O
parent    O
compound    O
of    O
a    O
large    O
group    O
of    O
progestins    O
,    O
the    O
norethisterone    B-SteroidHormone114745635
(    O
17α-ethynyl-19-nortestosterone    O
)    O
derivatives    O
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-SteroidHormone114745635
,    O
Ethisterone    B-SteroidHormone114745635
,    O
and    O
Lynestrenol    B-SteroidHormone114745635
.    O

Conversely    O
,    O
replacement    O
of    O
the    O
C17α    O
alkyl    O
group    O
with    O
an    O
ethynyl    O
group    O
greatly    O
reduces    O
but    O
does    O
not    O
abolish    O
androgenic    O
activity    O
,    O
as    O
in    O
ethisterone    B-SteroidHormone114745635
(    O
17α-ethynyltestosterone    O
)    O
and    O
norethisterone    B-SteroidHormone114745635
(    O
17α-ethynyl-19-nortestosterone    O
)    O
.    O

The    O
functional    O
opposite    O
of    O
EIS    O
is    O
hyperestrogenism    B-SteroidHormone114745635
,    O
for    O
instance    O
that    O
seen    O
in    O
aromatase    B-SteroidHormone114745635
excess    I-SteroidHormone114745635
syndrome    I-SteroidHormone114745635
.    O

Hyperestrogenism    B-SteroidHormone114745635

Fluclorolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
(    O
flucloronide    O
)    O
=    O
6α-fluoro-9α,11β-dichloro-16α,17α,21-trihydroxypregna-1,4-dien-3,20-dione    O
cyclic    O
16α,17α-acetal    O
with    O
acetone    O

Starting    O
in    O
2011    O
,    O
POGO    O
conducted    O
an    O
investigation    O
into    O
conflicts    O
of    O
interest    O
of    O
an    O
advisory    O
committee    O
at    O
the    O
Food    O
and    O
Drug    O
Administration    O
that    O
was    O
reviewing    O
the    O
Yaz    O
and    O
Yasmin    B-SteroidHormone114745635
birth    O
control    O
pills    O
.    O

Drospirenone    B-SteroidHormone114745635

This    O
was    O
determined    O
to    O
be    O
due    O
to    O
metabolic    O
conversion    O
of    O
spirorenone    O
into    O
drospirenone    B-SteroidHormone114745635
(    O
1,2-dihydrospirorenone    O
)    O
by    O
the    O
enzyme    O
Δ1-hydrase    O
,    O
a    O
transformation    O
that    O
occurs    O
only    O
in    O
monkeys    O
and    O
humans    O
.    O

Spironolactone    O
is    O
closely    O
structurally    O
related    O
to    O
other    O
clinically    O
used    O
spirolactones    O
such    O
as    O
canrenone    O
,    O
potassium    O
canrenoate    O
,    O
drospirenone    B-SteroidHormone114745635
,    O
and    O
eplerenone    B-SteroidHormone114745635
,    O
as    O
well    O
as    O
to    O
the    O
never    O
-    O
marketed    O
spirolactones    O
SC-5233    O
(    O
6,7-dihydrocanrenone    O
;    O
7α-desthioacetylspironolactone    O
)    O
,    O
SC-8109    O
(    O
19-nor-6,7-dihydrocanrenone    O
)    O
,    O
spiroxasone    O
,    O
prorenone    O
(    O
SC-23133    O
)    O
,    O
mexrenone    O
(    O
SC-25152    O
,    O
ZK-32055    O
)    O
,    O
dicirenone    O
(    O
SC-26304    O
)    O
,    O
spirorenone    O
(    O
ZK-35973    O
)    O
,    O
and    O
mespirenone    O
(    O
ZK-94679    O
)    O
.    O

Some    O
,    O
such    O
as    O
those    O
containing    O
cyproterone    O
acetate    O
or    O
drospirenone    B-SteroidHormone114745635
,    O
also    O
have    O
additional    O
direct    O
antiandrogen    O
activity    O
.    O

A    O
new    O
4th    O
generation    O
progestin    O
,    O
drospirenone    B-SteroidHormone114745635
,    O
used    O
in    O
some    O
oral    O
contraceptives    O
may    O
further    O
heighten    O
the    O
risk    O
of    O
gallstone    O
disease    O
and    O
cholecystectomy    O
;    O
however    O
,    O
the    O
increased    O
risk    O
is    O
quite    O
modest    O
and    O
not    O
likely    O
to    O
be    O
clinically    O
meaningful    O
.    O

4-Hydroxytestosterone    B-SteroidHormone114745635
(    O
4-OHT    B-SteroidHormone114745635
)    O
,    O
also    O
known    O
as    O
4,17β-dihydroxyandrost-4-en-3-one    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
testosterone    O
that    O
was    O
never    O
marketed    O
.    O

For    O
those    O
who    O
are    O
unresponsive    O
to    O
somatostatin    O
analogues    O
,    O
or    O
for    O
whom    O
they    O
are    O
otherwise    O
contraindicated    O
,    O
it    O
is    O
possible    O
to    O
treat    O
using    O
one    O
of    O
the    O
dopamine    O
agonists    O
,    O
bromocriptine    O
or    O
cabergoline    B-SteroidHormone114745635
.    O

Cabergoline    B-SteroidHormone114745635
is    O
derived    O
from    O
a    O
number    O
of    O
ergot    O
alkaloids    O
one    O
of    O
which    O
is    O
lysergic    O
acid    O
and    O
Simvastatin    O
is    O
based    O
on    O
Lovastatin    O
.    O

Dopamine    O
agonists    O
include    O
bromocriptine    O
,    O
pergolide    O
,    O
pramipexole    O
,    O
ropinirole    O
,    O
piribedil    O
,    O
cabergoline    B-SteroidHormone114745635
,    O
apomorphine    O
and    O
lisuride    O
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    B-SteroidHormone114745635
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    O
increase    O
prolactin    O
levels    O
.    O

Prolactinomas    O
are    O
most    O
often    O
treated    O
with    O
cabergoline    B-SteroidHormone114745635
or    O
quinagolide    O
(    O
both    O
dopamine    O
agonists    O
)    O
,    O
which    O
decrease    O
tumor    O
size    O
as    O
well    O
as    O
alleviates    O
symptoms    O
,    O
followed    O
by    O
serial    O
imaging    O
to    O
detect    O
any    O
increase    O
in    O
size    O
.    O

Another    O
chemical    O
which    O
is    O
considered    O
to    O
be    O
responsible    O
for    O
the    O
male    O
refractory    O
period    O
is    O
prolactin    O
,    O
which    O
represses    O
dopamine    O
,    O
which    O
is    O
responsible    O
for    O
sexual    O
arousal    O
.    O
Because    O
of    O
this    O
,    O
there    O
is    O
currently    O
an    O
experimental    O
interest    O
in    O
drugs    O
which    O
inhibit    O
prolactin    O
,    O
such    O
as    O
cabergoline    B-SteroidHormone114745635
(    O
also    O
known    O
as    O
Cabeser    O
,    O
or    O
Dostinex    O
)    O
.    O

Cabergoline    B-SteroidHormone114745635

Fluperolone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

Cinchocaine    O
is    O
the    O
active    O
ingredient    O
in    O
some    O
topical    O
hemorrhoid    O
creams    O
such    O
as    O
Proctosedyl    B-SteroidHormone114745635
.    O

include    O
,    O
megestrol    O
acetate    O
,    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
spironolactone    O
.    O

A    O
variety    O
of    O
analogues    O
of    O
medroxyprogesterone    O
acetate    O
,    O
such    O
as    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
megestrol    O
acetate    O
,    O
were    O
subsequently    O
developed    O
and    O
introduced    O
as    O
well    O
.    O

In    O
1969    O
,    O
along    O
with    O
a    O
variety    O
of    O
other    O
progestogens    O
including    O
progesterone    O
,    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
megestrol    O
acetate    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
ethynerone    O
,    O
and    O
chloroethynyl    O
norgestrel    O
,    O
anagestone    O
acetate    O
was    O
found    O
to    O
induce    O
the    O
development    O
of    O
mammary    O
gland    O
tumors    O
in    O
Beagle    O
dogs    O
after    O
extensive    O
treatment    O
(    O
2–7    O
years    O
)    O
with    O
very    O
high    O
doses    O
(    O
10–25    O
times    O
the    O
recommended    O
human    O
dose    O
)    O
,    O
though    O
notably    O
not    O
with    O
1–2    O
times    O
the    O
human    O
dosage    O
.    O

Subsequent    O
investigation    O
found    O
that    O
17α-hydroxyprogesterone    O
derivatves    O
included    O
anagestone    O
acetate    O
,    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
megestrol    O
acetate    O
produced    O
similar    O
mammary    O
gland    O
tumors    O
,    O
and    O
that    O
their    O
ability    O
to    O
do    O
so    O
correlated    O
directly    O
with    O
their    O
progestogenic    O
actions    O
.    O

It    O
is    O
a    O
17α-hydroxyprogesterone    O
derivative    O
and    O
a    O
derivative    O
of    O
the    O
less    O
potent    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Ciclesonide    B-SteroidHormone114745635
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
aceponate    I-SteroidHormone114745635
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
buteprate    I-SteroidHormone114745635
,    O
hydrocortisone    B-SteroidHormone114745635
butyrate    I-SteroidHormone114745635
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-SteroidHormone114745635
,    O
and    O
tixocortol    B-SteroidHormone114745635
pivalate    I-SteroidHormone114745635
.    O

Gestaclone    B-SteroidHormone114745635
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
SH-1040    B-SteroidHormone114745635
)    O
,    O
also    O
known    O
as    O
6-chloro-1α,2α:16α,17-"bis"methylene-4,6-pregnadiene-3,20-dione    B-SteroidHormone114745635
,    O
is    O
a    O
steroidal    O
progestin    O
of    O
unique    O
chemical    O
structure    O
derived    O
from    O
progesterone    O
that    O
was    O
first    O
described    O
in    O
1967    O
and    O
was    O
never    O
marketed    O
.    O

As    O
the    O
sodium    O
salt    O
,    O
sodium    O
estradiol    O
sulfate    O
,    O
E2S    O
is    O
present    O
as    O
a    O
minor    O
constituent    O
(    O
0.9%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
CEEs    O
)    O
,    O
or    O
Premarin    B-SteroidHormone114745635
.    O

Later    O
,    O
the    O
scientists    O
helped    O
form    O
the    O
company    O
Ayerst    O
,    O
McKenna    O
and    O
Harrison    O
,    O
Ltd    O
(    O
later    O
,    O
Wyeth    O
)    O
who    O
marketed    O
Premarin    B-SteroidHormone114745635
,    O
a    O
controversial    O
HRT    O
drug    O
based    O
on    O
pregnant    O
mare    O
's    O
urine    O
.    O

Pregnant    B-SteroidHormone114745635
mare    I-SteroidHormone114745635
urine    I-SteroidHormone114745635

17β-Dihydroequilin    O
,    O
or    O
β-dihydroequilin    O
,    O
also    O
known    O
as    O
7-dehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),7-tetraen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.7%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

17α-Dihydroequilenin    O
,    O
or    O
α-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17α-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17α-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
17α-estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
1.2%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

17β-Dihydroequilenin    O
,    O
or    O
β-dihydroequilenin    O
,    O
also    O
known    O
as    O
6,8-didehydro-17β-estradiol    O
,    O
as    O
well    O
as    O
estra-1,3,5(10),6,8-pentaen-3,17β-diol    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estradiol    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
0.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

8,9-Dehydroestrone    O
,    O
or    O
Δ8-estrone    O
,    O
also    O
known    O
as    O
estra-1,3,5(10),8-tetraen-3-ol-17-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroidal    O
estrogen    O
found    O
in    O
horses    O
that    O
is    O
closely    O
related    O
to    O
equilin    B-SteroidHormone114745635
,    O
equilenin    B-SteroidHormone114745635
,    O
and    O
estrone    O
,    O
and    O
,    O
as    O
the    O
3-sulfate    O
ester    O
sodium    O
salt    O
,    O
is    O
a    O
minor    O
constituent    O
(    O
3.5%    O
)    O
of    O
conjugated    O
equine    O
estrogens    O
(    O
Premarin    B-SteroidHormone114745635
)    O
.    O

South    O
Korea    O
originally    O
won    O
the    O
bronze    O
medal    O
,    O
but    O
was    O
later    O
disqualified    O
after    O
Park    O
Tae    O
-    O
hwan    O
tested    O
positive    O
for    O
Nebido    B-SteroidHormone114745635
.    O

South    O
Korea    O
originally    O
won    O
the    O
bronze    O
medal    O
,    O
but    O
was    O
later    O
disqualified    O
after    O
Park    O
Tae    O
-    O
hwan    O
tested    O
positive    O
for    O
Nebido    B-SteroidHormone114745635
.    O

Park    O
Tae    O
-    O
hwan    O
of    O
South    O
Korea    O
originally    O
won    O
the    O
bronze    O
medal    O
,    O
but    O
was    O
later    O
disqualified    O
after    O
he    O
tested    O
positive    O
for    O
Nebido    B-SteroidHormone114745635
.    O

Along    O
with    O
testosterone    O
cypionate    O
,    O
testosterone    O
enanthate    O
,    O
testosterone    O
propionate    O
,    O
and    O
testosterone    B-SteroidHormone114745635
undecanoate    I-SteroidHormone114745635
,    O
testosterone    O
buciclate    O
is    O
one    O
of    O
the    O
most    O
studied    O
testosterone    O
esters    O
.    O

Testosterone    O
buciclate    O
also    O
lasts    O
longer    O
than    O
testosterone    B-SteroidHormone114745635
undecanoate    I-SteroidHormone114745635
,    O
which    O
has    O
elimination    O
half    O
-    O
lives    O
and    O
mean    O
residence    O
times    O
of    O
20.9    O
days    O
and    O
34.9    O
days    O
in    O
tea    O
seed    O
oil    O
and    O
33.9    O
days    O
and    O
36.0    O
days    O
in    O
castor    O
oil    O
,    O
respectively    O
.    O

Phytoestrogen    B-SteroidHormone114745635
,    O
plant    O
compounds    O
with    O
estrogen    O
-    O
like    O
biological    O
activity    O
,    O
such    O
as    O
genistein    B-SteroidHormone114745635
,    O
formononetin    B-SteroidHormone114745635
,    O
biochanin    O
A    O
and    O
daidzein    O
,    O
as    O
well    O
as    O
a    O
mixture    O
of    O
these    O
phytoestrogens    O
were    O
found    O
able    O
to    O
reduce    O
E    O
-    O
selectin    O
as    O
well    O
as    O
VCAM-1    O
and    O
ICAM-1    O
on    O
cell    O
surface    O
and    O
in    O
culture    O
supernatant    O
.    O

Formononetin    B-SteroidHormone114745635

Unlike    O
5α-dihydroprogesterone    O
,    O
5β-DHP    O
does    O
not    O
possess    O
affinity    O
for    O
the    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
hence    O
,    O
is    O
not    O
a    O
progestogen    O
.    O

One    O
example    O
of    O
this    O
is    O
the    O
loss    O
of    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
upon    O
anti    O
-    O
estrogen    O
treatment    O
of    O
breast    O
cancer    O

It    O
binds    O
to    O
the    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
with    O
approximately    O
22%    O
of    O
the    O
affinity    O
of    O
progesterone    O
.    O

Progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
agonist    O

It    O
binds    O
to    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
(    O
Ki    O
=    O
320    O
nM    O
)    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
Ki    O
=    O
20    O
nM    O
)    O
and    O
acts    O
as    O
a    O
weak    O
but    O
clinically    O
relevant    O
inhibitor    O
of    O
5α-reductase    O
(    O
IC50    O
=    O
1.4    O
μM    O
)    O
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
partial    O
agonist    O
(    O
Ki    O
=    O
201    O
nM    O
)    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    B-SteroidHormone114745635
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    B-SteroidHormone114745635
and    O
antiprogestogen    O
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

In    O
general    O
,    O
ERs    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PRs    O
)    O
are    O
gene    O
activators    O
,    O
with    O
increased    O
mRNA    O
and    O
subsequent    O
protein    O
synthesis    O
following    O
hormone    O
exposure    O
.    O

NOMAC    O
is    O
a    O
potent    O
and    O
pure    O
progestogen    O
,    O
acting    O
as    O
a    O
selective    O
,    O
high    O
-    O
affinity    O
full    O
agonist    O
of    O
the    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
(    O
Ki    O
=    O
3    O
nM    O
,    O
67–303%    O
of    O
the    O
of    O
progesterone    O
)    O
,    O
and    O
is    O
said    O
to    O
have    O
higher    O
potency    O
and    O
substantially    O
improved    O
selectivity    O
for    O
the    O
PR    O
relative    O
to    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
the    O
6-hydrogenated    O
or    O
non-6    O
-    O
7-double    O
bonded    O
analogue    O
of    O
megestrol    O
acetate    O
and    O
the    O
most    O
widely    O
used    O
progestin    O
)    O
.    O

Women    O
affected    O
with    O
triple    O
negative    O
breast    O
cancer    O
(    O
TNBC    O
)    O
(    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
negative    O
,    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
negative    O
,    O
and    O
HER2/neu    O
negative    O
)    O
under    O
the    O
age    O
of    O
50    O

As    O
a    O
SPRM    O
,    O
ulipristal    O
acetate    O
has    O
partial    O
agonistic    O
as    O
well    O
as    O
antagonistic    O
effects    O
on    O
the    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

It    O
has    O
been    O
found    O
to    O
possess    O
slightly    O
lower    O
affinity    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
relative    O
to    O
nandrolone    O
in    O
rat    O
and    O
rabbit    O
tissue    O
bioassays    O
,    O
whereas    O
trenbolone    O
was    O
found    O
to    O
possess    O
the    O
same    O
affinity    O
for    O
the    O
AR    O
as    O
dienolone    O
but    O
several    O
-    O
fold    O
increased    O
affinity    O
for    O
the    O
PR    O
.    O

It    O
contains    O
10    O
NR    O
-    O
interacting    O
boxes    O
(    O
LXXLL    O
motifs    O
)    O
and    O
functions    O
as    O
a    O
coregulator    O
of    O
several    O
nuclear    O
receptors    O
via    O
its    O
LXXLL    O
motifs    O
including    O
ESR1    O
,    O
ESR2    O
,    O
ERR    O
-    O
alpha    O
,    O
PR    B-SteroidHormone114745635
,    O
GR    B-SteroidHormone114745635
,    O
AR    B-SteroidHormone114745635
,    O
and    O
RXR    O
.    O

In    O
addition    O
,    O
JDP2    O
has    O
been    O
shown    O
to    O
directly    O
associate    O
with    O
the    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
and    O
functionally    O
acts    O
as    O
a    O
coactivator    O
of    O
progesterone    O
-    O
dependent    O
PR    O
-    O
mediated    O
gene    O
transcription    O
.    O

The    O
"    O
O    O
"-    O
acetate    O
ester    O
of    O
cloxotestosterone    O
,    O
cloxotestosterone    O
acetate    O
(    O
brand    O
name    O
Caprosem    B-SteroidHormone114745635
)    O
,    O
in    O
contrast    O
to    O
cloxotestosterone    O
,    O
has    O
been    O
marketed    O
.    O

Mebolazine    B-SteroidHormone114745635
(dimethazine,    I-SteroidHormone114745635
dymethazine)    I-SteroidHormone114745635

Barrios    O
originally    O
finished    O
4th    O
in    O
the    O
2012    O
Summer    O
Olympics    O
,    O
but    O
she    O
moved    O
up    O
a    O
position    O
after    O
Darya    O
Pishchalnikova    O
was    O
disqualified    O
for    O
testing    O
positive    O
for    O
the    O
anabolic    O
steroid    O
oxandrolone    B-SteroidHormone114745635
.    O

On    O
1    O
May    O
2013    O
,    O
the    O
IOC    O
stripped    O
Russian    O
discus    O
thrower    O
Darya    O
Pishchalnikova    O
of    O
her    O
silver    O
medal    O
in    O
the    O
women    O
's    O
discus    O
throw    O
after    O
testing    O
positive    O
for    O
Oxandrolone    B-SteroidHormone114745635
(    O
an    O
anabolic    O
steroid    O
)    O
.    O

However    O
,    O
the    O
validity    O
of    O
her    O
record    O
and    O
title    O
was    O
called    O
into    O
question    O
by    O
a    O
positive    O
blood    O
test    O
result    O
for    O
the    O
banned    O
steroids    O
oxandrolone    B-SteroidHormone114745635
and    O
stanozolol    B-SteroidHormone114745635
,    O
and    O
she    O
was    O
"    O
provisionally    O
suspended    O
"    O
by    O
the    O
International    O
Weightlifting    O
Federation    O
.    O

In    O
June    O
2016    O
,    O
IWF    O
announced    O
that    O
retests    O
of    O
the    O
samples    O
taken    O
from    O
the    O
2012    O
Olympics    O
indicated    O
that    O
Zulfiya    O
Chinshanlo    O
had    O
tested    O
positive    O
for    O
prohibited    O
substances    O
,    O
namely    O
Oxandrolone    B-SteroidHormone114745635
and    O
Stanazolol    B-SteroidHormone114745635
.    O

Anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
like    O
oxandrolone    B-SteroidHormone114745635
may    O
be    O
beneficial    O
in    O
cancer    O
cachexia    O
but    O
their    O
use    O
is    O
recommended    O
for    O
maximal    O
2    O
weeks    O
since    O
a    O
longer    O
duration    O
of    O
treatment    O
increases    O
the    O
burden    O
from    O
side    O
effects    O
.    O

Oxandrolone    B-SteroidHormone114745635

Oxandrolone    B-SteroidHormone114745635

The    O
infamous    O
"    O
duchess    O
"    O
cocktail    O
administered    O
to    O
Russian    O
athletes    O
at    O
the    O
Sochi    O
Winter    O
Olympics    O
consisted    O
of    O
oxandrolone    B-SteroidHormone114745635
,    O
metenolone    O
,    O
and    O
trenbolone    B-SteroidHormone114745635
.    O

Flunisolide    B-SteroidHormone114745635

Flunisolide    B-SteroidHormone114745635

Betamethasone    B-SteroidHormone114745635
,    O
betamethasone    O
sodium    O
phosphate    O
,    O
dexamethasone    O
,    O
dexamethasone    O
sodium    O
phosphate    O
,    O
and    O
fluocortolone    B-SteroidHormone114745635

Beclometasone    O
,    O
betamethasone    B-SteroidHormone114745635
,    O
dexamethasone    O
,    O
fluocortolone    B-SteroidHormone114745635
,    O
halometasone    B-SteroidHormone114745635
,    O
and    O
mometasone    O
.    O

Desoxymethyltestosterone    B-SteroidHormone114745635

Desoxymethyltestosterone    B-SteroidHormone114745635
(DMT)    I-SteroidHormone114745635

Corticosteroids    O
such    O
as    O
prednisolone    O
and    O
deflazacort    B-SteroidHormone114745635
lead    O
to    O
short    O
-    O
term    O
improvements    O
in    O
muscle    O
strength    O
and    O
function    O
up    O
to    O
2    O
years    O
.    O

Benorterone    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
names    O
SKF-7690    O
,    O
FC-612    O
)    O
,    O
also    O
known    O
as    O
17α-methyl    O
-    O
B    O
-    O
nortestosterone    O
,    O
is    O
a    O
steroidal    O
,    O
pure    O
antiandrogen    B-SteroidHormone114745635
that    O
was    O
never    O
marketed    O
.    O

Delanterone    O
(    O
INN    O
)    O
(    O
developmental    O
code    O
name    O
GBR-21162    O
)    O
,    O
also    O
known    O
as    O
1α-methylandrosta-4,16-dien-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
described    O
as    O
an    O
anti    O
-    O
acne    O
agent    O
which    O
was    O
never    O
marketed    O
.    O

Metogest    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
SC-14207    O
)    O
,    O
also    O
known    O
as    O
16,16-dimethyl-19-nortestosterone    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
that    O
was    O
patented    O
in    O
1975    O
and    O
investigated    O
as    O
a    O
treatment    O
for    O
acne    O
but    O
was    O
never    O
marketed    O
.    O

Nordinone    O
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
11α-hydroxy-17,17-dimethyl-18-norandrosta-4,13-dien-3-one    O
,    O
is    O
a    O
naturally    O
occurring    O
steroid    O
with    O
antiandrogen    B-SteroidHormone114745635
properties    O
isolated    O
as    O
a    O
metabolite    O
from    O
the    O
fungus    O
"    O
Monocillium    O
nordinii    O
"    O
.    O

Osaterone    O
acetate    O
(    O
brand    O
name    O
Ypozane    O
;    O
former    O
developmental    O
code    O
name    O
TZP-4238    O
)    O
,    O
also    O
known    O
as    O
17α-acetoxy-6-chloro-2-oxa-6-dehydroprogesterone    O
,    O
as    O
well    O
as    O
2-oxachloromadinone    O
acetate    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
and    O
progestogen    O
used    O
in    O
veterinary    O
medicine    O
in    O
Europe    O
in    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
in    O
dogs    O
.    O

Oxendolone    O
(    O
INN    O
,    O
USAN    O
,    O
JAN    O
)    O
(    O
brand    O
names    O
Prostetin    O
,    O
Roxenone    O
;    O
former    O
developmental    O
code    O
name    O
TSAA-291    O
)    O
,    O
also    O
known    O
as    O
16β-ethyl-19-nortestosterone    O
or    O
16β-ethylestr-4-en-17β-ol-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
and    O
progestin    O
of    O
the    O
19-nortestosterone    O
group    O
that    O
has    O
been    O
marketed    O
in    O
Japan    O
by    O
Takeda    O
for    O
the    O
treatment    O
of    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
since    O
1981    O
.    O

Rosterolone    O
(    O
INN    O
)    O
(    O
developmental    O
code    O
name    O
SH-434    O
)    O
,    O
also    O
known    O
as    O
17α-propylmesterolone    O
or    O
1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
that    O
was    O
first    O
reported    O
in    O
1984    O
and    O
was    O
developed    O
for    O
topical    O
administration    O
but    O
was    O
never    O
marketed    O
.    O

Topterone    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
name    O
WIN-17665    O
)    O
,    O
also    O
known    O
as    O
17α-propyltestosterone    O
or    O
17α-propylandrost-4-en-17β-ol-3-one    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
that    O
was    O
first    O
reported    O
in    O
1978    O
and    O
was    O
developed    O
for    O
topical    O
administration    O
but    O
,    O
due    O
to    O
poor    O
effectiveness    O
,    O
was    O
never    O
marketed    O
.    O

Zanoterone    O
(    O
INN    O
,    O
USAN    O
)    O
(    O
former    O
developmental    O
codename    O
WIN-49596    O
)    O
,    O
also    O
known    O
as    O
(    O
5α,17α)-1'-(methylsulfonyl)-1'-H    O
-    O
pregn-20-yno[3,2-c]pyrazol-17-ol    O
,    O
is    O
a    O
steroidal    O
antiandrogen    B-SteroidHormone114745635
that    O
was    O
never    O
marketed    O
.    O

Relative    O
to    O
spironolactone    O
,    O
it    O
has    O
markedly    O
reduced    O
antiandrogen    B-SteroidHormone114745635
activity    O
(    O
approximately    O
one    O
-    O
tenth    O
of    O
the    O
antimineralocorticoid    O
dosage    O
equivalent    O
antiandrogen    O
activity    O
of    O
spironolactone    O
)    O
.    O

As    O
testosterone    O
surge    O
does    O
not    O
occur    O
with    O
GnRH    O
antagonists    O
,    O
there    O
is    O
no    O
need    O
for    O
patients    O
to    O
receive    O
an    O
antiandrogen    B-SteroidHormone114745635
as    O
flare    O
protection    O
during    O
prostate    O
cancer    O
treatment    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    B-SteroidHormone114745635
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    B-SteroidHormone114745635
and    O
antiprogestogen    O
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogens    O
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    O
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogen    B-SteroidHormone114745635
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    B-SteroidHormone114745635
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    B-SteroidHormone114745635
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

In    O
accordance    O
,    O
NOMAC    O
is    O
a    O
potent    O
antigonadotropin    O
and    O
exhibits    O
no    O
androgenic    O
,    O
estrogenic    O
,    O
glucocorticoid    O
,    O
or    O
antimineralocorticoid    O
activity    O
,    O
but    O
does    O
possess    O
some    O
antiandrogen    B-SteroidHormone114745635
activity    O
(    O
see    O
below    O
)    O
.    O

NOMAC    O
has    O
weak    O
or    O
moderate    O
antiandrogen    B-SteroidHormone114745635
activity    O
(    O
5    O
to    O
20    O
times    O
less    O
than    O
that    O
of    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
a    O
strong    O
antiandrogen    O
)    O
,    O
with    O
approximately    O
12–31%    O
of    O
the    O
of    O
testosterone    O
for    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
)    O
.    O

Medications    O
consist    O
mostly    O
of    O
antiandrogen    B-SteroidHormone114745635
and    O
include    O
:    O

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    B-SteroidHormone114745635
,    O
as    O
in    O
topterone    O
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-SteroidHormone114745635
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    B-SteroidHormone114745635
)    O
.    O

In    O
contrast    O
,    O
dienogest    B-SteroidHormone114745635
,    O
the    O
17α-cyanomethyl    O
derivative    O
of    O
dienolone    O
,    O
is    O
a    O
potent    O
progestogen    O
and    O
antiandrogen    B-SteroidHormone114745635
.    O

Analogues    O
with    O
longer    O
C17α    O
chains    O
such    O
as    O
propyltestosterone    O
(    O
topterone    O
)    O
have    O
further    O
greatly    O
reduced    O
androgenic    O
activity    O
or    O
even    O
antiandrogen    B-SteroidHormone114745635
activity    O
.    O

It    O
did    O
,    O
however    O
,    O
show    O
some    O
androgenic    O
and    O
antiandrogen    B-SteroidHormone114745635
activity    O
"    O
in    O
vitro    O
"    O
.    O

Along    O
with    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
,    O
and    O
estradiol    B-SteroidHormone114745635
benzoate    I-SteroidHormone114745635
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

Along    O
with    O
estradiol    B-SteroidHormone114745635
benzoate    I-SteroidHormone114745635
,    O
estradiol    O
dipropionate    O
was    O
one    O
of    O
the    O
first    O
estradiol    O
esters    O
to    O
be    O
developed    O
,    O
having    O
been    O
patented    O
in    O
1937    O
,    O
was    O
assessed    O
in    O
clinical    O
studies    O
by    O
1939    O
,    O
and    O
has    O
been    O
marketed    O
by    O
Schering    O
as    O
Progynon    B-SteroidHormone114745635
DP    I-SteroidHormone114745635
and    O
Ciba    O
Pharmaceutical    O
Products    O
as    O
Di-Ovocylin    B-SteroidHormone114745635
since    O
at    O
least    O
1940    O
.    O

Estradiol    B-SteroidHormone114745635
benzoate    I-SteroidHormone114745635

Low    O
-    O
dosage    O
steroidal    O
eye    O
-    O
drops    O
,    O
such    O
as    O
prednisone    O
,    O
fluorometholone    B-SteroidHormone114745635
,    O
loteprednol    B-SteroidHormone114745635
(    O
Lotemax    O
0.5%    O
)    O
or    O
rimexolone    B-SteroidHormone114745635
.    O

FML    B-SteroidHormone114745635

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-SteroidHormone114745635
,    O
medrysone    O
,    O
betamethasone    B-SteroidHormone114745635
or    O
dexamethasone    O
.    O

Cyproterone    B-SteroidHormone114745635

However    O
,    O
although    O
it    O
is    O
described    O
as    O
not    O
being    O
a    O
progestogen    O
,    O
benorterone    O
was    O
found    O
to    O
produce    O
"    O
a    O
highly    O
variable    O
decrease    O
in    O
plasma    O
testosterone    O
levels    O
"    O
(    O
the    O
reasons    O
for    O
this    O
are    O
unclear    O
,    O
as    O
other    O
pure    O
antiandrogens    O
such    O
as    O
cyproterone    B-SteroidHormone114745635
(    O
"    O
not    O
"    O
CPA    O
)    O
and    O
bicalutamide    O
do    O
not    O
do    O
this    O
and    O
instead    O
produce    O
consistent    O
increases    O
in    O
testosterone    O
levels    O
)    O
.    O

Norboletone    B-SteroidHormone114745635
(norbolethone)    I-SteroidHormone114745635

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-SteroidHormone114745635
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-SteroidHormone114745635
,    O
bolenol    B-SteroidHormone114745635
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-SteroidHormone114745635
.    O

In    O
addition    O
,    O
according    O
to    O
the    O
respected    O
French    O
paper    O
"    O
L'Equipe    O
,    O
"    O
Tzekos    O
was    O
directly    O
dealing    O
with    O
the    O
creator    O
of    O
norbolethone    B-SteroidHormone114745635
and    O
THG    O
(    O
tetrahydrogestrinone    B-SteroidHormone114745635
)    O
Patrick    O
Arnold    O
,    O
the    O
father    O
of    O
pro    O
-    O
hormone    O
craze    O
and    O
some    O
undetectable    O
designer    O
steroids    O
.    O

Estraguard    B-SteroidHormone114745635

Dienestrol    B-SteroidHormone114745635

#    O
Nonsteroidal    O
stilbestrol    O
estrogens    O
including    O
:    O
diethylstilbestrol    O
,    O
dienestrol    B-SteroidHormone114745635
and    O
Hexestrol    O

meprednisone    B-SteroidHormone114745635
(    O
INN    O
)    O

Brassinosteroids    B-SteroidHormone114745635
(    O
BRs    O
)    O
are    O
a    O
class    O
of    O
polyhydroxysteroids    O
that    O
have    O
been    O
recognized    O
as    O
a    O
sixth    O
class    O
of    O

They    O
are    O
also    O
linked    O
to    O
cell    O
enlargement    O
and    O
cell    O
wall    O
changes    O
induced    O
by    O
other    O
plant    O
hormones    O
such    O
as    O
gibberellin    O
,    O
cytokinin    O
,    O
ethylene    O
and    O
brassinosteroids    B-SteroidHormone114745635
.    O

Dienedione    B-SteroidHormone114745635

Dienedione    B-SteroidHormone114745635
(    O
the    O
17-keto    O
analogue    O
of    O
dienolone    O
,    O
also    O
known    O
as    O
19-nor-4,9-androstadienedione    O
)    O
is    O
thought    O
to    O
be    O
a    O
prohormone    O
of    O
dienolone    O
,    O
while    O
methyldienolone    B-SteroidHormone114745635
and    O
ethyldienolone    O
are    O
orally    O
active    O
17α-alkylated    O
AAS    O
derivatives    O
of    O
dienolone    O
.    O

Notable    O
examples    O
include    O
the    O
non-17α-alkylated    O
trenbolone    B-SteroidHormone114745635
and    O
the    O
17α-alkylated    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
and    O
metribolone    B-SteroidHormone114745635
(    O
R-1881    O
)    O
,    O
as    O
well    O
as    O
the    O
17α-alkylated    O
designer    O
steroids    O
norboletone    B-SteroidHormone114745635
and    O
tetrahydrogestrinone    B-SteroidHormone114745635
(    O
THG    O
)    O
.    O

Metribolone    B-SteroidHormone114745635
(    O
methyltrienolone    O
,    O
R-1881    O
;    O
17α-methyl-δ9,11    O
-    O
19-NT    O
)    O

Metribolone    B-SteroidHormone114745635

Metribolone    B-SteroidHormone114745635
(methyltrienolone)    I-SteroidHormone114745635

Dermabet    B-SteroidHormone114745635

Diprolene    B-SteroidHormone114745635

Diprosone    B-SteroidHormone114745635

Lotrisone    B-SteroidHormone114745635

He    O
tested    O
positive    O
for    O
betamethasone    B-SteroidHormone114745635
,    O
a    O
substance    O
that    O
was    O
banned    O
in    O
2016    O
.    O

Treatment    O
usually    O
involves    O
topical    O
corticosteroids    O
(    O
such    O
as    O
betamethasone    B-SteroidHormone114745635
,    O
clobetasol    O
,    O
dexamethasone    O
,    O
and    O
triamcinolone    O
)    O
and    O
analgesics    O
,    O
or    O
if    O
these    O
are    O
ineffective    O
and    O
the    O
condition    O
is    O
severe    O
,    O
the    O
systemic    O
corticosteroids    O
may    O
be    O
used    O
.    O

Betamethasone    B-SteroidHormone114745635

Beclometasone    O
,    O
betamethasone    B-SteroidHormone114745635
,    O
dexamethasone    O
,    O
fluocortolone    B-SteroidHormone114745635
,    O
halometasone    B-SteroidHormone114745635
,    O
and    O
mometasone    O
.    O

Commonly    O
used    O
solutions    O
are    O
of    O
fluorometholone    B-SteroidHormone114745635
,    O
medrysone    O
,    O
betamethasone    B-SteroidHormone114745635
or    O
dexamethasone    O
.    O

A    O
pregnadiene    B-SteroidHormone114745635
is    O
a    O
diene    O
derivative    O
of    O
a    O
pregnane    B-SteroidHormone114745635
.    O

Currently    O
used    O
androgens    O
for    O
male    O
hormone    B-SteroidHormone114745635
replacement    I-SteroidHormone114745635
therapy    I-SteroidHormone114745635
are    O
typically    O
injectable    O
or    O
skin    O
delivery    O
formulations    O
of    O
testosterone    O
or    O
testosterone    O
esters    O
.    O

They    O
are    O
used    O
in    O
androgen    B-SteroidHormone114745635
replacement    I-SteroidHormone114745635
therapy    I-SteroidHormone114745635
(    O
ART    O
)    O
,    O
among    O
other    O
indications    O
.    O

Androgen    B-SteroidHormone114745635
replacement    I-SteroidHormone114745635
therapy    I-SteroidHormone114745635

Treatment    O
includes    O
surgical    O
correction    O
of    O
mild    O
gynecomastia    O
,    O
minor    O
hypospadias    O
repair    O
,    O
and    O
testosterone    B-SteroidHormone114745635
supplementation    I-SteroidHormone114745635
.    O

It    O
was    O
developed    O
in    O
collaboration    O
by    O
the    O
Contraceptive    O
Development    O
Branch    O
(    O
CDB    O
)    O
of    O
the    O
National    O
Institute    O
of    O
Child    O
Health    O
and    O
Human    O
Development    O
(    O
NICHD    O
)    O
and    O
the    O
World    O
Health    O
Organization    O
(    O
WHO    O
)    O
in    O
the    O
1970s    O
and    O
early    O
1980s    O
for    O
use    O
in    O
androgen    B-SteroidHormone114745635
replacement    I-SteroidHormone114745635
therapy    I-SteroidHormone114745635
for    O
male    O
hypogonadism    O
and    O
as    O
a    O
potential    O
male    O
contraceptive    O
.    O

medrogestone    B-SteroidHormone114745635
(    O
INN    O
)    O

6-Methyl-16-dehydropregnenolone    O
acetate    O
(    O
5    O
)    O
is    O
the    O
key    O
intermediate    O
to    O
the    O
preparation    O
of    O
both    O
melengesterol    O
acetate    O
and    O
medrogestone    B-SteroidHormone114745635
.    O

Medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
medrogestone    B-SteroidHormone114745635
are    O
weak    O
inhibitors    O
of    O
3β-HSD    O
which    O
may    O
substantially    O
inhibit    O
it    O
at    O
high    O
dosages    O
.    O

Feeding    O
11-ketotestosterone    B-SteroidHormone114745635
coated    O
scallops    O
to    O
toadfish    O
increases    O
their    O
calling    O
behavior    O
,    O
which    O
identifies    O
11-ketotestosterone    O
,    O
an    O
androgen    O
hormone    O
,    O
as    O
a    O
mediator    O
of    O
midshipman    O
fish    O
vocalization    O
.    O

11-Ketotestosterone    B-SteroidHormone114745635
(    O
11-KT    B-SteroidHormone114745635
)    O
is    O
an    O
oxidized    O
form    O
of    O
testosterone    O
that    O
contains    O
a    O
keto    O
group    O
at    O
the    O
C11    O
position    O
.    O

Methyl-1-testosterone    B-SteroidHormone114745635
(methyl-δ1-DHT)    I-SteroidHormone114745635

Metenolone    O
itself    O
is    O
not    O
used    O
as    O
an    O
AAS    O
,    O
and    O
the    O
drug    O
is    O
instead    O
supplied    O
as    O
metenolone    O
acetate    O
for    O
oral    O
administration    O
and    O
as    O
metenolone    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
for    O
depot    O
intramuscular    O
injection    O
.    O

Shavershian    O
often    O
used    O
phrases    O
such    O
as    O
"    O
riding    O
bicycles    O
"    O
,    O
which    O
,    O
according    O
to    O
"    O
The    O
Daily    O
Telegraph    O
"    O
,    O
is    O
"    O
gym    O
slang    O
for    O
using    O
a    O
cycle    B-SteroidHormone114745635
of    I-SteroidHormone114745635
steroids    I-SteroidHormone114745635
"    O
.    O

Also    O
eligible    O
was    O
Rafael    O
Palmeiro    O
,    O
who    O
recorded    O
over    O
3000    O
hits    O
and    O
500    O
home    O
runs    O
,    O
which    O
would    O
typically    O
foreshadow    O
a    O
first    O
-    O
ballot    O
election    O
;    O
however    O
,    O
his    O
candidacy    O
has    O
generated    O
controversy    O
due    O
to    O
his    O
testing    O
positive    O
for    O
steroids    B-SteroidHormone114745635
.    O

Some    O
athletes    O
and    O
body    O
builders    O
use    O
anastrozole    O
as    O
part    O
of    O
their    O
steroid    B-SteroidHormone114745635
cycle    I-SteroidHormone114745635
to    O
reduce    O
and    O
prevent    O
symptoms    O
of    O
excess    O
estrogen    O
--    O
gynecomastia    O
,    O
emotional    O
lability    O
and    O
water    O
retention    O
.    O

Exemestane    B-SteroidHormone114745635
,    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
breast    O
cancer    O
,    O
is    O
an    O
inhibitor    O
of    O
the    O
aromatase    O
enzyme    O
.    O

Certain    O
medications    O
that    O
block    O
the    O
effect    O
of    O
estrogen    O
(    O
i.e.    O
tamoxifen    O
,    O
raloxifen    O
,    O
exemestane    B-SteroidHormone114745635
)    O
can    O
reduce    O
the    O
risk    O
by    O
about    O
50%    O
but    O
also    O
have    O
side    O
effects    O
.    O

Breast    O
cancer    O
in    O
post    O
-    O
menopausal    O
women    O
with    O
advanced    O
hormone    O
-    O
receptor    O
positive    O
,    O
HER2-negative    O
type    O
cancer    O
,    O
in    O
conjunction    O
with    O
exemestane    B-SteroidHormone114745635
(    O
US    O
FDA    O
July    O
2012    O
)    O

Interim    O
phase    O
III    O
trial    O
results    O
in    O
2011    O
showed    O
that    O
adding    O
Afinitor    O
(    O
everolimus    O
)    O
to    O
exemestane    B-SteroidHormone114745635
therapy    O
against    O
advanced    O
breast    O
cancer    O
can    O
significantly    O
improve    O
progression    O
-    O
free    O
survival    O
compared    O
with    O
exemestane    O
therapy    O
alone    O
.    O

List    O
of    O
estrogen    O
esters    O
–    O
estrogen    B-SteroidHormone114745635
ester    I-SteroidHormone114745635

Estradiol    O
diundecylenate    O
(    O
brand    O
name    O
Etrosteron    O
)    O
,    O
or    O
estradiol    O
diundecenoate    O
,    O
also    O
known    O
as    O
17β-estradiol    O
3,17β-diundec-10-enoate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-SteroidHormone114745635
ester    I-SteroidHormone114745635
–    O
specifically    O
,    O
the    O
3,17β-diundecylenate    O
ester    O
of    O
estradiol    O
–    O
which    O
is    O
marketed    O
in    O
Argentina    O
.    O

Estrone    O
cyanate    O
,    O
or    O
estrone    O
3-O    O
-    O
cyanate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-SteroidHormone114745635
ester    I-SteroidHormone114745635
–    O
specifically    O
,    O
the    O
3-O    O
-    O
cyanate    O
ester    O
of    O
estrone    O
–    O
that    O
was    O
investigated    O
for    O
use    O
in    O
oral    O
contraceptives    O
but    O
was    O
found    O
to    O
be    O
of    O
relatively    O
low    O
potency    O
and    O
ultimately    O
was    O
never    O
marketed    O
.    O

Estriol    O
triacetate    O
,    O
also    O
known    O
as    O
estra-1,3,5(10)-triene-3,16α,17β-triol    O
3,16α,17β-triacetate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-SteroidHormone114745635
ester    I-SteroidHormone114745635
–    O
specifically    O
,    O
the    O
triacetate    O
ester    O
of    O
estriol    O
–    O
which    O
was    O
never    O
marketed    O
.    O

Estradiol    O
mustard    O
(    O
developmental    O
code    O
name    O
NSC-112259    O
)    O
,    O
also    O
known    O
as    O
chlorphenacyl    O
estradiol    O
diester    O
,    O
as    O
well    O
as    O
estradiol    O
3,17β-bis(4-(bis(2-chloroethyl)amino)phenyl)acetate    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
estrogen    O
and    O
alkylating    O
antineoplastic    O
agent    O
and    O
a    O
chlorphenacyl    O
nitrogen    O
mustard    O
-    O
coupled    O
estrogen    B-SteroidHormone114745635
ester    I-SteroidHormone114745635
that    O
was    O
never    O
marketed    O
.    O

Estradiol    O
butyrate    O
benzoate    O
,    O
or    O
estradiol    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
,    O
also    O
known    O
as    O
estra-1,3,5(10)-triene-3,17β-diol    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
,    O
is    O
a    O
semisynthetic    O
,    O
steroidal    O
estrogen    O
and    O
an    O
estrogen    B-SteroidHormone114745635
ester    I-SteroidHormone114745635
–    O
specifically    O
,    O
the    O
3-benzoate    O
17β-n    O
-    O
butyrate    O
diester    O
of    O
estradiol    O
–    O
which    O
was    O
never    O
marketed    O
.    O

etonogestrel    B-SteroidHormone114745635
(    O
INN    O
)    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

Clobetasone    B-SteroidHormone114745635
=    O
9α-fluoro-16β-methyl-17α-hydroxy-21-chloropregna-1,4-diene-3,11,20-trione    O

Delmadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
a    O
progestin    O
and    O
antigonadotropin    O
used    O
as    O
an    O
antiandrogen    O

Delmadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

Tibolone    B-SteroidHormone114745635

Tibolone    B-SteroidHormone114745635

Tibolone    B-SteroidHormone114745635

Estradiol    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
and    O
estradiol    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Digit    B-SteroidHormone114745635
ratio    I-SteroidHormone114745635

Digit    B-SteroidHormone114745635
ratio    I-SteroidHormone114745635

The    O
digit    B-SteroidHormone114745635
ratio    I-SteroidHormone114745635
is    O
the    O
ratio    O
of    O
the    O
lengths    O
of    O
different    O
digits    O
or    O
fingers    O
typically    O
measured    O
from    O
the    O
midpoint    O
of    O
bottom    O
crease    O
(    O
where    O
the    O
finger    O
joins    O
the    O
hand    O
)    O
to    O
the    O
tip    O
of    O
the    O
finger    O
.    O

A    O
2010    O
British    O
study    O
found    O
that    O
a    O
large    O
2D:4D    O
digit    B-SteroidHormone114745635
ratio    I-SteroidHormone114745635
,    O
an    O
indication    O
of    O
high    O
prenatal    O
estrogen    O
exposure    O
,    O
was    O
a    O
"    O
positive    O
correlate    O
of    O
psychopathy    O
in    O
females    O
,    O
and    O
a    O
positive    O
correlate    O
of    O
callous    O
affect    O
(    O
psychopathy    O
sub    O
-    O
scale    O
)    O
in    O
males    O
"    O
.    O

The    O
MONARCH    O
3    O
study    O
is    O
investigating    O
the    O
effectiveness    O
of    O
Abemaciclib    O
,    O
plus    O
either    O
anastrozole    O
or    O
letrozole    B-SteroidHormone114745635
,    O
as    O
a    O
first    O
-    O
line    O
treatment    O
for    O
women    O
with    O
breast    O
cancer    O
.    O

File    O
:    O
Letrozole.svg|Structure    O
of    O
letrozole    B-SteroidHormone114745635
,    O
an    O
oral    O
nonsteroidal    O
aromatase    O
inhibitor    O
for    O
the    O
treatment    O
of    O
certain    O
breast    O
cancers    O
.    O

Instead    O
of    O
in    O
vitro    O
fertilization    O
,    O
they    O
opted    O
to    O
switch    O
Danielle    O
to    O
Femara    B-SteroidHormone114745635
and    O
attempted    O
intrauterine    O
insemination    O
again    O
,    O
ultimately    O
becoming    O
pregnant    O
with    O
Blayke    O
.    O

Letrozole    B-SteroidHormone114745635
(    O
INN    O
,    O
trade    O
name    O
Femara    B-SteroidHormone114745635
)    O
is    O
an    O
orally    O
active    O
nonsteroidal    O
aromatase    O
inhibitor    O
for    O
the    O
treatment    O
of    O
hormonally    O
-    O
responsive    O
breast    O
cancer    O
after    O
surgery    O
.    O

letrozole    B-SteroidHormone114745635
(    O
aromatase    O
inhibitor    O
,    O
used    O
in    O
breast    O
cancer    O
)    O

estradiol    B-SteroidHormone114745635
undecylate    I-SteroidHormone114745635
(    O
INN    O
)    O

Estradiol    B-SteroidHormone114745635
undecylate    I-SteroidHormone114745635
,    O
or    O
estradiol    B-SteroidHormone114745635
undecanoate    I-SteroidHormone114745635
,    O
sold    O
under    O
the    O
brand    O
name    O
Progynon    B-SteroidHormone114745635
Depot    I-SteroidHormone114745635
100    I-SteroidHormone114745635
among    O
others    O
,    O
is    O
an    O
estrogen    O
which    O
is    O
or    O
has    O
been    O
used    O
in    O
Europe    O
,    O
including    O
in    O
Germany    O
,    O
the    O
Netherlands    O
,    O
Switzerland    O
,    O
and    O
Monaco    O
.    O

Estradiol    B-SteroidHormone114745635
undecylate    I-SteroidHormone114745635

Trestolone    B-SteroidHormone114745635

Trestolone    B-SteroidHormone114745635
(    O
MENT    O
;    O
7α-methyl-19-NT    O
)    O

Fluticasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635

It    O
contains    O
fluticasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635
,    O
an    O
inhaled    O
corticosteroid    O
,    O
and    O
vilanterol    O
,    O
an    O
ultra    O
-    O
long    O
-    O
acting    O
β2    O
agonist    O
(    O
ultra    O
-    O
LABA    O
)    O
.    O

DHEA    O
is    O
the    O
5-dehydro    O
analogue    O
of    O
epiandrosterone    B-SteroidHormone114745635
(    O
5α-androstan-3β-ol-17-one    O
)    O
and    O
is    O
also    O
known    O
as    O
5-dehydroepiandrosterone    O
or    O
as    O
δ5-epiandrosterone    O
.    O

These    O
isomers    O
are    O
also    O
technically    O
"    O
DHEA    O
"    O
,    O
since    O
they    O
are    O
dehydroepiandrosterones    O
in    O
which    O
hydrogens    O
are    O
removed    O
from    O
the    O
epiandrosterone    B-SteroidHormone114745635
skeleton    O
.    O

A    O
Δ5    O
-    O
3-ketosteroid    O
isomerase    O
-    O
disrupted    O
mutant    O
of    O
strain    O
TA441    O
can    O
grow    O
on    O
dehydroepiandrosterone    B-SteroidHormone114745635
,    O
which    O
has    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
but    O
can    O
not    O
grow    O
on    O
epiandrosterone    B-SteroidHormone114745635
,    O
which    O
lacks    O
a    O
double    O
bond    O
at    O
Δ5    O
,    O
indicating    O
that    O
"    O
C.    O
testosteroni    O
"    O
KSI    O
is    O
responsible    O
for    O
transfer    O
of    O
the    O
double    O
bond    O
from    O
Δ5    O
to    O
Δ4    O
and    O
transfer    O
of    O
the    O
double    O
bond    O
by    O
hydrogenation    O
at    O
Δ5    O
and    O
following    O
dehydrogenation    O
at    O
Δ4    O
is    O
not    O
possible    O
.    O

Melengestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

There    O
are    O
three    O
natural    O
hormones    O
(    O
estradiol    O
,    O
progesterone    O
,    O
and    O
testosterone    O
)    O
and    O
their    O
synthetic    O
alternatives    O
(    O
zeranol    O
,    O
melengestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
trenbolone    O
acetate    O
)    O
have    O
been    O
approved    O
by    O
the    O
for    O
use    O
in    O
Canadian    O
beef    O
production    O
.    O

Propetandrol    B-SteroidHormone114745635
(propethandrol)    I-SteroidHormone114745635

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-SteroidHormone114745635
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-SteroidHormone114745635
,    O
bolenol    B-SteroidHormone114745635
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-SteroidHormone114745635
.    O

It    O
is    O
a    O
prodrug    O
of    O
norethisterone    B-SteroidHormone114745635
,    O
with    O
both    O
quingestanol    B-SteroidHormone114745635
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
serving    O
as    O
intermediates    O
in    O
the    O
transformation    O
.    O

diflorasone    B-SteroidHormone114745635
(    O
INN    O
)    O

A    O
free    B-SteroidHormone114745635
androgen    I-SteroidHormone114745635
index    I-SteroidHormone114745635
expresses    O
the    O
ratio    O
of    O
testosterone    O
to    O
SHBG    O
and    O
can    O
be    O
used    O
to    O
summarize    O
the    O
activity    O
of    O
free    O
testosterone    O
.    O

Tiomesterone    B-SteroidHormone114745635

Mibolerone    B-SteroidHormone114745635

Mibolerone    B-SteroidHormone114745635

19-Norandrostenedione    B-SteroidHormone114745635

Silandrone    B-SteroidHormone114745635

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Haldrone    B-SteroidHormone114745635

In    O
March    O
2016    O
,    O
it    O
was    O
revealed    O
that    O
Slice    O
had    O
tested    O
positive    O
for    O
nandrolone    O
and    O
an    O
elevated    O
testosterone    O
to    O
epitestosterone    B-SteroidHormone114745635
ratio    O
(    O
T    O
/    O
E    O
ratio    O
)    O
in    O
a    O
pre    O
-    O
fight    O
drug    O
test    O
.    O

In    O
the    O
ensuing    O
years    O
nasal    O
spray    O
preparations    O
containing    O
testosterone    O
or    O
androstenedione    B-SteroidHormone114745635
were    O
developed    O
in    O
collaboration    O
with    O
Jenapharm    O
,    O
tested    O
,    O
and    O
used    O
in    O
top    O
athletes    O
—    O
some    O
of    O
whom    O
did    O
not    O
like    O
this    O
mode    O
of    O
application    O
.    O
Doping    O
tests    O
at    O
the    O
time    O
used    O
the    O
T    O
:    O
E    O
(    O
testosterone    O
:    O
epitestosterone    B-SteroidHormone114745635
)    O
ratio    O
.    O

Since    O
1983    O
,    O
Jenapharm    O
had    O
produced    O
preparations    O
of    O
epitestosterone    B-SteroidHormone114745635
propionate    O
,    O
a    O
biologically    O
inactive    O
compound    O
that    O
had    O
no    O
commercial    O
value    O
but    O
was    O
prepared    O
exclusively    O
for    O
the    O
governmental    O
doping    O
system    O
.    O

In    O
June    O
that    O
year    O
she    O
tested    O
positive    O
for    O
excess    O
testosterone    O
against    O
her    O
epitestosterone    B-SteroidHormone114745635
levels    O
and    O
the    O
IAAF    O
gave    O
her    O
a    O
two    O
-    O
year    O
ban    O
from    O
the    O
sport    O
,    O
stretching    O
from    O
June    O
2005    O
to    O
June    O
2007    O
.    O

He    O
was    O
also    O
found    O
to    O
have    O
an    O
elevated    O
testosterone    O
/    O
epitestosterone    B-SteroidHormone114745635
(    O
T    O
/    O
E    O
)    O
ratio    O
of    O
6.4:1    O
,    O
which    O
is    O
above    O
the    O
maximum    O
allowed    O
limit    O
of    O
4:1    O
.    O

On    O
5    O
August    O
2006    O
Phonak    O
dismissed    O
Floyd    O
Landis    O
after    O
confirmation    O
that    O
a    O
urine    O
sample    O
taken    O
after    O
his    O
Stage    O
17    O
win    O
twice    O
tested    O
positive    O
for    O
synthetic    O
testosterone    O
as    O
well    O
as    O
a    O
ratio    O
of    O
testosterone    O
to    O
epitestosterone    B-SteroidHormone114745635
nearly    O
three    O
times    O
the    O
limit    O
allowed    O
by    O
World    O
Anti    O
-    O
Doping    O
Agency    O
rules    O
.    O

Spironolactone    O
is    O
closely    O
structurally    O
related    O
to    O
other    O
clinically    O
used    O
spirolactones    O
such    O
as    O
canrenone    O
,    O
potassium    O
canrenoate    O
,    O
drospirenone    B-SteroidHormone114745635
,    O
and    O
eplerenone    B-SteroidHormone114745635
,    O
as    O
well    O
as    O
to    O
the    O
never    O
-    O
marketed    O
spirolactones    O
SC-5233    O
(    O
6,7-dihydrocanrenone    O
;    O
7α-desthioacetylspironolactone    O
)    O
,    O
SC-8109    O
(    O
19-nor-6,7-dihydrocanrenone    O
)    O
,    O
spiroxasone    O
,    O
prorenone    O
(    O
SC-23133    O
)    O
,    O
mexrenone    O
(    O
SC-25152    O
,    O
ZK-32055    O
)    O
,    O
dicirenone    O
(    O
SC-26304    O
)    O
,    O
spirorenone    O
(    O
ZK-35973    O
)    O
,    O
and    O
mespirenone    O
(    O
ZK-94679    O
)    O
.    O

Difficult    O
or    O
resistant    O
cases    O
of    O
hypokalemia    O
may    O
be    O
amenable    O
to    O
a    O
potassium    O
-    O
sparing    O
diuretic    O
,    O
such    O
as    O
amiloride    O
,    O
triamterene    O
,    O
spironolactone    O
,    O
or    O
eplerenone    B-SteroidHormone114745635
.    O

Eplerenone    B-SteroidHormone114745635
is    O
the    O
9    O
-    O
11α-epoxy    O
analogue    O
of    O
mexrenone    O
.    O

Important    O
antimineralocorticoids    O
are    O
spironolactone    O
and    O
eplerenone    B-SteroidHormone114745635
.    O

gestonorone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
(    O
INN    O
)    O

The    O
C17α    O
caproate    O
ester    O
of    O
gestronol    O
,    O
gestonorone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
(    O
gestronol    O
hexanoate    O
)    O
,    O
in    O
contrast    O
,    O
has    O
been    O
marketed    O
.    O

Progestogen    O
esters    O
of    O
other    O
groups    O
of    O
progestins    O
have    O
also    O
been    O
introduced    O
,    O
including    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivatives    O
gestonorone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
segesterone    O
acetate    O
(    O
nestorone    O
)    O
,    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
norgestomet    O
(    O
11β-methyl-17α-acetoxy-19-norprogesterone    O
)    O
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
and    O
quingestanol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Roxibolone    B-SteroidHormone114745635

Depo-Estradiol    B-SteroidHormone114745635

Along    O
with    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
,    O
and    O
estradiol    B-SteroidHormone114745635
benzoate    I-SteroidHormone114745635
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

Prior    O
to    O
the    O
development    O
and    O
introduction    O
of    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
and    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
in    O
the    O
1950s    O
,    O
estradiol    O
dipropionate    O
and    O
estradiol    O
benzoate    O
were    O
the    O
most    O
widely    O
used    O
estradiol    O
esters    O
.    O

Examples    O
include    O
testosterone    O
cypionate    O
,    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
,    O
hydrocortisone    O
cypionate    O
,    O
and    O
oxabolone    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
.    O

Cortisporin    B-SteroidHormone114745635
is    O
a    O
drug    O
consisting    O
of    O
Neomycin    O
,    O
bacitracin    O
,    O
polymyxin    O
B    O
and    O
hydrocortisone    O
.    O

Estropipate    B-SteroidHormone114745635
(    O
Ogen    O
,    O
Ortho    O
-    O
Est    O
)    O
(    O
a    O
salt    O
of    O
estrone    O
sulfate    O
and    O
piperazine    O
)    O

Fludrocortisone    B-SteroidHormone114745635
is    O
also    O
used    O
,    O
although    O
based    O
on    O
more    O
limited    O
evidence    O
.    O

Fluorine    O
-    O
containing    O
fludrocortisone    B-SteroidHormone114745635
is    O
one    O
of    O
the    O
most    O
common    O
of    O
these    O
drugs    O
.    O

Hyporeninemic    O
hypoaldosteronism    O
is    O
amenable    O
to    O
fludrocortisone    B-SteroidHormone114745635
treatment    O
,    O
but    O
the    O
accompanying    O
hypertension    O
and    O
edema    O
can    O
prove    O
a    O
problem    O
in    O
these    O
patients    O
,    O
so    O
often    O
a    O
diuretic    O
(    O
such    O
as    O
the    O
thiazide    O
diuretic    O
,    O
bendrofluazide    O
,    O
or    O
a    O
loop    O
diuretic    O
,    O
such    O
as    O
furosemide    O
)    O
is    O
used    O
to    O
control    O
the    O
hyperkalemia    O
.    O

Fludrocortisone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
deoxycorticosterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
are    O
,    O
by    O
definition    O
,    O
mineralocorticoids    O
rather    O
than    O
glucocorticoids    O
,    O
but    O
they    O
do    O
have    O
minor    O
glucocorticoid    O
potency    O
and    O
are    O
included    O
in    O
this    O
table    O
to    O
provide    O
perspective    O
on    O
mineralocorticoid    O
potency    O
.    O

An    O
example    O
of    O
a    O
synthetic    O
mineralocorticoid    O
is    O
fludrocortisone    B-SteroidHormone114745635
(    O
Florinef    O
)    O
.    O

Fludrocortisone    B-SteroidHormone114745635
,    O
a    O
synthetic    O
mineralocorticoid    O
.    O

Desowen    B-SteroidHormone114745635

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

Chlorotrianisene    B-SteroidHormone114745635

Chlorotrianisene    B-SteroidHormone114745635

Chlorotrianisene    B-SteroidHormone114745635

Zearalanone    B-SteroidHormone114745635

Zearalanone    B-SteroidHormone114745635

Methyldienolone    B-SteroidHormone114745635

Dienedione    B-SteroidHormone114745635
(    O
the    O
17-keto    O
analogue    O
of    O
dienolone    O
,    O
also    O
known    O
as    O
19-nor-4,9-androstadienedione    O
)    O
is    O
thought    O
to    O
be    O
a    O
prohormone    O
of    O
dienolone    O
,    O
while    O
methyldienolone    B-SteroidHormone114745635
and    O
ethyldienolone    O
are    O
orally    O
active    O
17α-alkylated    O
AAS    O
derivatives    O
of    O
dienolone    O
.    O

desoximetasone    B-SteroidHormone114745635
(    O
INN    O
)    O

Ointment    O
and    O
creams    O
containing    O
coal    O
tar    O
,    O
dithranol    O
,    O
corticosteroids    O
(    O
i.e.    O
desoximetasone    B-SteroidHormone114745635
)    O
,    O
fluocinonide    B-SteroidHormone114745635
,    O
vitamin    O
D3    O
analogs    O
(    O
for    O
example    O
,    O
calcipotriol    O
)    O
,    O
and    O
retinoids    O
are    O
routinely    O
used    O
.    O

Halog    B-SteroidHormone114745635

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonist    O
(    O
Ki    O
=    O
224    O
nM    O
)    O

As    O
a    O
glucocorticoid    O
,    O
dexamethasone    O
is    O
an    O
agonist    O
of    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
GR    O
)    O
.    O

NR3C1    B-SteroidHormone114745635
,    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
and    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635

Free    O
cortisol    O
passes    O
easily    O
through    O
cellular    O
membranes    O
,    O
where    O
they    O
bind    O
intracellular    O
cortisol    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Glucocorticoids    O
are    O
corticosteroids    O
that    O
bind    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
GR    O
)    O
,    O
that    O
is    O
present    O
in    O
almost    O
every    O
vertebrate    O
animal    O
cell    O
.    O

GCs    O
affect    O
cells    O
by    O
binding    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
GR    O
)    O
.    O

Glucocorticoids    O
bind    O
to    O
the    O
cytosolic    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
GR    O
)    O
,    O
a    O
type    O
of    O
nuclear    O
receptor    O
that    O
is    O
activated    O
by    O
ligand    O
binding    O
.    O

Glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635

Dexamethasone    O
-    O
a    O
synthetic    O
glucocorticoid    O
binds    O
more    O
powerfully    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
than    O
cortisol    O
does    O
.    O

is    O
a    O
transcriptional    O
corepressor    O
for    O
nuclear    O
receptors    O
such    O
as    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
and    O
a    O
coactivator    O
for    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

It    O
contains    O
10    O
NR    O
-    O
interacting    O
boxes    O
(    O
LXXLL    O
motifs    O
)    O
and    O
functions    O
as    O
a    O
coregulator    O
of    O
several    O
nuclear    O
receptors    O
via    O
its    O
LXXLL    O
motifs    O
including    O
ESR1    O
,    O
ESR2    O
,    O
ERR    O
-    O
alpha    O
,    O
PR    B-SteroidHormone114745635
,    O
GR    B-SteroidHormone114745635
,    O
AR    B-SteroidHormone114745635
,    O
and    O
RXR    O
.    O

Glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635

For    O
mild    O
-    O
moderate    O
eczema    O
a    O
weak    O
steroid    O
may    O
be    O
used    O
(    O
e.g.    O
,    O
hydrocortisone    O
)    O
,    O
while    O
in    O
more    O
severe    O
cases    O
a    O
higher    O
-    O
potency    O
steroid    O
(    O
e.g.    O
,    O
clobetasol    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
)    O
may    O
be    O
used    O
.    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
mometasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635
.    O

A    O
propionate    O
ester    O
of    O
clobetasol    O
,    O
clobetasol    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
has    O
also    O
been    O
marketed    O
,    O
and    O
is    O
far    O
more    O
widely    O
used    O
in    O
comparison    O
.    O

Triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
triamcinolone    O
alcohol    O
,    O
amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
and    O
halcinonide    B-SteroidHormone114745635

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

Rosterolone    O
is    O
a    O
derivative    O
of    O
mesterolone    B-SteroidHormone114745635
,    O
which    O
,    O
in    O
contrast    O
,    O
is    O
an    O
androgen    O
and    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Mesterolone    B-SteroidHormone114745635

Hypergonadism    B-SteroidHormone114745635

α-Zearalenol    O
is    O
a    O
nonsteroidal    O
estrogen    O
of    O
the    O
resorcylic    O
acid    O
lactone    O
group    O
related    O
to    O
mycoestrogen    B-SteroidHormone114745635
found    O
in    O
"    O
Fusarium    O
spp    O
"    O
.    O

Zeranol    O
(    O
INN    O
,    O
USAN    O
,    O
BAN    O
)    O
(    O
brand    O
names    O
Frideron    O
,    O
Ralabol    O
,    O
Ralgro    O
,    O
Ralone    O
,    O
Zerano    O
;    O
developmental    O
code    O
names    O
MK-188    O
,    O
P-1496    O
)    O
,    O
or    O
zearanol    O
,    O
also    O
known    O
as    O
α-zearalanol    O
or    O
simply    O
zearalanol    O
,    O
is    O
a    O
synthetic    O
nonsteroidal    O
estrogen    O
of    O
the    O
resorcylic    O
acid    O
lactone    O
group    O
related    O
to    O
mycoestrogen    B-SteroidHormone114745635
found    O
in    O
fungi    O
in    O
the    O
"    O
Fusarium    O
"    O
genus    O
and    O
is    O
used    O
mainly    O
as    O
an    O
anabolic    O
agent    O
in    O
veterinary    O
medicine    O
.    O

Some    O
other    O
examples    O
of    O
putative    O
EDCs    O
are    O
polychlorinated    O
dibenzo    O
-    O
dioxins    O
(    O
PCDDs    O
)    O
and    O
-furans    O
(    O
PCDFs    O
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
PAHs    O
)    O
,    O
phenol    O
derivatives    O
and    O
a    O
number    O
of    O
pesticides    O
(    O
most    O
prominent    O
being    O
organochlorine    O
insecticides    O
like    O
endosulfan    O
,    O
kepone    O
(    O
chlordecone    O
)    O
and    O
DDT    O
and    O
its    O
derivatives    O
,    O
the    O
herbicide    O
atrazine    O
,    O
and    O
the    O
fungicide    O
vinclozolin    O
)    O
,    O
the    O
contraceptive    O
17-alpha    O
ethinylestradiol    O
,    O
as    O
well    O
as    O
naturally    O
occurring    O
phytoestrogens    B-SteroidHormone114745635
such    O
as    O
genistein    B-SteroidHormone114745635
and    O
mycoestrogens    B-SteroidHormone114745635
such    O
as    O
zearalenone    O
.    O

Quinbolone    B-SteroidHormone114745635
,    O
the    O
17-cyclopentenyl    O
enol    O
ether    O
of    O
boldenone    O
.    O

Quinbolone    B-SteroidHormone114745635

The    O
key    O
phytochemical    O
constituents    O
of    O
the    O
herb    O
are    O
pregnane    B-SteroidHormone114745635
glycosides    O
,    O
flavone    O
glycosides    O
,    O
megastigmane    O
glycosides    O
,    O
and    O
saponins    O
.    O

Estrane    O
and    O
pregnane    B-SteroidHormone114745635

Dexamethasone    O
is    O
a    O
synthetic    O
pregnane    B-SteroidHormone114745635
corticosteroid    O
and    O
derivative    O
of    O
cortisol    O
(    O
hydrocortisone    O
)    O
and    O
is    O
also    O
known    O
as    O
1-dehydro-9α-fluoro-16α-methylhydrocortisone    O
or    O
as    O
9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O
.    O

Prednisone    O
is    O
a    O
synthetic    O
pregnane    B-SteroidHormone114745635
corticosteroid    O
and    O
derivative    O
of    O
cortisone    O
and    O
is    O
also    O
known    O
as    O
δ1-cortisone    O
or    O
1,2-dehydrocortisone    O
or    O
as    O
17α,21-dihydroxypregna-1,4-diene-3,11,20-trione    O
.    O

Hydrocortisone    O
,    O
also    O
known    O
as    O
11β,17α,21-trihydroxypregn-4-ene-3,20-dione    O
,    O
is    O
a    O
naturally    O
occurring    O
pregnane    B-SteroidHormone114745635
steroid    O
.    O

Cortisone    O
(    O
or    O
)    O
,    O
also    O
known    O
as    O
17α,21-dihydroxypregn-4-ene-3,11,20-trione    O
,    O
is    O
a    O
pregnane    B-SteroidHormone114745635
(    O
21-carbon    O
)    O
steroid    O
hormone    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-SteroidHormone114745635
like    O
pregnenolone    B-SteroidHormone114745635
,    O
pregnanediol    O
,    O
allopregnanedione    O
,    O
and    O
allopregnanolone    O
.    O

Long    O
-    O
term    O
exposure    O
to    O
glucocorticoid    O
medications    O
,    O
such    O
as    O
asthma    O
and    O
anti    O
-    O
inflammatory    O
medication    O
,    O
has    O
been    O
shown    O
to    O
create    O
deficits    O
in    O
memory    O
and    O
attention    O
both    O
during    O
and    O
,    O
to    O
a    O
lesser    O
extent    O
,    O
after    O
treatment    O
,    O
a    O
condition    O
known    O
as    O
"    O
steroid    B-SteroidHormone114745635
dementia    I-SteroidHormone114745635
.    O
"    O

1-Testosterone    B-SteroidHormone114745635

1-Testosterone    B-SteroidHormone114745635
(    O
dihydroboldenone    O
;    O
δ1-DHT    O
)    O

Mesabolone    O
–    O
17β-(1-methyloxycyclohexyl    O
)    O
ether    O
of    O
1-testosterone    B-SteroidHormone114745635
(    O
dihydroboldenone    O
)    O

moxestrol    B-SteroidHormone114745635
(    O
INN    O
)    O

Moxestrol    B-SteroidHormone114745635

4-Androstene-3,6,17-trione    B-SteroidHormone114745635

Combinations    O
containing    O
third-    O
or    O
fourth    O
-    O
generation    O
progestins    O
such    O
as    O
desogestrel    B-SteroidHormone114745635
,    O
drospirenone    B-SteroidHormone114745635
,    O
or    O
norgestimate    B-SteroidHormone114745635
are    O
preferred    O
for    O
women    O
with    O
acne    O
due    O
to    O
their    O
stronger    O
antiandrogenic    O
effects    O
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

No    O
statistically    O
significant    O
increase    O
in    O
risk    O
was    O
associated    O
with    O
the    O
other    O
formulations    O
of    O
oral    O
contraceptive    O
(    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
norgestrel    O
and    O
norgestimate    B-SteroidHormone114745635
)    O
.    O

difluprednate    B-SteroidHormone114745635
(    O
INN    O
)    O

Etynodiol    B-SteroidHormone114745635

etynodiol    B-SteroidHormone114745635
(    O
INN    O
)    O

Gestodene    B-SteroidHormone114745635
is    O
a    O
19-nortestosterone    O
derivative    O
with    O
antimineralocorticoid    O
properties    O
.    O

gestodene    B-SteroidHormone114745635
(    O
INN    O
)    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

Melengestrol    B-SteroidHormone114745635

Ciclesonide    B-SteroidHormone114745635
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
aceponate    I-SteroidHormone114745635
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
buteprate    I-SteroidHormone114745635
,    O
hydrocortisone    B-SteroidHormone114745635
butyrate    I-SteroidHormone114745635
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-SteroidHormone114745635
,    O
and    O
tixocortol    B-SteroidHormone114745635
pivalate    I-SteroidHormone114745635
.    O

In    O
"    O
Drosophila    O
"    O
,    O
hormones    O
such    O
as    O
ecdysone    B-SteroidHormone114745635
and    O
juvenile    O
hormone    O
can    O
promote    O
the    O
expression    O
of    O
certain    O
miRNAs    O
.    O

Very    O
detailed    O
studies    O
have    O
been    O
done    O
on    O
JH    O
,    O
JH    O
acid    O
,    O
ecdysone    B-SteroidHormone114745635
,    O
and    O
JH    O
titers    O
have    O
been    O
done    O
in    O
precisely    O
timed    O
larvae    O
of    O
Manduca    O
sexta    O
as    O
a    O
function    O
of    O
development    O
during    O
the    O
fifth    O
larval    O
stadium    O
.    O

(    O
A    O
very    O
similar    O
timing    O
of    O
peaks    O
of    O
JH    O
esterase    O
and    O
ecdysone    B-SteroidHormone114745635
has    O
been    O
observed    O
in    O
"    O
Galleria    O
mellonella    O
"    O
.    O

These    O
data    O
are    O
consistent    O
with    O
a    O
classical    O
model    O
for    O
lepidopterans    O
where    O
JH    O
is    O
high    O
at    O
each    O
larval    O
molt    O
,    O
but    O
must    O
rise    O
together    O
with    O
ecdysone    B-SteroidHormone114745635
prior    O
to    O
pupation    O
to    O
initiate    O
the    O
pupal    O
molt    O
.    O

These    O
glands    O
secrete    O
an    O
ecdysteroid    B-SteroidHormone114745635
called    O
ecdysone    B-SteroidHormone114745635
,    O
or    O
the    O
moulting    O
hormone    O
,    O
which    O
initiates    O
the    O
epidermal    O
moulting    O
process    O
.    O

Most    O
studies    O
of    O
phytoestrogens    B-SteroidHormone114745635
in    O
soy    O
have    O
identified    O
the    O
isoflavones    O
genistein    B-SteroidHormone114745635
and    O
daidzein    O
as    O
its    O
principal    O
phytoestrogenic    O
substances    O
.    O

In    O
addition    O
to    O
pharmaceuticals    O
,    O
some    O
herbal    O
breast    O
enlargement    O
supplements    O
contain    O
phytoestrogen    B-SteroidHormone114745635
such    O
as    O
8-prenylnaringenin    O
(    O
found    O
in    O
hops    O
)    O
and    O
miroestrol    O
(    O
a    O
constituent    O
of    O
"    O
Pueraria    O
mirifica    O
"    O
)    O
and    O
thus    O
may    O
be    O
regarded    O
as    O
a    O
form    O
of    O
hormonal    O
breast    O
enhancement    O
.    O

Isoflavonoids    O
are    O
a    O
class    O
of    O
flavonoid    O
phenolic    O
compounds    O
,    O
many    O
of    O
which    O
are    O
biologically    O
active    O
.    O
Isoflavonoids    O
and    O
their    O
derivatives    O
are    O
sometimes    O
referred    O
to    O
as    O
phytoestrogen    B-SteroidHormone114745635
,    O
as    O
many    O
isoflavonoid    O
compounds    O
have    O
biological    O
effects    O
via    O
the    O
estrogen    O
receptor    O
.    O

Isoflavone    O
phytoestrogens    B-SteroidHormone114745635
-    O
found    O
primarily    O
in    O
soy    O
,    O
peanuts    O
,    O
and    O
other    O
members    O
of    O
the    O
Fabaceae    O
family    O

Genistein    B-SteroidHormone114745635
is    O
an    O
isoflavone    O
that    O
is    O
described    O
as    O
an    O
angiogenesis    O
inhibitor    O
and    O
a    O
phytoestrogen    B-SteroidHormone114745635
.    O

although    O
,    O
timing    O
of    O
phytoestrogen    B-SteroidHormone114745635
use    O
is    O
also    O
important    O
.    O

Other    O
forms    O
of    O
endocrine    O
disruptors    O
are    O
phytoestrogens    B-SteroidHormone114745635
(    O
plant    O
hormones    O
)    O
.    O

Some    O
other    O
examples    O
of    O
putative    O
EDCs    O
are    O
polychlorinated    O
dibenzo    O
-    O
dioxins    O
(    O
PCDDs    O
)    O
and    O
-furans    O
(    O
PCDFs    O
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
PAHs    O
)    O
,    O
phenol    O
derivatives    O
and    O
a    O
number    O
of    O
pesticides    O
(    O
most    O
prominent    O
being    O
organochlorine    O
insecticides    O
like    O
endosulfan    O
,    O
kepone    O
(    O
chlordecone    O
)    O
and    O
DDT    O
and    O
its    O
derivatives    O
,    O
the    O
herbicide    O
atrazine    O
,    O
and    O
the    O
fungicide    O
vinclozolin    O
)    O
,    O
the    O
contraceptive    O
17-alpha    O
ethinylestradiol    O
,    O
as    O
well    O
as    O
naturally    O
occurring    O
phytoestrogens    B-SteroidHormone114745635
such    O
as    O
genistein    B-SteroidHormone114745635
and    O
mycoestrogens    B-SteroidHormone114745635
such    O
as    O
zearalenone    O
.    O

Phytoestrogen    B-SteroidHormone114745635
,    O
plant    O
compounds    O
with    O
estrogen    O
-    O
like    O
biological    O
activity    O
,    O
such    O
as    O
genistein    B-SteroidHormone114745635
,    O
formononetin    B-SteroidHormone114745635
,    O
biochanin    O
A    O
and    O
daidzein    O
,    O
as    O
well    O
as    O
a    O
mixture    O
of    O
these    O
phytoestrogens    O
were    O
found    O
able    O
to    O
reduce    O
E    O
-    O
selectin    O
as    O
well    O
as    O
VCAM-1    O
and    O
ICAM-1    O
on    O
cell    O
surface    O
and    O
in    O
culture    O
supernatant    O
.    O

Although    O
there    O
is    O
only    O
preclinical    O
evidence    O
for    O
a    O
possible    O
mechanism    O
,    O
the    O
meta    O
-    O
analysis    O
report    O
stated    O
that    O
soy    O
phytoestrogens    B-SteroidHormone114745635
–    O
the    O
isoflavones    O
,    O
genistein    B-SteroidHormone114745635
and    O
daidzein    O
–    O
may    O
be    O
involved    O
in    O
reducing    O
serum    O
cholesterol    O
levels    O
.    O

To    O
reach    O
the    O
recommended    O
amount    O
of    O
fibre    O
,    O
consumption    O
of    O
dietary    O
fibre    O
from    O
foods    O
(    O
e.g.    O
plants    O
,    O
vegetables    O
,    O
legumes    O
,    O
and    O
grains    O
)    O
instead    O
of    O
supplements    O
is    O
preferred    O
because    O
they    O
contain    O
additional    O
beneficial    O
nutrients    O
and    O
non    O
-    O
nutritive    O
components    O
(    O
e.g.    O
antioxidants    O
and    O
phytoestrogens    B-SteroidHormone114745635
)    O
.    O

Furazabol    B-SteroidHormone114745635

Furazabol    B-SteroidHormone114745635

A    O
2008    O
report    O
demonstrated    O
evidence    O
of    O
the    O
effects    O
of    O
feminizing    B-SteroidHormone114745635
chemicals    I-SteroidHormone114745635
on    O
male    O
development    O
in    O
each    O
class    O
of    O
vertebrate    O
species    O
as    O
a    O
worldwide    O
phenomenon    O
;    O
these    O
chemical    O
are    O
suspected    O
of    O
reducing    O
the    O
sex    O
ratio    O
and    O
sperm    O
counts    O
in    O
humans    O
.    O

A    O
2008    O
report    O
provides    O
further    O
evidence    O
of    O
effects    O
of    O
feminizing    B-SteroidHormone114745635
chemicals    I-SteroidHormone114745635
on    O
male    O
development    O
in    O
each    O
class    O
of    O
vertebrate    O
species    O
as    O
a    O
worldwide    O
phenomenon    O
,    O
possibly    O
leading    O
to    O
a    O
decline    O
in    O
the    O
sex    O
ratio    O
in    O
humans    O
and    O
a    O
possible    O
decline    O
in    O
sperm    O
counts    O
.    O

Alkylphenols    O
are    O
xenoestrogens    B-SteroidHormone114745635
.    O

Xenoestrogen    B-SteroidHormone114745635

BPA    O
is    O
a    O
xenoestrogen    B-SteroidHormone114745635
,    O
exhibiting    O
estrogen    O
-    O
mimicking    O
,    O
hormone    O
-    O
like    O
properties    O
that    O
raise    O
concern    O
about    O
its    O
suitability    O
in    O
some    O
consumer    O
products    O
and    O
food    O
containers    O
.    O

This    O
may    O
be    O
the    O
mechanism    O
by    O
which    O
BPA    O
acts    O
as    O
a    O
xenoestrogen    B-SteroidHormone114745635
.    O

Allylestrenol    B-SteroidHormone114745635

Extension    O
of    O
the    O
C17α    O
alkyl    O
chain    O
longer    O
than    O
an    O
ethyl    O
group    O
abolishes    O
androgenic    O
activity    O
and    O
converts    O
the    O
drug    O
into    O
an    O
antiandrogen    B-SteroidHormone114745635
,    O
as    O
in    O
topterone    O
(    O
17α-propyltestosterone    O
)    O
and    O
allylestrenol    B-SteroidHormone114745635
(    O
17α-allyl-3-deketo-19-nortestosterone    O
)    O
(    O
an    O
extended    O
-    O
chain    O
variant    O
of    O
ethylestrenol    B-SteroidHormone114745635
)    O
.    O

Progestin    B-SteroidHormone114745635
challenge    I-SteroidHormone114745635

Calusterone    B-SteroidHormone114745635

Calusterone    B-SteroidHormone114745635

Metalloestrogen    B-SteroidHormone114745635
:    O
cadmium    O
,    O
others    O

Halotestin    B-SteroidHormone114745635

Fluoxymesterone    B-SteroidHormone114745635

Fluoxymesterone    B-SteroidHormone114745635

"    O
'    O
Rare    O
(    O
50    O
]    O
]    O
=    O
2.5    O
nM    O
)    O
and    O
17,20-lyase    O
(    O
IC50    O
=    O
15    O
nM    O
)    O
(    O
six    O
-    O
fold    O
more    O
selective    O
for    O
inhibition    O
of    O
17α-hydroxylase    O
over    O
17,20-lyase    O
)    O
that    O
are    O
expressed    O
in    O
testicular    O
,    O
adrenal    O
,    O
and    O
prostatic    O
tumor    O
tissues    O
.    O
CYP17    O
catalyzes    O
two    O
sequential    O
reactions    O
:    O
(    O
a    O
)    O
the    O
conversion    O
of    O
pregnenolone    O
and    O
progesterone    O
to    O
their    O
17α-hydroxy    O
derivatives    O
by    O
its    O
17α-hydroxylase    O
activity    O
,    O
and    O
(    O
b    O
)    O
the    O
subsequent    O
formation    O
of    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
and    O
androstenedione    B-SteroidHormone114745635
,    O
respectively    O
,    O
by    O
its    O
17,20-lyase    O
activity    O
.    O
DHEA    O
and    O
androstenedione    O

In    O
1998    O
,    O
gold    O
medalist    O
Randy    O
Barnes    O
was    O
tested    O
positive    O
for    O
androstenedione    B-SteroidHormone114745635
(    O
an    O
over    O
-    O
the    O
-    O
counter    O
supplement    O
famously    O
used    O
by    O
Mark    O
McGwire    O
)    O
,    O
and    O
was    O
subsequently    O
suspended    O
from    O
competition    O
in    O
the    O
Olympic    O
Games    O
for    O
life    O
.    O

17β-Hydroxysteroid    O
dehydrogenase    O
(    O
17β-HSD    O
)    O
inhibitors    O
prevent    O
the    O
reversible    O
conversion    O
of    O
the    O
weak    O
androgens    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
and    O
4-androstenedione    B-SteroidHormone114745635
into    O
the    O
more    O
potent    O
androgen    O
testosterone    O
and    O
the    O
weak    O
estrogen    O
estrone    O
into    O
the    O
more    O
potent    O
estrogen    O
estradiol    O
.    O

LH    O
induces    O
the    O
production    O
of    O
androgens    O
by    O
the    O
theca    O
cells    O
,    O
most    O
notably    O
androstendione    B-SteroidHormone114745635
,    O
which    O
are    O
aromatized    O
by    O
granulosa    O
cells    O
to    O
produce    O
estrogens    O
,    O
primarily    O
estradiol    O
.    O

A    O
deficiency    O
in    O
the    O
HSD17B3    O
gene    O
is    O
characterized    O
biochemically    O
by    O
decreased    O
levels    O
of    O
testosterone    O
and    O
increased    O
levels    O
of    O
androstenedione    O
as    O
a    O
result    O
of    O
the    O
defect    O
in    O
conversion    O
of    O
androstenedione    O
into    O
testosterone    O
,    O
this    O
leads    O
to    O
clinically    O
important    O
higher    O
ratio    O
of    O
androstenedione    B-SteroidHormone114745635
to    O
testosterone    O

Androstenedione    B-SteroidHormone114745635
is    O
a    O
hormone    O
that    O
is    O
converted    O
to    O
testosterone    O
by    O
enzymatic    O
activity    O
.    O

In    O
the    O
largest    O
nandrolone    O
study    O
performed    O
on    O
621    O
athletes    O
at    O
the    O
1998    O
Nagano    O
Olympic    O
Games    O
,    O
no    O
athlete    O
tested    O
over    O
0.4    O
μg    O
/    O
L.    O
19-Norandrosterone    O
was    O
identified    O
as    O
a    O
trace    O
contaminant    O
in    O
commercial    O
preparations    O
of    O
androstenedione    B-SteroidHormone114745635
,    O
which    O
until    O
2004    O
was    O
available    O
without    O
a    O
prescription    O
as    O
a    O
dietary    O
supplement    O
in    O
the    O
U.S.    O

By    O
inhibiting    O
3β-HSD    O
,    O
epostane    O
blocks    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-SteroidHormone114745635
(    O
and    O
also    O
the    O
conversion    O
of    O
dehydroepiandrosterone    B-SteroidHormone114745635
to    O
androstenedione    B-SteroidHormone114745635
)    O
,    O
thereby    O
functioning    O
as    O
an    O
antiprogestogen    O
and    O
terminating    O
pregnancy    O
.    O

In    O
the    O
ensuing    O
years    O
nasal    O
spray    O
preparations    O
containing    O
testosterone    O
or    O
androstenedione    B-SteroidHormone114745635
were    O
developed    O
in    O
collaboration    O
with    O
Jenapharm    O
,    O
tested    O
,    O
and    O
used    O
in    O
top    O
athletes    O
—    O
some    O
of    O
whom    O
did    O
not    O
like    O
this    O
mode    O
of    O
application    O
.    O
Doping    O
tests    O
at    O
the    O
time    O
used    O
the    O
T    O
:    O
E    O
(    O
testosterone    O
:    O
epitestosterone    B-SteroidHormone114745635
)    O
ratio    O
.    O

Levels    O
of    O
progesterone    O
,    O
17α-hydroxyprogesterone    O
,    O
androstenedione    B-SteroidHormone114745635
,    O
testosterone    O
,    O
and    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
were    O
elevated    O
in    O
the    O
sisters    O
,    O
while    O
concentrations    O
of    O
adrenal    O
steroids    O
including    O
cortisol    O
,    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
,    O
11β-hydroxyandrostenedione    O
,    O
11-deoxycortisol    O
,    O
and    O
21-deoxycortisol    O
were    O
within    O
normal    O
ranges    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
directly    O
stimulate    O
androgen    O
biosynthesis    O
in    O
the    O
gonads    O
via    O
inhibition    O
of    O
histone    O
deacetylases    O
and    O
has    O
been    O
associated    O
with    O
hyperandrogenism    B-SteroidHormone114745635
in    O
women    O
and    O
increased    O
4-androstenedione    B-SteroidHormone114745635
levels    O
in    O
men    O
.    O

Males    O
with    O
CAH    O
have    O
more    O
masculine    O
(    O
smaller    O
)    O
digit    O
ratios    O
than    O
control    O
males    O
,    O
which    O
also    O
suggests    O
that    O
prenatal    O
androgens    O
affect    O
digit    O
ratios    O
,    O
since    O
amniocentesis    O
samples    O
show    O
that    O
prenatal    O
levels    O
of    O
testosterone    O
are    O
in    O
the    O
high    O
normal    O
range    O
in    O
males    O
with    O
CAH    O
,    O
while    O
levels    O
of    O
the    O
weaker    O
androgen    O
androstenedione    B-SteroidHormone114745635
are    O
several    O
fold    O
higher    O
than    O
in    O
control    O
males    O
.    O

|rowspan=3|    O
Androstenedione    B-SteroidHormone114745635

Then    O
,    O
in    O
an    O
IAAF    O
out    O
-    O
of    O
-    O
competition    O
test    O
conducted    O
in    O
March    O
2005    O
,    O
Badji    O
tested    O
positive    O
for    O
the    O
illegal    O
substance    O
androstenedione    B-SteroidHormone114745635
.    O

4-Androstene-3,17-dione    B-SteroidHormone114745635

It    O
produces    O
androgens    O
,    O
mainly    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
,    O
DHEA    O
sulfate    O
(    O
DHEA    O
-    O
S    O
)    O
,    O
and    O
androstenedione    B-SteroidHormone114745635
(    O
the    O
precursor    O
to    O
testosterone    O
)    O
in    O
humans    O
.    O

This    O
includes    O
interconversion    O
of    O
DHEA    B-SteroidHormone114745635
and    O
androstenediol    O
,    O
androstenedione    B-SteroidHormone114745635
and    O
testosterone    O
,    O
and    O
estrone    O
and    O
estradiol    O
.    O

Androstenedione    B-SteroidHormone114745635
↔    O
Testosterone    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-SteroidHormone114745635
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    B-SteroidHormone114745635
from    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

DHEA    B-SteroidHormone114745635
to    O
androstenedione    B-SteroidHormone114745635

Androstenedione    B-SteroidHormone114745635

methallenestril    B-SteroidHormone114745635
(    O
INN    O
)    O

Methallenestril    B-SteroidHormone114745635

mometasone    B-SteroidHormone114745635
(    O
INN    O
)    O

Mometasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635
,    O
an    O
inhaled    O
corticosteroid    O
(    O
anti    O
-    O
inflammatory    O
)    O

A    O
variety    O
of    O
steroid    O
medications    O
,    O
from    O
anti    O
-    O
allergy    O
nasal    O
sprays    O
(    O
Nasonex    B-SteroidHormone114745635
,    O
Flonase    B-SteroidHormone114745635
)    O
to    O
topical    O
skin    O
creams    O
,    O
to    O
eye    O
drops    O
(    O
Tobradex    O
)    O
,    O
to    O
prednisone    O
have    O
been    O
implicated    O
in    O
the    O
development    O
of    O
CSR    O
.    O

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
mometasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635
.    O

Alclometasone    B-SteroidHormone114745635
=    O
7α-chloro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O

Fluocortin    B-SteroidHormone114745635
=    O
6α-fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20,21-trione    O

Micronor    B-SteroidHormone114745635

:    O
norethisterone    B-SteroidHormone114745635
(    O
contraceptive    O
)    O

In    O
contrast    O
,    O
the    O
non    O
-    O
halogenated    O
19-nortestosterone    O
derivatives    O
norgestrel    O
,    O
norethisterone    B-SteroidHormone114745635
,    O
noretynodrel    O
,    O
and    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
were    O
not    O
found    O
to    O
produce    O
such    O
nodules    O
.    O

It    O
is    O
a    O
chloroethynylated    O
derivative    O
of    O
norethisterone    B-SteroidHormone114745635
.    O

In    O
contrast    O
,    O
the    O
non    O
-    O
halogenated    O
19-nortestosterone    O
derivatives    O
norgestrel    O
,    O
norethisterone    B-SteroidHormone114745635
,    O
noretynodrel    O
,    O
and    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
which    O
are    O
much    O
less    O
potent    O
as    O
progestogens    O
,    O
did    O
not    O
produce    O
such    O
effects    O
at    O
the    O
dosages    O
tested    O
.    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Nandrolone    O
,    O
together    O
with    O
ethisterone    B-SteroidHormone114745635
(    O
17α-ethynyltestosterone    O
)    O
,    O
is    O
also    O
the    O
parent    O
compound    O
of    O
a    O
large    O
group    O
of    O
progestins    O
,    O
the    O
norethisterone    B-SteroidHormone114745635
(    O
17α-ethynyl-19-nortestosterone    O
)    O
derivatives    O
.    O

The    O
estranes    O
include    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
norethisterone    O
enanthate    O
,    O
lynestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
and    O
noretynodrel    O
,    O
while    O
the    O
gonanes    O
include    O
norgestrel    O
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
desogestrel    B-SteroidHormone114745635
,    O
etonogestrel    B-SteroidHormone114745635
,    O
gestodene    B-SteroidHormone114745635
,    O
norgestimate    B-SteroidHormone114745635
,    O
dienogest    B-SteroidHormone114745635
(    O
actually    O
a    O
17α-cyanomethyl-19-nortestosterone    O
derivative    O
)    O
,    O
and    O
norelgestromin    B-SteroidHormone114745635
.    O

In    O
1978    O
the    O
company    O
brought    O
to    O
market    O
the    O
first    O
once    O
-    O
a    O
-    O
week    O
oral    O
contraceptive    O
"    O
Deposiston    O
"    O
,    O
a    O
combination    O
of    O
ethinylestradiol    O
sulfonate    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    O
.    O

Treatment    O
with    O
a    O
progestin    O
,    O
norethisterone    B-SteroidHormone114745635
,    O
reduced    O
her    O
estradiol    O
concentrations    O
to    O
normal    O
levels    O
and    O
decreased    O
the    O
size    O
of    O
her    O
ovaries    O
and    O
the    O
number    O
of    O
ovarian    O
cysts    O
,    O
alleviating    O
her    O
hypothalamic    O
-    O
pituitary    O
-    O
gonadal    O
axis    O
hyperactivity    O
and    O
ovarian    O
pathology    O
.    O

Examples    O
include    O
drugs    O
such    O
as    O
Norethisterone    B-SteroidHormone114745635
,    O
Ethisterone    B-SteroidHormone114745635
,    O
and    O
Lynestrenol    B-SteroidHormone114745635
.    O

A    O
2001    O
comparative    O
study    O
of    O
the    O
IMS    O
LifeLink    O
Health    O
Plan    O
Claims    O
Database    O
interpreted    O
that    O
in    O
a    O
large    O
cohort    O
of    O
women    O
using    O
oral    O
contraceptives    O
,    O
there    O
was    O
found    O
a    O
small    O
,    O
statistically    O
significant    O
increase    O
in    O
the    O
risk    O
of    O
gallbladder    O
disease    O
associated    O
with    O
desogestrel    B-SteroidHormone114745635
,    O
drospirenone    O
and    O
norethisterone    B-SteroidHormone114745635
compared    O
with    O
levonorgestrel    B-SteroidHormone114745635
.    O

Conversely    O
,    O
replacement    O
of    O
the    O
C17α    O
alkyl    O
group    O
with    O
an    O
ethynyl    O
group    O
greatly    O
reduces    O
but    O
does    O
not    O
abolish    O
androgenic    O
activity    O
,    O
as    O
in    O
ethisterone    B-SteroidHormone114745635
(    O
17α-ethynyltestosterone    O
)    O
and    O
norethisterone    B-SteroidHormone114745635
(    O
17α-ethynyl-19-nortestosterone    O
)    O
.    O

Camila    O
,    O
brand    O
name    O
of    O
a    O
progestogen    O
-    O
only    O
pill    O
containing    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O

Good    O
was    O
pulled    O
from    O
his    O
initial    O
UFC    O
debut    O
on    O
November    O
12    O
,    O
2016    O
at    O
UFC    O
205    O
from    O
a    O
USADA    O
voilation    O
stemming    O
from    O
an    O
out    O
-    O
of    O
-    O
competition    O
sample    O
collected    O
ten    O
days    O
earlier    O
where    O
by    O
Good    O
ingested    O
1-androstenedione    B-SteroidHormone114745635
and    O
he    O
was    O
given    O
a    O
six    O
month    O
ban    O
.    O

1-Androstenedione    B-SteroidHormone114745635

Beclomethasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635

One    O
commonly    O
used    O
therapy    O
is    O
beclometasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
.    O

Delestrogen    B-SteroidHormone114745635

estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
(    O
INN    O
)    O

Along    O
with    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
,    O
and    O
estradiol    B-SteroidHormone114745635
benzoate    I-SteroidHormone114745635
,    O
estradiol    O
undecylate    O
is    O
or    O
has    O
been    O
used    O
as    O
an    O
intramuscular    O
estrogen    O
in    O
hormone    O
replacement    O
therapy    O
for    O
transgender    O
women    O
.    O

For    O
comparison    O
,    O
the    O
ester    O
chains    O
of    O
estradiol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
and    O
estradiol    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
have    O
2    O
,    O
5    O
,    O
and    O
7    O
carbon    O
atoms    O
,    O
respectively    O
.    O

Estradiol    O
undecylate    O
was    O
developed    O
,    O
along    O
with    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
,    O
in    O
1954    O
.    O

Prior    O
to    O
the    O
development    O
and    O
introduction    O
of    O
estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635
and    O
estradiol    B-SteroidHormone114745635
cypionate    I-SteroidHormone114745635
in    O
the    O
1950s    O
,    O
estradiol    O
dipropionate    O
and    O
estradiol    O
benzoate    O
were    O
the    O
most    O
widely    O
used    O
estradiol    O
esters    O
.    O

Estradiol    B-SteroidHormone114745635
valerate    I-SteroidHormone114745635

Under    O
the    O
developmental    O
code    O
name    O
MK-665    O
,    O
it    O
was    O
studied    O
in    O
combination    O
with    O
mestranol    O
as    O
an    O
oral    B-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
.    O

In    O
the    O
1999    O
ratings    O
for    O
88    O
countries    O
,    O
73%    O
of    O
countries    O
offered    O
condoms    O
to    O
at    O
least    O
half    O
their    O
population    O
,    O
65%    O
of    O
countries    O
offered    O
the    B-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
54%    O
offered    O
IUDs    O
,    O
42%    O
offered    O
female    O
sterilization    O
,    O
and    O
26%    O
offered    O
male    O
sterilization    O
.    O

In    O
1970    O
,    O
Nelson    O
called    O
for    O
Congressional    O
hearings    O
on    O
the    O
safety    O
of    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
which    O
were    O
famously    O
called    O
"    O
The    O
Nelson    O
Pill    O
Hearings    O
.    O
"    O

Terry    O
Prone    O
demonstrated    O
her    O
view    O
that    O
soaps    O
,    O
rather    O
than    O
"    O
dusty    O
old    O
current    O
affairs    O
programmes    O
"    O
,    O
had    O
been    O
central    O
to    O
social    O
change    O
.    O
"    O
The    O
Riordans    O
"    O
caused    O
scandal    O
when    O
one    O
of    O
the    O
characters    O
,    O
named    O
Maggie    O
,    O
went    O
on    O
the    B-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

Oftentimes    O
,    O
for    O
women    O
treating    O
acne    O
,    O
spironolactone    O
is    O
prescribed    O
and    O
paired    O
with    O
a    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

The    O
DU    O
spectrophotometer    O
was    O
also    O
used    O
in    O
the    O
study    O
of    O
steroids    O
by    O
researchers    O
like    O
Alejandro    O
Zaffaroni    O
,    O
who    O
helped    O
to    O
develop    O
the    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
the    O
nicotine    O
patch    O
,    O
and    O
corticosteroids    O
.    O

She    O
is    O
currently    O
working    O
on    O
her    O
third    O
film    O
,    O
"    O
Sweetening    O
the    O
Pill    O
,    O
"    O
a    O
film    O
that    O
aims    O
to    O
address    O
the    O
side    O
effects    O
of    O
taking    O
the    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

The    O
first    O
highly    O
successful    O
instance    O
being    O
the    O
discovery    O
in    O
1947    O
of    O
the    O
tuber    O
"    O
Barbasco    O
"    O
(    O
"    O
Dioscorea    O
composita    O
"    O
)    O
which    O
has    O
a    O
high    O
content    O
of    O
diosgenin    O
,    O
revolutionizing    O
the    O
production    O
of    O
synthetic    O
hormones    O
in    O
the    O
1950s    O
and    O
1960s    O
and    O
eventually    O
leading    O
to    O
the    O
invention    O
of    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

There    O
is    O
currently    O
contention    O
over    O
whether    O
hormonal    O
contraception    O
methods    O
have    O
post    O
-    O
fertilization    O
methods    O
,    O
specifically    O
the    O
most    O
popular    O
hormonal    O
method    O
-    O
the    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
(    O
COCP    O
)    O
.    O

The    O
advent    O
of    O
the    B-SteroidHormone114745635
pill    I-SteroidHormone114745635
and    O
other    O
forms    O
of    O
birth    O
control    O
,    O
the    O
Women    O
's    O
Liberation    O
movement    O
,    O
and    O
the    O
legalization    O
of    O
abortion    O
in    O
many    O
countries    O
are    O
believed    O
to    O
have    O
led    O
to    O
a    O
wider    O
practice    O
of    O
casual    O
sex    O
.    O

Many    O
common    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
could    O
be    O
used    O
for    O
the    O
Yuzpe    O
regimen    O
,    O
although    O
their    O
manufacturers    O
did    O
not    O
label    O
the    O
pills    O
for    O
this    O
use    O
.    O

The    O
Food    O
and    O
Drug    O
Administration    O
announces    O
it    O
will    O
approve    O
birth    O
control    O
as    O
an    O
additional    O
indication    O
for    O
Searle    O
's    O
Enovid    O
,    O
making    O
Enovid    O
the    O
world    O
's    O
first    O
approved    O
oral    B-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

In    O
1966    O
,    O
the    O
band    O
was    O
suspended    O
for    O
several    O
games    O
for    O
the    O
infamous    O
"    O
birth    O
control    O
"    O
show    O
where    O
they    O
formed    O
a    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
a    O
calendar    O
(    O
for    O
the    O
rhythm    O
method    O
)    O
,    O
and    O
a    O
chastity    O
belt    O
.    O

4    O
December    O
–    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pills    I-SteroidHormone114745635
become    O
available    O
on    O
the    O
National    O
Health    O
Service    O
after    O
their    O
availability    O
is    O
backed    O
by    O
Health    O
Minister    O
Enoch    O
Powell    O
.    O

The    O
PDA    O
discovered    O
that    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pills    I-SteroidHormone114745635
were    O
used    O
by    O
only    O
20%    O
of    O
the    O
population    O
because    O
getting    O
them    O
required    O
access    O
to    O
medical    O
personnel    O
.    O

On    O
her    O
break    O
,    O
Peggy    O
goes    O
to    O
the    O
office    O
of    O
a    O
doctor    O
recommended    O
by    O
the    O
all    O
-    O
knowing    O
Joan    O
,    O
where    O
she    O
gets    O
a    O
prescription    O
for    O
the    O
recently    O
introduced    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
which    O
at    O
the    O
time    O
was    O
not    O
supposed    O
to    O
be    O
prescribed    O
to    O
unmarried    O
women    O
or    O
married    O
women    O
without    O
their    O
husband    O
's    O
consent    O
.    O

The    O
first    O
large    O
-    O
scale    O
human    O
trial    O
of    O
the    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
was    O
carried    O
out    O
in    O
Puerto    O
Rico    O
in    O
the    O
1950s    O
.    O

Carl    O
Djerassi    O
-    O
chemist    O
,    O
developed    O
the    O
first    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
nominated    O
as    O
one    O
of    O
the    O
greatest    O
medical    O
discoveries    O
in    O
the    O
last    O
166    O
years    O

Such    O
preparations    O
were    O
used    O
in    O
early    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

Tanaka    O
's    O
views    O
on    O
abortion    O
became    O
well    O
publicized    O
and    O
controversial    O
:    O
Other    O
Japanese    O
feminists    O
protested    O
in    O
favour    O
of    O
legalization    O
of    O
the    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
during    O
the    O
same    O
era    O
.    O

If    O
they    O
took    O
contraceptive    B-SteroidHormone114745635
pills    I-SteroidHormone114745635
,    O
he    O
told    O
them    O
to    O
stop    O
it    O
and    O
they    O
felt    O
they    O
had    O
to    O
obey    O
.    O

It    O
is    O
also    O
used    O
as    O
an    O
oral    B-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
with    O
estradiol    O
(    O
as    O
Zoely    O
)    O
.    O

She    O
funded    O
most    O
of    O
the    O
research    O
necessary    O
to    O
develop    O
the    O
first    B-SteroidHormone114745635
birth    I-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

Estradiol    O
and    O
progesterone    O
,    O
taken    O
in    O
various    O
forms    O
including    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
mimics    O
the    O
hormonal    O
levels    O
of    O
the    O
menstrual    O
cycle    O
and    O
engage    O
in    O
negative    O
feedback    O
of    O
folliculogenesis    O
and    O
ovulation    O
.    O

In    O
those    O
with    O
more    O
significant    O
symptoms    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
or    O
the    O
diuretic    O
spironolactone    O
may    O
be    O
useful    O
.    O

In    O
those    O
with    O
more    O
significant    O
symptoms    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
may    O
be    O
useful    O
.    O

Hormonal    O
contraception    O
is    O
commonly    O
used    O
;    O
common    O
forms    O
include    O
the    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
and    O
the    O
contraceptive    O
patch    O
.    O

Before    O
the    O
highly    O
effective    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
was    O
available    O
,    O
women    O
planning    O
professional    O
careers    O
,    O
which    O
required    O
a    O
long    O
-    O
term    O
,    O
expensive    O
commitment    O
,    O
had    O
to    O
"    O
pay    O
the    O
penalty    O
of    O
abstinence    O
or    O
cope    O
with    O
considerable    O
uncertainty    O
regarding    O
pregnancy    O
.    O
"    O
This    O
control    O
over    O
their    O
reproductive    O
decisions    O
allowed    O
women    O
to    O
more    O
easily    O
make    O
long    O
-    O
term    O
decisions    O
about    O
their    O
education    O
and    O
professional    O
opportunities    O
.    O

Given    O
that    O
older    O
studies    O
show    O
no    O
difference    O
in    O
incidence    O
between    O
men    O
and    O
women    O
,    O
it    O
has    O
been    O
suggested    O
that    O
the    O
use    O
of    O
oral    B-SteroidHormone114745635
contraceptives    I-SteroidHormone114745635
in    O
women    O
is    O
behind    O
the    O
disparity    O
between    O
the    O
sexes    O
.    O

The    O
decline    O
in    O
the    O
fertility    O
rate    O
is    O
associated    O
with    O
the    O
introduction    O
of    O
the    B-SteroidHormone114745635
pill    I-SteroidHormone114745635
in    O
1960    O
,    O
the    O
completion    O
of    O
legalization    O
of    O
artificial    O
birth    O
control    O
methods    O
,    O
the    O
introduction    O
of    O
federal    O
funding    O
to    O
make    O
family    O
planning    O
services    O
more    O
available    O
to    O
the    O
young    O
and    O
low    O
income    O
,    O
and    O
the    O
legalization    O
of    O
abortion    O
.    O

The    O
Editor    O
of    O
"    O
The    O
Irish    O
Times    O
"    O
,    O
Douglas    O
Gageby    O
,    O
is    O
in    O
favour    O
of    O
open    O
debate    O
over    O
the    O
contraceptive    B-SteroidHormone114745635
pill    I-SteroidHormone114745635
in    O
the    O
correspondence    O
columns    O
of    O
his    O
newspaper    O
,    O
and    O
reflects    O
on    O
the    O
emerging    O
difficulties    O
of    O
censorship    O
.    O

Other    O
elements    O
of    O
the    O
sexual    O
revolution    O
included    O
the    O
development    O
of    O
The    B-SteroidHormone114745635
Pill    I-SteroidHormone114745635
,    O
Mary    O
Quant    O
's    O
miniskirt    O
and    O
the    O
1967    O
legalisation    O
of    O
homosexuality    O
.    O

Min    O
Chueh    O
Chang    O
(    O
張明覺    O
)    O
-    O
co    O
-    O
inventor    O
of    O
the    O
first    B-SteroidHormone114745635
birth    I-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
;    O
made    O
significant    O
contributions    O
to    O
the    O
development    O
of    O
in    O
vitro    O
fertilisation    O

With    O
the    O
appearance    O
of    O
the    O
first    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptives    I-SteroidHormone114745635
in    O
1960    O
,    O
dissenters    O
in    O
the    O
Church    O
argued    O
for    O
a    O
reconsideration    O
of    O
the    O
Church    O
positions    O
.    O

Gregory    O
Goodwin    O
Pincus    O
,    O
one    O
of    O
the    O
three    O
"    O
fathers    O
"    O
of    O
the    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635

Behaviors    O
surrounding    O
the    O
testing    O
period    O
have    O
been    O
extreme    O
under    O
some    O
reports    O
,    O
with    O
doctors    O
in    O
Tianjin    O
purportedly    O
prescribing    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
to    O
female    O
students    O
whose    O
parents    O
wanted    O
to    O
ensure    O
the    O
girls    O
were    O
not    O
menstruating    O
at    O
the    O
time    O
of    O
examination    O
.    O

With    O
the    O
discovery    O
of    O
the    O
chemical    O
properties    O
of    O
the    O
barbasco    O
root    O
,    O
world    O
market    O
prices    O
for    O
steroids    O
and    O
other    O
synthetic    O
hormones    O
plummeted    O
-    O
making    O
them    O
feasible    O
for    O
large    O
scale    O
production    O
of    O
medicines    O
for    O
common    O
ailments    O
such    O
as    O
arthritis    O
or    O
Addison    O
's    O
disease    O
,    O
and    O
eventually    O
as    O
the    O
basis    O
for    O
the    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

Carl    O
Djerassi    O
-    O
the    O
inventor    O
of    O
the    O
first    B-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
.    O

Ethinylestradiol    O
/    O
levonorgestrel    O
(    O
also    O
ethinyl    O
estradiol    O
/    O
levonorgestrel    O
)    O
is    O
a    O
combined    B-SteroidHormone114745635
birth    I-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
made    O
up    O
of    O
ethinylestradiol    O
,    O
an    O
estrogen    O
and    O
levonorgestrel    B-SteroidHormone114745635
a    O
progestin    O
.    O

The    O
1960s    O
introduced    O
the    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
—    O
and    O
the    O
potential    O
for    O
women    O
to    O
gain    O
greater    O
control    O
over    O
their    O
reproductive    O
lives    O
.    O

The    O
majority    O
of    O
studies    O
indicate    O
antibiotics    O
do    O
not    O
interfere    O
with    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
such    O
as    O
clinical    O
studies    O
that    O
suggest    O
the    O
failure    O
rate    O
of    O
contraceptive    O
pills    O
caused    O
by    O
antibiotics    O
is    O
very    O
low    O
(    O
about    O
1%    O
)    O
.    O

During    O
the    O
Francisco    O
Franco    O
years    O
,    O
the    O
ban    O
on    O
the    O
sale    O
of    O
contraceptives    O
was    O
complete    O
and    O
rigid    O
at    O
least    O
in    O
theory    O
,    O
even    O
though    O
the    O
introduction    O
of    O
the    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
had    O
brought    O
contraception    O
to    O
at    O
least    O
half    O
a    O
million    O
Spanish    O
women    O
by    O
1975    O
.    O

The    O
song    O
tells    O
a    O
story    O
of    O
a    O
wife    O
who    O
is    O
upset    O
about    O
her    O
husband    O
getting    O
her    O
pregnant    O
year    O
after    O
year    O
,    O
but    O
is    O
now    O
happy    O
because    O
she    O
can    O
control    O
her    O
own    O
reproductive    O
choices    O
because    O
she    O
has    O
"    O
the    B-SteroidHormone114745635
Pill    I-SteroidHormone114745635
"    O
(    O
which    O
had    O
been    O
introduced    O
in    O
1960    O
)    O
.    O

Mestranol    O
/    O
norethynodrel    O
was    O
the    O
first    O
combined    B-SteroidHormone114745635
oral    I-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
(    O
COCP    O
)    O
being    O
mestranol    O
and    O
norethynodrel    O
.    O

He    O
is    O
best    O
known    O
for    O
the    O
major    O
role    O
he    O
played    O
in    O
the    O
development    O
of    O
the    O
first    O
birth    B-SteroidHormone114745635
control    I-SteroidHormone114745635
pill    I-SteroidHormone114745635
,    O
colloquially    O
called    O
"    O
the    O
pill    O
"    O
.    O

Older    O
high    O
-    O
dose    O
estrogen    O
oral    B-SteroidHormone114745635
contraceptive    I-SteroidHormone114745635
pills    I-SteroidHormone114745635
could    O
cause    O
features    O
of    O
ICP    O
.    O

Mauldin    O
,    O
a    O
divorced    O
mother    O
of    O
two    O
,    O
was    O
working    O
for    O
32    O
hours    O
per    O
week    O
at    O
a    O
rate    O
of    O
US$    O
12.14    O
per    O
hour    O
and    O
spending    O
$    O
30    O
a    O
month    O
on    O
birth-control    B-SteroidHormone114745635
pills    I-SteroidHormone114745635
.    O

Aldosterone    O
synthase    O
converts    O
11-deoxycorticosterone    B-SteroidHormone114745635
to    O
corticosterone    O
,    O
to    O
18-hydroxycorticosterone    B-SteroidHormone114745635
,    O
and    O
finally    O
to    O
aldosterone    O
:    O

In    O
the    O
potential    O
case    O
where    O
aldosterone    O
synthase    O
is    O
not    O
metabolically    O
active    O
the    O
body    O
accumulates    O
11-deoxycorticosterone    B-SteroidHormone114745635
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
11-deoxycorticosterone    B-SteroidHormone114745635
,    O
and    O
one    O
product    O
,    O
20-hydroxy-3-oxopregn-4-en-21-al    O
.    O

Fludrocortisone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
deoxycorticosterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
are    O
,    O
by    O
definition    O
,    O
mineralocorticoids    O
rather    O
than    O
glucocorticoids    O
,    O
but    O
they    O
do    O
have    O
minor    O
glucocorticoid    O
potency    O
and    O
are    O
included    O
in    O
this    O
table    O
to    O
provide    O
perspective    O
on    O
mineralocorticoid    O
potency    O
.    O

New    O
York    O
New    O
York    O
Yankees    O
outfielder    O
Matt    O
Lawton    O
tested    O
positive    O
for    O
boldenone    B-SteroidHormone114745635
,    O
in    O
violation    O
of    O
Major    O
League    O
Baseball    O
drug    O
policy    O
,    O
and    O
will    O
be    O
suspended    O
for    O
the    O
first    O
ten    O
games    O
of    O
the    O
2006    O
season    O
.    O

Anabolic    O
androgenic    O
steroid    O
(    O
AAS    O
)    O
use    O
can    O
also    O
increase    O
the    O
amount    O
of    O
RBCs    O
and    O
,    O
therefore    O
,    O
impact    O
the    O
hematocrit    O
,    O
in    O
particular    O
the    O
compounds    O
boldenone    B-SteroidHormone114745635
and    O
oxymetholone    B-SteroidHormone114745635
.    O

Boldenone    B-SteroidHormone114745635
,    O
also    O
known    O
as    O
Δ1-testosterone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
the    O
1(2)-dehydrogenated    O
analogue    O
of    O
testosterone    O
.    O

Boldenone    B-SteroidHormone114745635

The    O
drug    O
is    O
also    O
the    O
17α-methylated    O
derivative    O
of    O
boldenone    B-SteroidHormone114745635
(    O
δ1-testosterone    O
)    O
and    O
the    O
δ1    O
analogue    O
of    O
methyltestosterone    O
(    O
17α-methyltestosterone    O
)    O
.    O

In    O
February    O
2012    O
,    O
Thompson    O
,    O
alongside    O
Comunicaciones    O
teammates    O
Adolfo    O
Machado    O
and    O
Marvin    O
Ceballos    O
,    O
was    O
temporarily    O
suspended    O
from    O
playing    O
by    O
FIFA    O
after    O
a    O
positive    O
test    O
on    O
the    O
banned    O
substance    O
boldenone    B-SteroidHormone114745635
.    O

Amir    O
Aliakbari    O
of    O
Iran    O
originally    O
won    O
the    O
gold    O
medal    O
,    O
but    O
was    O
disqualified    O
after    O
he    O
tested    O
positive    O
for    O
Anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

In    O
the    O
episode    O
,    O
Marge    O
develops    O
agoraphobia    O
in    O
response    O
to    O
a    O
traumatic    O
mugging    O
and    O
overcomes    O
the    O
fear    O
through    O
exercise    O
and    O
bodybuilding    O
,    O
which    O
ultimately    O
leads    O
to    O
her    O
taking    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
and    O
experiencing    O
a    O
change    O
in    O
personality    O
.    O

That    O
medal    O
was    O
lost    O
a    O
couple    O
of    O
days    O
later    O
when    O
it    O
was    O
found    O
that    O
he    O
had    O
used    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
.    O

In    O
1990    O
,    O
the    O
US    O
Congress    O
passed    O
an    O
omnibus    O
crime    O
bill    O
,    O
the    O
Crime    O
Control    O
Act    O
of    O
1990    O
,    O
that    O
amended    O
the    O
Federal    O
Food    O
,    O
Drug    O
,    O
and    O
Cosmetic    O
Act    O
,    O
that    O
classified    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
as    O
controlled    O
substances    O
and    O
added    O
a    O
new    O
section    O
which    O
reads    O
:    O

Clostebol    B-SteroidHormone114745635
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
4-chlorotestosterone    B-SteroidHormone114745635
,    O
usually    O
as    O
the    O
ester    O
clostebol    O
acetate    O
,    O
is    O
a    O
synthetic    O
anabolic    B-SteroidHormone114745635
androgenic    I-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
.    O

However    O
,    O
the    O
MLB    O
has    O
received    O
some    O
criticism    O
because    O
the    O
consequences    O
for    O
amphetamine    O
use    O
are    O
dramatically    O
less    O
severe    O
than    O
for    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
,    O
with    O
the    O
first    O
offense    O
bringing    O
only    O
a    O
warning    O
and    O
further    O
testing    O
.    O

Trenbolone    O
enanthate    O
(    O
nickname    O
Trenabol    O
)    O
,    O
or    O
trenbolone    O
heptanoate    O
,    O
also    O
known    O
as    O
19-nor-δ9,11-testosterone    O
17β-enanthate    O
or    O
as    O
19-norandrost-4,9,11-trien-17β-ol-3-one    O
17β-enanthate    O
,    O
is    O
a    O
synthetic    O
,    O
injected    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
derivative    O
of    O
19-nortestosterone    O
(    O
nandrolone    O
)    O
that    O
was    O
never    O
marketed    O
.    O

Howard    O
Bryant    O
in    O
the    O
Acknowledgments    O
section    O
of    O
"    O
Juicing    O
the    O
Game    O
"    O
,    O
his    O
2005    O
book    O
about    O
steroids    B-SteroidHormone114745635
in    O
baseball    O
,    O
said    O
of    O
Halberstam    O
's    O
assistance    O
:    O
"    O
He    O
provided    O
me    O
with    O
a    O
succinct    O
road    O
map    O
and    O
the    O
proper    O
mind    O
-    O
set    O
.    O
"    O

The    O
various    O
factory    O
team    O
sponsors    O
were    O
taking    O
a    O
vigorous    O
zero    O
tolerance    O
policies    O
particularly    O
ever    O
since    O
the    O
revelations    O
of    O
Ronnie    O
Anderson    O
's    O
admitted    O
10    O
year    O
drug    O
habit    O
as    O
he    O
revealed    O
in    O
quotes    O
in    O
the    O
December    O
8    O
,    O
1986    O
issue    O
of    O
"    O
Sports    O
Illustrated    O
"    O
and    O
rumors    O
and    O
accusations    O
of    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
by    O
top    O
pro    O
racer    O
Pete    O
Loncarevich    O
which    O
were    O
never    O
substantiated    O
.    O

These    O
caused    O
health    O
problems    O
for    O
her    O
in    O
later    O
life    O
,    O
including    O
a    O
liver    O
tumor    O
she    O
attributed    O
to    O
the    O
use    O
of    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
and    O
birth    O
control    O
pills    O
.    O

They    O
know    O
each    O
other    O
from    O
university    O
and    O
he    O
is    O
studying    O
for    O
a    O
PhD.    O
Is    O
apparently    O
extremely    O
well    O
endowed    O
,    O
having    O
compared    O
his    O
penis    O
to    O
a    O
can    O
of    O
Red    O
Bull    O
and    O
his    O
testicles    O
to    O
Ribena    O
berries    O
on    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Nandrolone    O
is    O
an    O
injected    O
anabolic–androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
which    O
is    O
used    O
medically    O
in    O
the    O
form    O
of    O
esters    O
such    O
as    O
nandrolone    O
decanoate    O
(    O
brand    O
name    O
Deca    O
-    O
Durabolin    O
)    O
and    O
nandrolone    O
phenylpropionate    O
(    O
brand    O
name    O
Durabolin    O
)    O
.    O

On    O
February    O
12    O
,    O
2013    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
Perepetchenov    O
of    O
his    O
2004    O
Olympic    O
medal    O
after    O
both    O
probes    O
were    O
retested    O
and    O
showed    O
traces    O
of    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Selective    O
androgen    O
receptor    O
modulators    O
may    O
also    O
be    O
used    O
by    O
athletes    O
to    O
assist    O
in    O
training    O
and    O
increase    O
physical    O
stamina    O
and    O
fitness    O
,    O
potentially    O
producing    O
effects    O
similar    O
to    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
but    O
with    O
significantly    O
fewer    O
side    O
effects    O
.    O

SARMs    O
are    O
a    O
new    O
class    O
of    O
drugs    O
which    O
produce    O
tissue    O
-    O
specific    O
anabolic    O
effects    O
in    O
some    O
tissues    O
such    O
as    O
muscle    O
and    O
bone    O
,    O
but    O
without    O
stimulating    O
androgen    O
receptors    O
in    O
other    O
tissues    O
such    O
as    O
in    O
the    O
prostate    O
gland    O
,    O
thus    O
avoiding    O
side    O
effects    O
such    O
as    O
benign    O
prostatic    O
hypertrophy    O
which    O
can    O
occur    O
following    O
treatment    O
with    O
unselective    O
androgens    O
like    O
testosterone    O
or    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Rhesus    O
growth    O
hormone    O
was    O
never    O
used    O
by    O
physicians    O
to    O
treat    O
human    O
patients    O
,    O
but    O
rhesus    O
GH    O
was    O
part    O
of    O
the    O
lore    O
of    O
the    O
underground    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
community    O
in    O
those    O
years    O
,    O
and    O
fraudulent    O
versions    O
may    O
have    O
been    O
bought    O
and    O
sold    O
in    O
gyms    O
.    O

In    O
the    O
book    O
,    O
he    O
freely    O
admits    O
that    O
his    O
athletes    O
were    O
taking    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
,    O
as    O
he    O
claims    O
all    O
top    O
athletes    O
at    O
the    O
time    O
were    O
,    O
and    O
also    O
claims    O
that    O
Johnson    O
could    O
not    O
possibly    O
have    O
tested    O
positive    O
for    O
that    O
particular    O
steroid    O
since    O
Johnson    O
actually    O
preferred    O
furazabol    B-SteroidHormone114745635
.    O

The    O
subsequent    O
release    O
of    O
state    O
documents    O
showed    O
Madetzky    O
was    O
given    O
an    O
annual    O
amount    O
of    O
2390    O
mg    O
of    O
Oral    O
-    O
Turinabol    O
(    O
a    O
banned    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
)    O
during    O
her    O
career    O
under    O
coach    O
Gerhard    O
Böttcher    O
.    O

In    O
addition    O
to    O
the    O
sports    O
storylines    O
,    O
the    O
strip    O
also    O
deals    O
with    O
issues    O
facing    O
teenagers    O
such    O
as    O
teen    O
pregnancy    O
,    O
steroids    B-SteroidHormone114745635
,    O
and    O
drug    O
abuse    O
.    O

Cloxotestosterone    B-SteroidHormone114745635
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
17β-chloral    B-SteroidHormone114745635
hemiacetal    I-SteroidHormone114745635
testosterone    I-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
an    O
androgen    O
ether    O
–    O
specifically    O
,    O
the    O
17β-chloro    O
hemiacetal    O
ether    O
of    O
testosterone    O
–    O
which    O
was    O
never    O
marketed    O
.    O

Penmesterol    O
(    O
INN    O
)    O
(    O
brand    O
names    O
Pandrocine    O
,    O
Testopan    O
;    O
former    O
developmental    O
code    O
name    O
RP-12222    O
)    O
,    O
or    O
penmestrol    O
,    O
also    O
known    O
as    O
17α-methyltestosterone    O
3-cyclopentyl    O
enol    O
ether    O
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
that    O
was    O
developed    O
in    O
the    O
early    O
1960s    O
.    O

Rosterolone    O
is    O
a    O
derivative    O
of    O
mesterolone    B-SteroidHormone114745635
,    O
which    O
,    O
in    O
contrast    O
,    O
is    O
an    O
androgen    O
and    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Metenolone    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
(    O
brand    O
names    O
Nibal    B-SteroidHormone114745635
Injection    I-SteroidHormone114745635
,    O
Primobolan    B-SteroidHormone114745635
Depot    I-SteroidHormone114745635
)    O
,    O
or    O
methenolone    B-SteroidHormone114745635
enanthate    I-SteroidHormone114745635
,    O
is    O
an    O
injected    O
anabolic–androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
of    O
the    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
group    O
.    O

In    O
February    O
2009    O
,    O
"    O
Sports    O
Illustrated    O
"    O
reported    O
that    O
Alex    O
Rodriguez    O
tested    O
positive    O
for    O
two    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
,    O
testosterone    O
and    O
metenolone    O
enanthate    O
,    O
while    O
playing    O
for    O
the    O
Texas    O
Rangers    O
in    O
2003    O
.    O

Boldenone    B-SteroidHormone114745635
,    O
also    O
known    O
as    O
Δ1-testosterone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
the    O
1(2)-dehydrogenated    O
analogue    O
of    O
testosterone    O
.    O

Uzbekistan    O
's    O
Elmira    O
Ramileva    O
,    O
the    O
69    O
kilogram    O
weightlifter    O
,    O
tested    O
positive    O
for    O
an    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Sammartino    O
took    O
steroids    B-SteroidHormone114745635
during    O
the    O
mid-1980s    O
.    O

The    O
main    O
event    O
was    O
originally    O
scheduled    O
as    O
an    O
interim    O
lightweight    O
championship    O
fight    O
;    O
however    O
,    O
then    O
-    O
lightweight    O
champion    O
Sean    O
Sherk    O
was    O
stripped    O
of    O
his    O
title    O
after    O
the    O
California    O
State    O
Athletic    O
Commission    O
upheld    O
his    O
suspension    O
for    O
testing    O
positive    O
for    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
Nandrolone    O
.    O

Initially    O
the    O
company    O
produced    O
a    O
wide    O
range    O
of    O
generic    O
steroids    O
,    O
including    O
corticosteroids    O
,    O
but    O
later    O
on    O
it    O
focused    O
on    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
,    O
estrogens    O
and    O
progestins    O
.    O

East    O
Germany    O
had    O
been    O
running    O
a    O
state    O
-    O
sponsored    O
mass    O
doping    O
program    O
for    O
its    O
athletes    O
with    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
,    O
mostly    O
with    O
Oral    O
Turinabol    O
,    O
a    O
product    O
that    O
Jenapharm    O
had    O
developed    O
.    O

The    O
first    O
original    O
product    O
developed    O
at    O
Jenapharm    O
was    O
4-chlorodehydromethyltestosterone    O
,    O
an    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
which    O
was    O
marketed    O
under    O
the    O
name    O
Oral    O
Turinabol    O
.    O

Taking    O
additional    O
testosterone    O
,    O
as    O
in    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
,    O
will    O
increase    O
results    O
.    O

A    O
humorous    O
,    O
yet    O
fairly    O
accurate    O
shorthand    O
description    O
of    O
a    O
Harrier    O
is    O
that    O
of    O
"    O
a    O
Beagle    O
on    O
steroids    B-SteroidHormone114745635
.    O
"    O

Neuropsychiatric    O
:    O
steroid    B-SteroidHormone114745635
psychosis    I-SteroidHormone114745635
,    O
and    O
anxiety    O
,    O
depression    O
.    O

The    O
possible    O
correlation    O
between    O
testosterone    O
and    O
aggression    O
could    O
explain    O
the    O
"    O
roid    O
rage    O
"    O
that    O
can    O
result    O
from    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
,    O
although    O
an    O
effect    O
of    O
abnormally    O
high    O
levels    O
of    O
steroids    O
does    O
not    O
prove    O
an    O
effect    O
at    O
physiological    O
levels    O
.    O

A    O
2006    O
Cochrane    O
review    O
did    O
not    O
find    O
evidence    O
sufficient    O
for    O
the    O
use    O
of    O
androgenic    B-SteroidHormone114745635
anabolic    I-SteroidHormone114745635
steroids    I-SteroidHormone114745635
.    O

Hydrogenation    O
of    O
these    O
compounds    O
produces    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
with    O
oral    O
bioavailability    O
,    O
such    O
as    O
Norethandrolone    O
.    O

On    O
13    O
August    O
2012    O
,    O
the    O
International    O
Olympic    O
Committee    O
stripped    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
of    O
her    O
gold    O
medal    O
after    O
testing    O
positive    O
for    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
metenolone    B-SteroidHormone114745635
,    O
and    O
the    O
gold    O
medal    O
was    O
subsequently    O
awarded    O
to    O
silver    O
medalist    O
Valerie    O
Adams    O
from    O
New    O
Zealand    O
.    O

On    O
August    O
13    O
,    O
International    O
Olympic    O
Committee    O
decided    O
the    O
shot    O
putter    O
Nadzeya    O
Astapchuk    O
,    O
the    O
nation    O
's    O
only    O
track    O
and    O
field    O
medalist    O
,    O
to    O
strip    O
off    O
her    O
gold    O
medal    O
at    O
the    O
London    O
games    O
after    O
she    O
was    O
tested    O
positive    O
for    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
metenolone    B-SteroidHormone114745635
.    O

He    O
was    O
later    O
convicted    O
for    O
distribution    O
of    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
.    O

This    O
saves    O
the    O
United    O
States    O
Olympic    O
Committee    O
from    O
a    O
potentially    O
embarrassing    O
situation    O
,    O
as    O
Montgomery    O
has    O
been    O
officially    O
charged    O
with    O
steroids    B-SteroidHormone114745635
use    O
.    O

The    O
results    O
came    O
in    O
on    O
the    O
day    O
of    O
the    O
announcement    O
and    O
revealed    O
Silva    O
tested    O
positive    O
for    O
drostanolone    B-SteroidHormone114745635
metabolites    O
,    O
which    O
is    O
an    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Six    O
days    O
later    O
,    O
Japanese    O
news    O
agency    O
Kyodo    O
News    O
reported    O
that    O
Indian    O
middle    O
distance    O
runner    O
Sunita    O
Rani    O
had    O
tested    O
positive    O
for    O
a    O
banned    O
substance    O
,    O
which    O
was    O
later    O
confirmed    O
by    O
Lee    O
Choon    O
-    O
Sup    O
,    O
Deputy    O
Secretary    O
General    O
of    O
the    O
Busan    O
Asian    O
Games    O
Organizing    O
Committee    O
;    O
an    O
unofficial    O
report    O
stated    O
that    O
the    O
substance    O
was    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
nandrolone    O
.    O

Anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
like    O
oxandrolone    B-SteroidHormone114745635
may    O
be    O
beneficial    O
in    O
cancer    O
cachexia    O
but    O
their    O
use    O
is    O
recommended    O
for    O
maximal    O
2    O
weeks    O
since    O
a    O
longer    O
duration    O
of    O
treatment    O
increases    O
the    O
burden    O
from    O
side    O
effects    O
.    O

These    O
included    O
the    O
promotion    O
of    O
appetite    O
stimulants    O
,    O
tonics    O
and    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
to    O
parents    O
of    O
malnourished    O
children    O
.    O

This    O
categorically    O
excludes    O
the    O
use    O
of    O
substances    O
like    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
,    O
insulin    O
,    O
diuretics    O
and    O
human    O
growth    O
hormone    O
.    O

It    O
was    O
announced    O
in    O
1997    O
that    O
Truyol    O
had    O
tested    O
positive    O
for    O
an    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
and    O
stimulant    O
during    O
a    O
Challenger    O
tournament    O
the    O
previous    O
year    O
in    O
Ostend    O
,    O
Belgium    O
.    O

Under    O
his    O
aegis    O
,    O
central    O
and    O
local    O
government    O
funding    O
of    O
sports    O
centres    O
and    O
other    O
sports    O
facilities    O
was    O
rapidly    O
increased    O
,    O
and    O
he    O
also    O
initiated    O
the    O
first    O
testing    O
for    O
use    O
of    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
in    O
sport    O
.    O

Use    O
of    O
certain    O
medications    O
such    O
as    O
androgens    O
/    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
,    O
phenytoin    O
,    O
and    O
minoxidil    O
.    O

He    O
was    O
named    O
in    O
the    O
Mitchell    O
Report    O
,    O
which    O
detailed    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
in    O
MLB    O
,    O
on    O
December    O
13    O
,    O
2007    O
.    O

According    O
to    O
the    O
report    O
,    O
Donnels    O
purchased    O
both    O
human    O
growth    O
hormone    O
and    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
from    O
Kirk    O
Radomski    O
between    O
2000    O
-    O
2004    O
.    O

McLeod    O
only    O
finished    O
third    O
but    O
second    O
placed    O
Martti    O
Vainio    O
had    O
been    O
disqualified    O
for    O
taking    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
.    O

In    O
September    O
1994    O
while    O
playing    O
for    O
FC    O
Dinamo    O
Minsk    O
,    O
Byalkevich    O
was    O
banned    O
from    O
European    O
competitions    O
for    O
one    O
year    O
by    O
UEFA    O
after    O
testing    O
positive    O
for    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
following    O
a    O
UEFA    O
Cup    O
match    O
.    O

Gherasim    O
tested    O
positive    O
for    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
at    O
the    O
Amsterdam    O
Marathon    O
in    O
2002    O
and    O
received    O
a    O
two    O
-    O
year    O
doping    O
ban    O
.    O

The    O
2014    O
-    O
15    O
list    O
of    O
NCAA    O
banned    O
drugs    O
includes    O
the    O
following    O
classes    O
:    O
stimulants    O
(    O
except    O
for    O
phenylephrine    O
and    O
pseudoephedrine    O
,    O
which    O
are    O
permitted    O
)    O
;    O
anabolic    B-SteroidHormone114745635
agent    I-SteroidHormone114745635
;    O
diuretics    O
and    O
other    O
masking    O
agents    O
;    O
"    O
street    O
drugs    O
"    O
(    O
the    O
NCAA    O
gives    O
as    O
examples    O
heroin    O
,    O
marijuana    O
,    O
tetrahydrocannabinol    O
(    O
THC    O
)    O
,    O
and    O
synthetic    O
cannabinoids    O
)    O
;    O
peptide    O
hormones    O
and    O
analogues    O
;    O
anti    O
-    O
estrogens    O
,    O
and    O
beta-2    O
agonists    O
.    O

After    O
the    O
fight    O
,    O
the    O
California    O
State    O
Athletic    O
Commission    O
(    O
CSAC    O
)    O
announced    O
that    O
Sherk    O
had    O
tested    O
positive    O
for    O
Nandrolone    O
,    O
a    O
banned    O
steroid    B-SteroidHormone114745635
,    O
in    O
a    O
urine    O
test    O
the    O
day    O
prior    O
to    O
the    O
fight    O
.    O

anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
–    O
hormones    O
that    O
build    O
muscle    O
tissue    O

:    O
"    O
N.B.    O
Sub    O
-    O
paragraphs    O
(    O
b    O
)    O
,    O
(    O
c    O
)    O
,    O
(    O
d    O
)    O
and    O
(    O
e    O
)    O
all    O
refer    O
to    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
that    O
were    O
banned    O
in    O
1996    O
(    O
unless    O
referenced    O
otherwise    O
)    O
"    O
:    O

The    O
classic    O
anabolic    O
hormones    O
are    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
,    O
which    O
stimulate    O
protein    O
synthesis    O
,    O
muscle    O
growth    O
,    O
and    O
insulin    O
.    O

Metandienone    B-SteroidHormone114745635
(    O
INN    O
)    O
(    O
brand    O
names    O
Averbol    B-SteroidHormone114745635
,    O
Dianabol    B-SteroidHormone114745635
,    O
Danabol    B-SteroidHormone114745635
,    O
Metanabol    B-SteroidHormone114745635
,    O
Naposim    B-SteroidHormone114745635
,    O
Vetanabol    B-SteroidHormone114745635
)    O
,    O
or    O
methandienone    B-SteroidHormone114745635
(    O
BAN    O
)    O
,    O
also    O
commonly    O
known    O
as    O
methandrostenolone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
17α-methylated    O
derivative    O
of    O
testosterone    O
which    O
was    O
formerly    O
used    O
medically    O
but    O
has    O
since    O
been    O
discontinued    O
in    O
most    O
countries    O
.    O

Letrozole    O
is    O
sometimes    O
used    O
as    O
a    O
treatment    O
for    O
gynecomastia    O
,    O
although    O
it    O
is    O
probably    O
most    O
effective    O
at    O
this    O
if    O
caught    O
in    O
an    O
early    O
stage    O
(    O
such    O
as    O
in    O
users    O
of    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
)    O
.    O

In    O
July    O
1997    O
,    O
Titus    O
was    O
sentenced    O
to    O
21    O
months    O
in    O
prison    O
for    O
violating    O
his    O
probation    O
by    O
using    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

Since    O
adolescence    O
,    O
Breivik    O
had    O
spent    O
much    O
time    O
on    O
weight    O
training    O
,    O
and    O
started    O
using    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
.    O

His    O
appearance    O
at    O
the    O
Olympics    O
proved    O
to    O
be    O
his    O
last    O
official    O
competition    O
in    O
Olympic    O
weightlifting    O
,    O
as    O
he    O
retired    O
from    O
weightlifting    O
,    O
vowing    O
never    O
to    O
return    O
unless    O
the    O
sport    O
is    O
"    O
cleaned    O
up    O
"    O
of    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
.    O

In    O
a    O
November    O
2005    O
interview    O
with    O
"    O
ESPN    O
The    O
Magazine    O
"    O
,    O
Joyner    O
revealed    O
that    O
he    O
had    O
briefly    O
used    O
steroids    B-SteroidHormone114745635
.    O

After    O
six    O
years    O
out    O
of    O
the    O
Western    O
Australian    O
side    O
,    O
he    O
returned    O
to    O
play    O
six    O
one    O
-    O
day    O
matches    O
for    O
WA    O
in    O
the    O
2000/01    O
season    O
and    O
after    O
the    O
last    O
of    O
these    O
matches    O
,    O
he    O
returned    O
a    O
positive    O
drug    O
test    O
to    O
the    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
nandrolone    O
.    O

One    O
modern    O
day    O
method    O
of    O
achieving    O
above    O
average    O
abilities    O
include    O
performance    O
-    O
enhancing    O
drugs    O
;    O
these    O
include    O
substances    O
such    O
as    O
painkillers    O
,    O
blood    O
boosters    O
,    O
stimulants    O
,    O
and    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
,    O
but    O
can    O
also    O
encompass    O
substances    O
that    O
are    O
n't    O
fully    O
recognized    O
as    O
enhancers    O
such    O
as    O
caffeine    O
,    O
protein    O
supplements    O
,    O
and    O
vitamins    O
.    O

A    O
17α-alkylated    O
anabolic    O
steroid    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
that    O
features    O
an    O
alkyl    O
group    O
,    O
specifically    O
a    O
methyl    O
or    O
ethyl    O
group    O
,    O
at    O
the    O
C17α    O
position    O
.    O

Dienolone    O
(    O
developmental    O
code    O
name    O
RU-3118    O
;    O
online    O
product    O
names    O
Trenazone    O
,    O
Dienazone    O
)    O
,    O
or    O
nordienolone    O
,    O
also    O
known    O
as    O
19-nor-δ9(10)-testosterone    O
,    O
δ9(10)-nandrolone    O
,    O
or    O
estra-4,9(10)-dien-17β-ol-3-one    O
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
of    O
the    O
19-nortestosterone    O
group    O
that    O
was    O
never    O
marketed    O
.    O

Ethyltestosterone    O
,    O
or    O
17α-ethyltestosterone    O
,    O
also    O
known    O
as    O
17α-ethylandrost-4-en-17β-ol-3-one    O
or    O
17α-pregn-4-en-17-ol-3-one    O
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
of    O
the    O
17α-alkylated    O
group    O
related    O
to    O
methyltestosterone    O
which    O
was    O
never    O
marketed    O
.    O

List    O
of    O
androgens    O
/    O
anabolic    O
steroids    O
–    O
steroidal    O
androgens    O
/    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635

However    O
,    O
on    O
July    O
13    O
,    O
1981    O
,    O
the    O
International    O
Association    O
of    O
Athletics    O
Federations    O
banned    O
Plucknett    O
from    O
further    O
competition    O
after    O
he    O
had    O
tested    O
positive    O
for    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
,    O
and    O
the    O
records    O
were    O
removed    O
.    O

Šilhavá    O
tested    O
positive    O
for    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
at    O
the    O
European    O
Cup    O
in    O
Moscow    O
in    O
August    O
1985    O
and    O
was    O
subsequently    O
banned    O
for    O
life    O
by    O
the    O
European    O
Athletics    O
Federation    O
.    O

Schwarzenegger    O
has    O
admitted    O
to    O
using    O
performance    O
-    O
enhancing    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
while    O
they    O
were    O
legal    O
,    O
writing    O
in    O
1977    O
that    O
"    O
steroids    O
were    O
helpful    O
to    O
me    O
in    O
maintaining    O
muscle    O
size    O
while    O
on    O
a    O
strict    O
diet    O
in    O
preparation    O
for    O
a    O
contest    O
.    O

In    O
Giambi    O
suffered    O
several    O
ailments    O
,    O
and    O
was    O
also    O
dogged    O
by    O
the    O
BALCO    O
steroids    B-SteroidHormone114745635
scandal    O
.    O

Metenolone    B-SteroidHormone114745635
,    O
or    O
methenolone    B-SteroidHormone114745635
,    O
also    O
known    O
as    O
methylandrostenolone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
dihydrotestosterone    B-SteroidHormone114745635
(    O
DHT    O
)    O
.    O

He    O
left    O
WWE    O
on    O
September    O
15    O
,    O
2004    O
when    O
his    O
steroid    B-SteroidHormone114745635
usage    O
came    O
to    O
light    O
following    O
a    O
staph    O
infection    O
.    O

Former    O
U.S.    O
Senator    O
George    O
J.    O
Mitchell    O
publicly    O
releases    O
a    O
report    O
,    O
accusing    O
89    O
retired    O
and    O
active    O
Major    O
League    O
Baseball    O
players    O
of    O
anabolic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
use    O
.    O

AC    O
/    O
DC    O
singer    O
and    O
car    O
enthusiast    O
Brian    O
Johnson    O
cited    O
the    O
Maxi    O
as    O
the    O
worst    O
he    O
'd    O
driven    O
:    O
"    O
Like    O
a    O
matchbox    O
on    O
steroids    B-SteroidHormone114745635
.    O

John    O
follows    O
Hector    O
deeper    O
into    O
circuit    O
scene    O
,    O
using    O
a    O
variety    O
of    O
drugs    O
including    O
Special    O
K    O
,    O
GHB    O
,    O
cocaine    O
,    O
crystal    O
meth    O
and    O
,    O
suffering    O
from    O
body    O
dysmorphia    O
despite    O
being    O
in    O
terrific    O
physical    O
shape    O
,    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
.    O

4-Hydroxytestosterone    B-SteroidHormone114745635
(    O
4-OHT    B-SteroidHormone114745635
)    O
,    O
also    O
known    O
as    O
4,17β-dihydroxyandrost-4-en-3-one    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
derivative    O
of    O
testosterone    O
that    O
was    O
never    O
marketed    O
.    O

Kirk    O
J.    O
Radomski    O
(    O
born    O
1969    O
)    O
(    O
colloquially    O
known    O
by    O
players    O
as    O
Murdock    O
)    O
is    O
a    O
former    O
batboy    O
and    O
clubhouse    O
employee    O
for    O
the    O
New    O
York    O
Mets    O
Major    O
League    O
Baseball    O
team    O
from    O
1985–1995    O
,    O
who    O
on    O
April    O
27    O
,    O
2007    O
pleaded    O
guilty    O
in    O
United    O
States    O
district    O
court    O
to    O
money    O
laundering    O
and    O
illegal    O
distribution    O
of    O
anabolic    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
,    O
human    O
growth    O
hormone    O
,    O
Clenbuterol    O
,    O
amphetamines    O
and    O
other    O
drugs    O
to    O
"    O
dozens    O
of    O
current    O
and    O
former    O
Major    O
League    O
Baseball    O
players    O
,    O
and    O
associates    O
,    O
on    O
teams    O
throughout    O
Major    O
League    O
Baseball    O
.    O
"    O

Radomski    O
was    O
a    O
prominent    O
witness    O
in    O
former    O
United    O
States    O
Senate    O
Majority    O
Leader    O
George    O
J.    O
Mitchell    O
's    O
investigation    O
into    O
the    O
use    O
of    O
performance-enhancing    B-SteroidHormone114745635
substances    I-SteroidHormone114745635
in    O
Major    O
League    O
Baseball    O
.    O

In    O
humans    O
and    O
primates    O
it    O
also    O
produces    O
GnRH    B-SteroidHormone114745635
.    O

This    O
nucleus    O
has    O
been    O
shown    O
to    O
affect    O
the    O
release    O
of    O
GnRH(Gonadotropin-Releasing    B-SteroidHormone114745635
Hormone)    I-SteroidHormone114745635
in    O
several    O
ways    O
.    O

gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
secreted    O
by    O
the    O
hypothalamus    O

Gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
analogues    O
are    O
another    O
very    O
effective    O
option    O
for    O
antiandrogen    O
therapy    O
,    O
but    O
have    O
not    O
been    O
widely    O
employed    O
for    O
this    O
purpose    O
due    O
to    O
their    O
high    O
cost    O
and    O
limited    O
insurance    O
coverage    O
despite    O
many    O
now    O
being    O
available    O
as    O
generics    O
.    O

Gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635

The    O
underlying    O
cause    O
of    O
the    O
failure    O
in    O
production    O
of    O
LH    O
and    O
FSH    O
is    O
the    O
impairment    O
of    O
the    O
hypothalamus    O
to    O
release    O
the    O
hormone    O
GnRH    B-SteroidHormone114745635
which    O
in    O
normal    O
circumstances    O
induces    O
the    O
production    O
of    O
LH    O
and    O
FSH    O
.    O

Normally    O
the    O
hypothalamus    O
releases    O
a    O
hormone    O
called    O
gonadotropin    B-SteroidHormone114745635
releasing    I-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
.    O

Degarelix    O
has    O
an    O
immediate    O
onset    O
of    O
action    O
,    O
binding    O
to    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
receptors    O
in    O
the    O
pituitary    O
gland    O
and    O
blocking    O
their    O
interaction    O
with    O
GnRH    O
.    O

GnRH    O
antagonists    O
compete    O
with    O
natural    O
GnRH    O
for    O
binding    O
to    O
GnRH    B-SteroidHormone114745635
receptors    O
in    O
the    O
pituitary    O
gland    O
.    O

Deslorelin    O
acetate    O
is    O
an    O
injectable    O
gonadotropin    B-SteroidHormone114745635
releasing    I-SteroidHormone114745635
hormone    I-SteroidHormone114745635
super    O
-    O
agonist    O
(    O
GnRH    O
agonist    O
)    O
also    O
known    O
as    O
an    O
LHRH    O
agonist    O
.    O

Deslorelin    O
is    O
a    O
synthetic    O
analogue    O
of    O
a    O
naturally    O
occurring    O
luteinising    O
-    O
hormone    O
releasing    O
hormone    O
(    O
LHRH    B-SteroidHormone114745635
)    O
.    O

the    O
preoptic    O
area    O
(    O
where    O
LHRH    B-SteroidHormone114745635
neurons    O
are    O
located    O
)    O

#    O
Progesterone    O
suppresses    O
the    O
release    O
of    O
GnRH    B-SteroidHormone114745635
.    O

Physiologically    O
,    O
the    O
exposure    O
to    O
male    O
urine    O
induces    O
the    O
release    O
of    O
GnRH    B-SteroidHormone114745635
,    O
which    O
provokes    O
the    O
first    O
estrus    O
.    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogens    O
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    O
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogen    B-SteroidHormone114745635
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    O
.    O

Ghrelin    O
has    O
inhibitory    O
effects    O
on    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
secretion    O
.    O

Insulin    O
also    O
has    O
stimulatory    O
effects    O
on    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
from    O
the    O
hypothalamus    O
,    O
thus    O
favoring    O
fertility    O
.    O

GnRH    B-SteroidHormone114745635
and    O
gonadotropins    O
(    O
FSH    O
and    O
LH    O
)    O

It    O
is    O
colored    O
as    O
a    O
result    O
of    O
concentrating    O
carotenoids    O
(    O
including    O
lutein    O
)    O
from    O
the    O
diet    O
and    O
secretes    O
a    O
moderate    O
amount    O
of    O
estrogen    O
to    O
inhibit    O
further    O
release    O
of    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
and    O
thus    O
secretion    O
of    O
luteinizing    O
hormone    O
(    O
LH    O
)    O
and    O
follicle    O
-    O
stimulating    O
hormone    O
(    O
FSH    O
)    O
.    O

Prolactin    O
within    O
the    O
normal    O
reference    O
ranges    O
can    O
act    O
as    O
a    O
weak    O
gonadotropin    O
,    O
but    O
at    O
the    O
same    O
time    O
suppresses    O
GnRH    B-SteroidHormone114745635
secretion    O
.    O

Leptin    O
is    O
involved    O
in    O
reproduction    O
by    O
stimulating    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
from    O
the    O
hypothalamus    O
.    O

In    O
humans    O
,    O
via    O
white    O
adipocytes    O
(    O
fat    O
cells    O
)    O
,    O
production    O
of    O
the    O
hormone    O
leptin    O
(    O
an    O
adipokine    O
)    O
acts    O
on    O
the    O
hypothalamus    O
where    O
reproductive    O
hormone    O
Gonadotrophin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
GnRH    O
)    O
is    O
produced    O
.    O

Gonadotropin    O
-    O
releasing    O
hormone    O
(    O
GnRH    B-SteroidHormone114745635
)    O
:    O
regulates    O
the    O
release    O
of    O
follicle    O
stimulating    O
hormone    O
and    O
luteinizing    O
hormone    O
from    O
the    O
anterior    O
pituitary    O
;    O
this    O
pathway    O
plays    O
a    O
critical    O
role    O
in    O
reproductive    O
activity    O
and    O
development    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
)    O
,    O
danazol    B-SteroidHormone114745635
,    O
gestrinone    B-SteroidHormone114745635
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-SteroidHormone114745635
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Endocrine    O
systems    O
controlled    O
by    O
the    O
hypothalamus    O
are    O
regulated    O
by    O
anti    O
-    O
diuretic    O
hormone    O
(    O
ADH    O
)    O
,    O
corticotropin    O
-    O
releasing    O
hormone    O
,    O
gonadotropin-releasing    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
,    O
growth    O
hormone    O
-    O
releasing    O
hormone    O
,    O
oxytocin    O
,    O
all    O
of    O
which    O
are    O
secreted    O
by    O
the    O
hypothalamus    O
.    O

Stenbolone    B-SteroidHormone114745635
(    O
2-methyl-δ1-DHT    O
)    O

Stenbolone    B-SteroidHormone114745635

Cholesterol    O
(    O
(    O
3β)-cholest-5-en-3-ol    O
)    O
is    O
hydroxylated    O
by    O
cholesterol    O
side    O
-    O
chain    O
cleavage    O
enzyme    O
(    O
P450scc    O
)    O
to    O
form    O
22"R    O
"-    O
hydroxycholesterol    O
,    O
which    O
is    O
subsequently    O
hydroxlated    O
again    O
by    O
P450scc    O
to    O
form    O
20α,22"R    O
"-    O
dihydroxycholesterol    O
,    O
and    O
finally    O
the    O
bond    O
between    O
carbons    O
20    O
and    O
22    O
is    O
cleaved    O
by    O
P450scc    O
to    O
form    O
pregnenolone    B-SteroidHormone114745635
(    O
(    O
3β)-3-hydroxypregn-5-en-20-one    O
)    O
,    O
the    O
precursor    O
to    O
the    O
steroid    O
hormones    O
.    O

Cholesterol    O
(    O
(    O
3β)-cholest-5-en-3-ol    O
)    O
is    O
hydroxylated    O
by    O
cholesterol    O
side    O
-    O
chain    O
cleavage    O
enzyme    O
(    O
P450scc    O
)    O
to    O
form    O
22"R    O
"-    O
hydroxycholesterol    O
,    O
which    O
is    O
subsequently    O
hydroxlated    O
again    O
by    O
P450scc    O
to    O
form    O
20α,22"R    O
"-    O
dihydroxycholesterol    O
,    O
and    O
finally    O
the    O
bond    O
between    O
carbons    O
20    O
and    O
22    O
is    O
cleaved    O
by    O
P450scc    O
to    O
form    O
pregnenolone    B-SteroidHormone114745635
(    O
(    O
3β)-3-hydroxypregn-5-en-20-one    O
)    O
,    O
the    O
precursor    O
to    O
the    O
steroid    O
hormones    O
.    O

The    O
development    O
of    O
the    O
corpus    O
luteum    O
is    O
accompanied    O
by    O
an    O
increase    O
in    O
the    O
level    O
of    O
the    O
steroidogenic    O
enzyme    O
P450scc    O
that    O
converts    O
cholesterol    O
to    O
pregnenolone    B-SteroidHormone114745635
in    O
the    O
mitochondria    O
.    O

It    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
an    O
agonist    O
of    O
the    O
human    O
pregnane    O
X    O
receptor    O
,    O
albeit    O
with    O
an    O
EC50    O
that    O
is    O
more    O
than    O
an    O
order    O
of    O
magnitude    O
lower    O
than    O
that    O
of    O
other    O
endogenous    O
pregnane    B-SteroidHormone114745635
like    O
pregnenolone    B-SteroidHormone114745635
,    O
pregnanediol    O
,    O
allopregnanedione    O
,    O
and    O
allopregnanolone    O
.    O

The    O
first    O
enzymatic    O
step    O
in    O
the    O
production    O
of    O
all    O
steroid    O
hormones    O
is    O
cleavage    O
of    O
the    O
cholesterol    O
side    O
chain    O
,    O
a    O
reaction    O
that    O
forms    O
pregnenolone    B-SteroidHormone114745635
as    O
a    O
product    O
and    O
is    O
catalyzed    O
by    O
the    O
enzyme    O
P450scc    O
,    O
also    O
known    O
as    O
"    O
cholesterol    O
desmolase    O
"    O
.    O

3β-Hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
(    O
3β-HSD    O
)    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    B-SteroidHormone114745635
,    O
17α-hydroxyprogesterone    O
from    O
17α-hydroxypregnenolone    O
,    O
and    O
androstenedione    B-SteroidHormone114745635
from    O
dehydroepiandrosterone    B-SteroidHormone114745635
(    O
DHEA    O
)    O
in    O
the    O
adrenal    O
gland    O
.    O

Pregnenolone    B-SteroidHormone114745635
to    O
progesterone    O

P450scc    O
is    O
a    O
mitochondrial    O
enzyme    O
that    O
catalyzes    O
conversion    O
of    O
cholesterol    O
to    O
pregnenolone    B-SteroidHormone114745635
.    O

File    O
:    O
Pregnenolone    B-SteroidHormone114745635

norgestrienone    B-SteroidHormone114745635
(    O
INN    O
)    O

:    O
G03AC07    O
Norgestrienone    B-SteroidHormone114745635

Alclometasone    O
dipropionate    O
,    O
betamethasone    B-SteroidHormone114745635
dipropionate    I-SteroidHormone114745635
,    O
betamethasone    O
valerate    O
,    O
clobetasol    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
,    O
clobetasone    O
butyrate    O
,    O
fluprednidene    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
mometasone    B-SteroidHormone114745635
furoate    I-SteroidHormone114745635
.    O

Dimepregnen    O
(    O
INN    O
,    O
BAN    O
)    O
(    O
developmental    O
code    O
name    O
ST-1411    O
)    O
,    O
or    O
6α,16α-dimethylpregn-4-en-3β-ol-20-one    O
,    O
is    O
a    O
pregnene    B-SteroidHormone114745635
steroid    O
described    O
as    O
an    O
antiestrogen    O
that    O
was    O
synthesized    O
in    O
1968    O
and    O
was    O
never    O
marketed    O
.    O

Selective    B-SteroidHormone114745635
progesterone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635

Examples    O
include    O
Selective    O
Androgen    O
Receptor    O
Modulators    O
(    O
SARMs    O
)    O
,    O
Selective    O
Estrogen    O
Receptor    O
Modulators    O
(    O
SERM    B-SteroidHormone114745635
)    O
and    O
Selective    O
Progesterone    O
Receptor    O
Modulators    O
(    O
SPRM    B-SteroidHormone114745635
)    O
.    O

It    O
is    O
a    O
selective    B-SteroidHormone114745635
progesterone    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
(    O
SPRM    O
)    O
.    O

Oral    O
Turinabol    O
,    O
combining    O
the    O
chemical    O
structures    O
of    O
clostebol    O
and    O
metandienone    B-SteroidHormone114745635
,    O
was    O
widely    O
used    O
in    O
the    O
East    O
German    O
state    O
-    O
sponsored    O
doping    O
program    O
.    O

She    O
was    O
handed    O
an    O
eight    O
-    O
year    O
doping    O
ban    O
for    O
the    O
use    O
of    O
Methandienone    B-SteroidHormone114745635
and    O
Dehydrochloromathyltestosterone    O
.    O

Boldenone    O
was    O
synthesized    O
in    O
an    O
attempt    O
to    O
create    O
a    O
long    O
-    O
acting    O
injectable    O
methandrostenolone    B-SteroidHormone114745635
(    O
Dianabol    O
)    O
,    O
for    O
androgen    O
deficiency    O
disorders    O
.    O

Pulsabsakul    O
served    O
a    O
two    O
-    O
year    O
doping    O
ban    O
from    O
6    O
July    O
2011    O
to    O
6    O
July    O
2013    O
after    O
testing    O
positive    O
for    O
Methandienone    B-SteroidHormone114745635
.    O

In    O
March    O
2007    O
,    O
he    O
received    O
a    O
two    O
-    O
year    O
ban    O
after    O
testing    O
positive    O
for    O
17-epimethandienone    B-SteroidHormone114745635
.    O

Methandienone    B-SteroidHormone114745635

Metandienone    B-SteroidHormone114745635
(    O
INN    O
)    O
(    O
brand    O
names    O
Averbol    B-SteroidHormone114745635
,    O
Dianabol    B-SteroidHormone114745635
,    O
Danabol    B-SteroidHormone114745635
,    O
Metanabol    B-SteroidHormone114745635
,    O
Naposim    B-SteroidHormone114745635
,    O
Vetanabol    B-SteroidHormone114745635
)    O
,    O
or    O
methandienone    B-SteroidHormone114745635
(    O
BAN    O
)    O
,    O
also    O
commonly    O
known    O
as    O
methandrostenolone    B-SteroidHormone114745635
,    O
is    O
a    O
synthetic    O
,    O
orally    O
active    O
anabolic-androgenic    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
(    O
AAS    O
)    O
and    O
a    O
17α-methylated    O
derivative    O
of    O
testosterone    O
which    O
was    O
formerly    O
used    O
medically    O
but    O
has    O
since    O
been    O
discontinued    O
in    O
most    O
countries    O
.    O

Metandienone    B-SteroidHormone114745635
(methandrostenolone)    I-SteroidHormone114745635

In    O
September    O
2005    O
Baggaley    O
tested    O
positive    O
for    O
banned    O
steroids    O
(    O
stanozolol    B-SteroidHormone114745635
and    O
methandienone    B-SteroidHormone114745635
)    O
.    O

Large    O
amounts    O
of    O
fertile    O
eggs    O
,    O
he    O
said    O
,    O
are    O
equal    O
to    O
the    O
anabolic    O
steroid    O
Dianabol    B-SteroidHormone114745635
in    O
effectiveness    O
.    O

Prostanozol    B-SteroidHormone114745635
–    O
17β-tetrahydropyran    O
ether    O
of    O
the    O
17α-demethylated    O
analogue    O
of    O
stanozolol    B-SteroidHormone114745635

FSH    O
is    O
available    O
mixed    O
with    O
LH    O
activity    O
in    O
various    O
menotropins    B-SteroidHormone114745635
including    O
more    O
purified    O
forms    O
of    O
urinary    O
gonadotropins    O
such    O
as    O
Menopur    B-SteroidHormone114745635
,    O
as    O
well    O
as    O
without    O
LH    O
activity    O
as    O
recombinant    O
FSH    O
(    O
Gonapure    O
,    O
Gonal    O
F    O
,    O
Follistim    O
,    O
Follitropin    O
alpha    O
)    O
.    O

When    O
he    O
replies    O
with    O
a    O
no    O
,    O
she    O
tells    O
him    O
"    O
in    O
vitro    O
"    O
needs    O
twice    O
-    O
a    O
-    O
day    O
menotropin    B-SteroidHormone114745635
injections    O
and    O
she    O
can    O
not    O
do    O
them    O
herself    O
so    O
she    O
asks    O
House    O
to    O
do    O
it    O
.    O

Follicle    O
-    O
stimulating    O
hormone    O
(    O
FSH    O
)    O
as    O
a    O
recombinant    O
gonadotropin    O
preparation    O
replaced    O
Serono    O
's    O
Pergonal    B-SteroidHormone114745635
which    O
was    O
previously    O
isolated    O
from    O
post    O
-    O
menopausal    O
female    O
urine    O

Human    B-SteroidHormone114745635
menopausal    I-SteroidHormone114745635
gonadotrophin    I-SteroidHormone114745635
(    O
hMG    O
)    O
is    O
used    O
to    O
stimulate    O
sperm    O
production    O
in    O
men    O
and    O
for    O
multiple    O
egg    O
production    O
and    O
ovulation    O
induction    O
in    O
women    O
.    O

Low    O
-    O
dosage    O
steroidal    O
eye    O
-    O
drops    O
,    O
such    O
as    O
prednisone    O
,    O
fluorometholone    B-SteroidHormone114745635
,    O
loteprednol    B-SteroidHormone114745635
(    O
Lotemax    O
0.5%    O
)    O
or    O
rimexolone    B-SteroidHormone114745635
.    O

Steroid    B-SteroidHormone114745635
atrophy    I-SteroidHormone114745635

Lotemax    B-SteroidHormone114745635

loteprednol    B-SteroidHormone114745635
(    O
INN    O
)    O

Prinaberel    B-SteroidHormone114745635

Prinaberel    B-SteroidHormone114745635

Prinaberel    B-SteroidHormone114745635

In    O
March    O
2017    O
,    O
results    O
from    O
the    O
MONARCH    O
2    O
study    O
indicated    O
Abemaciclib    O
demonstrated    O
superior    O
progression    O
-    O
free    O
survival    O
(    O
PFS    O
)    O
over    O
placebo    O
plus    O
fulvestrant    O
in    O
patients    O
with    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
positive    O
and    O
HER2    O
negative    O
advanced    O
or    O
metastatic    O
breast    O
cancer    O
.    O

Quercetin    O
has    O
also    O
been    O
reported    O
to    O
have    O
estrogenic    O
(    O
female    O
sex    O
hormone    O
like    O
)    O
activities    O
by    O
activating    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Prinaberel    B-SteroidHormone114745635
(    O
INN    O
,    O
USAN    O
)    O
(    O
developmental    O
code    O
names    O
ERB-041    B-SteroidHormone114745635
,    O
WAY-202041    B-SteroidHormone114745635
)    O
is    O
a    O
synthetic    O
,    O
nonsteroidal    O
,    O
and    O
highly    O
selective    O
agonist    O
of    O
the    O
ERβ    O
subtype    O
of    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

One    O
example    O
of    O
this    O
is    O
the    O
loss    O
of    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
upon    O
anti    O
-    O
estrogen    O
treatment    O
of    O
breast    O
cancer    O

Estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
mixed    O
agonist    O
/    O
antagonist    O

Estrogen    B-SteroidHormone114745635
receptors    I-SteroidHormone114745635
are    O
important    O
in    O
both    O
maintaining    O
a    O
normal    O
mammary    O
gland    O
,    O
and    O
in    O
the    O
development    O
of    O
primary    O
and    O
secondary    O
breast    O
cancer    O
.    O

Estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
agonist    O
(    O
Ki    O
>    O
5    O
μM    O
;    O
EC50    O
>    O
5    O
μM    O
)    O

Estrogen    O
insensitivity    O
syndrome    O
(    O
EIS    O
)    O
,    O
or    O
estrogen    O
resistance    O
,    O
is    O
a    O
form    O
of    O
congenital    O
estrogen    O
deficiency    O
or    O
hypoestrogenism    B-SteroidHormone114745635
which    O
is    O
caused    O
by    O
a    O
defective    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
–    O
specifically    O
,    O
the    O
estrogen    O
receptor    O
alpha    O
(    O
ERα    O
)    O
–    O
that    O
results    O
in    O
an    O
inability    O
of    O
estrogen    O
to    O
mediate    O
its    O
biological    O
effects    O
in    O
the    O
body    O
.    O
Congenital    O
estrogen    O
deficiency    O
can    O
alternatively    O
be    O
caused    O
by    O
a    O
defect    O
in    O
aromatase    O
,    O
the    O
enzyme    O
responsible    O
for    O
the    O
biosynthesis    O
of    O
estrogens    O
,    O
a    O
condition    O
which    O
is    O
referred    O
to    O
as    O
aromatase    B-SteroidHormone114745635
deficiency    I-SteroidHormone114745635
and    O
is    O
similar    O
in    O
symptomatology    O
to    O
EIS    O
.    O

Estrogen    O
insensitivity    O
syndrome    O
,    O
a    O
condition    O
in    O
which    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
is    O
defective    O
and    O
unable    O
to    O
respond    O
to    O
estrogens    O
.    O

Kudzu    O
has    O
no    O
benefit    O
for    O
treating    O
cancer    O
and    O
is    O
specifically    O
contraindicated    O
in    O
people    O
with    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
-    O
positive    O
breast    O
cancer    O
.    O

Estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
has    O
been    O
shown    O
to    O
transactivate    O
other    O
transcription    O
factors    O
in    O
this    O
manner    O
,    O
despite    O
the    O
absence    O
of    O
an    O
estrogen    O
response    O
element    O
(    O
ERE    O
)    O
in    O
the    O
proximal    O
promoter    O
region    O
of    O
the    O
gene    O
.    O

Enclomifene    O
acts    O
by    O
antagonizing    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
in    O
the    O
pituitary    O
gland    O
,    O
which    O
reduces    O
negative    O
feedback    O
by    O
estrogen    O
on    O
the    O
hypothalamic    O
-    O
pituitary    O
-    O
gonadal    O
axis    O
,    O
thereby    O
increasing    O
gonadotropin    O
secretion    O
and    O
hence    O
gonadal    O
production    O
of    O
testosterone    O
.    O

The    O
trial    O
suggested    O
that    O
anastrozole    O
is    O
the    O
preferred    O
medical    O
therapy    O
for    O
postmenopausal    O
women    O
with    O
localized    O
breast    O
cancer    O
,    O
which    O
is    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
positive    O
.    O

Women    O
affected    O
with    O
triple    O
negative    O
breast    O
cancer    O
(    O
TNBC    O
)    O
(    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
negative    O
,    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
negative    O
,    O
and    O
HER2/neu    O
negative    O
)    O
under    O
the    O
age    O
of    O
50    O

BPA    O
has    O
been    O
found    O
to    O
bind    O
to    O
both    O
of    O
the    O
nuclear    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ERs    O
)    O
,    O
ERα    O
and    O
ERβ.    O
It    O
is    O
1000-    O
to    O
2000-fold    O
less    O
potent    O
than    O
estradiol    O
.    O

An    O
estrogen    O
receptor    O
test    O
is    O
a    O
laboratory    O
test    O
to    O
find    O
out    O
if    O
cancer    O
cells    O
have    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
proteins    O
to    O
which    O
estrogen    O
will    O
bind    O
)    O
.    O

p90rsk    O
also    O
regulates    O
transcription    O
factors    O
including    O
cAMP    O
response    O
element    O
-    O
binding    O
protein    O
(    O
CREB    O
)    O
;    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ERα    O
)    O
;    O
IκBα/NF-κB    O
;    O
and    O
c    O
-    O
Fos    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
and    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Apo    O
-    O
VLDL    O
-    O
II    O
is    O
produced    O
in    O
the    O
liver    O
and    O
secreted    O
into    O
the    O
blood    O
stream    O
when    O
induced    O
by    O
estrogen    B-SteroidHormone114745635
production    O
in    O
female    O
birds    O
.    O

Menerba    O
,    O
an    O
estrogen    O
receptor    O
beta    O
(    O
ERβ    O
)    O
agonist    O
(    O
ERBA    O
)    O
,    O
is    O
part    O
of    O
a    O
new    O
class    O
of    O
receptor    O
subtype    O
-    O
selective    O
estrogens    O
,    O
which    O
is    O
selective    O
in    O
transcriptional    O
regulation    O
to    O
one    O
of    O
the    O
two    O
known    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER    O
)    O
subtypes    O
.    O

Menerba    O
does    O
not    O
activate    O
the    O
ERα-regulated    O
proliferative    O
genes    O
,    O
c    O
-    O
myc    O
and    O
cyclin    O
D1    O
,    O
or    O
stimulate    O
MCF-7    O
breast    O
cancer    O
cell    O
proliferation    O
or    O
tumor    O
formation    O
,    O
demonstrating    O
that    O
it    O
may    O
be    O
a    O
viable    O
alternative    O
for    O
hormone    O
therapy    O
in    O
comparison    O
to    O
estrogens    O
that    O
non    O
-    O
selectively    O
activate    O
both    O
ER    B-SteroidHormone114745635
subtypes    I-SteroidHormone114745635
.    O

The    O
drug    O
possesses    O
relatively    O
low    O
affinity    O
for    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
and    O
must    O
be    O
given    O
at    O
high    O
dosages    O
to    O
achieve    O
significant    O
estrogenic    O
and    O
antigonadotropic    O
action    O
,    O
for    O
instance    O
,    O
0.8    O
to    O
1.6    O
g    O
/    O
day    O
.    O

Radiolabeled    O
[    O
16α-125I]iodo    O
-    O
E2    O
has    O
been    O
employed    O
in    O
imaging    O
to    O
study    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

The    O
steroid    O
is    O
only    O
very    O
weakly    O
estrogenic    O
,    O
and    O
is    O
able    O
to    O
antagonize    O
the    O
estrogenic    O
effects    O
of    O
estradiol    O
,    O
indicating    O
that    O
its    O
intrinsic    O
activity    O
at    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
is    O
less    O
than    O
that    O
of    O
estradiol    O
and    O
hence    O
that    O
it    O
possesses    O
the    O
profile    O
of    O
a    O
selective    B-SteroidHormone114745635
estrogen    I-SteroidHormone114745635
receptor    I-SteroidHormone114745635
modulator    I-SteroidHormone114745635
.    O

Upon    O
reassessment    O
many    O
decades    O
later    O
,    O
the    O
compound    O
was    O
found    O
to    O
bind    O
only    O
weakly    O
to    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
and    O
,    O
unexpectedly    O
,    O
did    O
not    O
actually    O
have    O
functional    O
activity    O
as    O
an    O
estrogen    O
or    O
antiestrogen    O
"    O
in    O
vitro    O
"    O
or    O
"    O
in    O
vivo    O
"    O
.    O

It    O
is    O
selectively    O
distributed    O
into    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
ER)-positive    O
tissues    O
such    O
as    O
ER    O
-    O
expressing    O
tumors    O
like    O
those    O
seen    O
in    O
breast    O
and    O
prostate    O
cancers    O
.    O

In    O
contrast    O
to    O
estradiol    O
,    O
the    O
binding    O
of    O
16α-hydroxyestrone    O
to    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
is    O
,    O
uniquely    O
,    O
covalent    O
and    O
irreversible    O
,    O
and    O
genotoxicity    O
and    O
aberrant    O
hyperproliferations    O
may    O
result    O
.    O

is    O
a    O
transcriptional    O
corepressor    O
for    O
nuclear    O
receptors    O
such    O
as    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
and    O
a    O
coactivator    O
for    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

However    O
,    O
some    O
genes    O
become    O
hypermethylated    O
with    O
age    O
,    O
including    O
genes    O
for    O
the    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
p16    O
,    O
and    O
insulin    O
-    O
like    O
growth    O
factor    O
2    O
.    O

In    O
studies    O
of    O
breast    O
cancer    O
prevention    O
,    O
lasofoxifene    O
showed    O
a    O
79%    O
reduction    O
in    O
breast    O
cancer    O
incidence    O
and    O
an    O
83%    O
reduction    O
specific    O
incidence    O
of    O
estrogen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
-    O
positive    O
breast    O
cancers    O
,    O
which    O
is    O
significantly    O
higher    O
than    O
reductions    O
found    O
with    O
the    O
related    O
SERMs    O
tamoxifen    O
and    O
raloxifene    O
.    O

Of    O
the    O
synthesis    O
problems    O
,    O
congenital    O
adrenal    O
hyperplasia    O
is    O
the    O
most    O
common    O
(    O
in    O
various    O
forms    O
:    O
21-hydroxylase    O
,    O
17α-hydroxylase    O
,    O
11β-hydroxylase    O
and    O
3β-hydroxysteroid    O
dehydrogenase    O
)    O
,    O
lipoid    B-SteroidHormone114745635
CAH    I-SteroidHormone114745635
due    O
to    O
deficiency    O
of    O
StAR    O
and    O
mitochondrial    O
DNA    O
mutations    O
.    O

Mutations    O
in    O
the    O
CYP11A1    O
gene    O
result    O
in    O
a    O
steroid    O
hormone    O
deficiency    O
,    O
causing    O
a    O
minority    O
of    O
cases    O
of    O
the    O
rare    O
and    O
potentially    O
fatal    O
condition    O
lipoid    B-SteroidHormone114745635
congenital    I-SteroidHormone114745635
adrenal    I-SteroidHormone114745635
hyperplasia    I-SteroidHormone114745635
.    O

fosfestrol    B-SteroidHormone114745635
(    O
INN    O
)    O

Fosfestrol    B-SteroidHormone114745635

Conversely    O
,    O
hyperandrogenism    B-SteroidHormone114745635
in    O
women    O
,    O
for    O
instance    O
due    O
to    O
polycystic    O
ovary    O
syndrome    O
(    O
PCOS    O
)    O
or    O
congenital    O
adrenal    O
hyperplasia    O
(    O
CAH    O
)    O
,    O
is    O
commonly    O
associated    O
with    O
acne    O
and    O
hirsutism    O
as    O
well    O
as    O
virilization    O
(    O
masculinization    O
)    O
in    O
general    O
.    O

The    O
International    O
Association    O
of    O
Athletics    O
Federations    O
(    O
IAAF    O
)    O
"    O
,    O
and    O
in    O
July    O
2015    O
the    O
CAS    O
issued    O
a    O
decision    O
to    O
suspend    O
its    O
sex    O
verification    O
policy    O
on    O
excluding    O
women    O
athletes    O
with    O
hyperandrogenism    B-SteroidHormone114745635
(    O
high    O
levels    O
of    O
testosterone    O
)    O
due    O
to    O
insufficient    O
evidence    O
of    O
a    O
link    O
between    O
high    O
androgen    O
levels    O
and    O
improved    O
athletic    O
performance    O
.    O

The    O
older    O
sister    O
had    O
chest    O
acne    O
,    O
which    O
could    O
be    O
attributed    O
to    O
hyperandrogenism    B-SteroidHormone114745635
(    O
see    O
below    O
)    O
.    O

Due    O
to    O
the    O
substantially    O
elevated    O
testosterone    O
levels    O
,    O
there    O
is    O
hyperandrogenism    B-SteroidHormone114745635
,    O
including    O
masculinization    O
of    O
the    O
preputial    O
glands    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
directly    O
stimulate    O
androgen    O
biosynthesis    O
in    O
the    O
gonads    O
via    O
inhibition    O
of    O
histone    O
deacetylases    O
and    O
has    O
been    O
associated    O
with    O
hyperandrogenism    B-SteroidHormone114745635
in    O
women    O
and    O
increased    O
4-androstenedione    B-SteroidHormone114745635
levels    O
in    O
men    O
.    O

The    O
condition    O
is    O
called    O
hyperandrogenism    B-SteroidHormone114745635
.    O

Hyperandrogenism    B-SteroidHormone114745635
is    O
a    O
medical    O
condition    O
where    O
there    O
are    O
excessive    O
levels    O
of    O
androgens    O
in    O
the    O
body    O
.    O

Quinestrol    B-SteroidHormone114745635

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

Methylprednisolone    B-SteroidHormone114745635

However    O
,    O
most    O
vasculitis    O
in    O
general    O
are    O
treated    O
with    O
steroids    O
(    O
e.g.    O
methylprednisolone    B-SteroidHormone114745635
)    O
because    O
the    O
underlying    O
cause    O
of    O
the    O
vasculitis    O
is    O
due    O
to    O
hyperactive    O
immunological    O
damage    O
.    O

Hydrocortisone    O
,    O
methylprednisolone    B-SteroidHormone114745635
,    O
prednisolone    O
,    O
prednisone    O
,    O
and    O
triamcinolone    O
(    O
short-    O
to    O
medium    O
-    O
acting    O
glucocorticoids    O
)    O
.    O

The    O
preservative    O
-    O
free    O
methylprednisolone    B-SteroidHormone114745635
acetate    O
(    O
MPA    O
)    O
injection    O
caused    O
limited    O
immunological    O
responsiveness    O
at    O
the    O
site    O
of    O
inoculation    O
,    O
allowed    O
the    O
fungus    O
to    O
be    O
vasculotropic    O
thus    O
resulting    O
in    O
a    O
necrotizing    O
fatal    O
disease    O
of    O
the    O
Central    O
nervous    O
system    O
(    O
CNS    O
)    O
.    O

In    O
adrenal    O
insufficiency    O
and    O
Addison    O
's    O
disease    O
,    O
dexamethasone    O
is    O
prescribed    O
when    O
the    O
patient    O
does    O
not    O
respond    O
well    O
to    O
prednisone    O
or    O
methylprednisolone    B-SteroidHormone114745635
.    O

Methylprednisolone    B-SteroidHormone114745635
therapy    O
shows    O
some    O
promise    O
in    O
short    O
-    O
term    O
prevention    O
of    O
attacks    O
,    O
even    O
though    O
its    O
mechanism    O
of    O
action    O
is    O
yet    O
to    O
be    O
discovered    O
.    O

The    O
patient    O
had    O
complete    O
resolution    O
of    O
symptoms    O
after    O
intravenous    O
therapy    O
with    O
methylprednisolone    B-SteroidHormone114745635
.    O

High    O
dose    O
immunosuppression    O
is    O
required    O
(    O
intravenous    O
methylprednisolone    B-SteroidHormone114745635
)    O
and    O
cyclophosphamide    O
,    O
plus    O
plasmapheresis    O
.    O

In    O
2007    O
Kyyrö    O
was    O
found    O
guilty    O
of    O
methylprednisolone    B-SteroidHormone114745635
doping    O
.    O

Urgent    O
medical    O
attention    O
in    O
this    O
phase    O
consists    O
of    O
fluid    O
resuscitation    O
efforts    O
,    O
mainly    O
the    O
intravenous    O
administration    O
of    O
saline    O
solution    O
plus    O
hetastarch    O
or    O
albumin    O
and    O
colloids    O
(    O
to    O
increase    O
the    O
remaining    O
blood    O
flow    O
to    O
vital    O
organs    O
like    O
the    O
kidneys    O
)    O
,    O
as    O
well    O
as    O
glucocorticoids    O
(    O
steroids    O
like    O
methylprednisolone    B-SteroidHormone114745635
,    O
to    O
reduce    O
or    O
stop    O
the    O
capillary    O
leak    O
)    O
.    O

The    O
use    O
of    O
hormone    O
replacement    O
therapy    O
in    O
transgender    O
and    O
intersex    O
people    O
and    O
people    O
with    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
imbalances    O
(    O
e.g.    O
,    O
hypogonadism    O
or    O
hyperandrogenism    B-SteroidHormone114745635
)    O
to    O
change    O
the    O
secondary    O
sexual    O
characteristics    O
from    O
masculine    O
to    O
feminine    O
and    O
vice    O
versa    O

progesterone    O
(    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
)    O

They    O
may    O
inhibit    O
the    O
production    O
of    O
cholesterol    O
and    O
other    O
sterols    O
,    O
sex    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
such    O
as    O
androgens    O
,    O
estrogens    O
,    O
and    O
progestogens    O
,    O
corticosteroids    O
such    O
as    O
glucocorticoids    O
and    O
mineralocorticoids    O
,    O
and    O
neurosteroids    O
.    O

The    O
prototypical    O
progestogen    O
is    O
progesterone    O
,    O
an    O
endogenous    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
.    O

Sex    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
such    O
as    O
estrogens    O
and    O
androgens    O
,    O
as    O
well    O
as    O
thyroid    O
hormones    O
,    O
are    O
subject    O
to    O
feedback    O
regulation    O
,    O
which    O
tends    O
to    O
limit    O
the    O
sensitivity    O
of    O
these    O
glands    O
.    O

While    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
levels    O
in    O
parthenogenetic    O
"    O
Cnemidophorus    O
uniparens    O
"    O
mimic    O
the    O
cycles    O
seen    O
in    O
their    O
sexual    O
relatives    O
,    O
their    O
nervous    O
systems    O
appear    O
to    O
have    O
evolved    O
unique    O
responses    O
to    O
female    O
sex    O
hormones    O
.    O

Sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
androgen    O
/    O
estrogen    O
)    O

In    O
1927    O
,    O
Selmar    O
Ascheim    O
(    O
1878–1965    O
)    O
and    O
Bernhard    O
Zondek    O
(    O
1891–1966    O
)    O
discovered    O
that    O
urine    O
of    O
pregnant    O
women    O
had    O
a    O
high    O
concentration    O
of    O
steroid    B-SteroidHormone114745635
sex    I-SteroidHormone114745635
hormones    I-SteroidHormone114745635
;    O
a    O
subsequent    O
discovery    O
was    O
made    O
that    O
urine    O
contained    O
sex    O
hormones    O
of    O
androgens    O
and    O
estrogens    O
,    O
as    O
well    O
as    O
the    O
pituitary    O
hormone    O
gonadotrophin    O
.    O

An    O
alternative    O
proposed    O
cause    O
is    O
inhibition    O
of    O
17α-hydroxylase    O
and    O
hence    O
sex    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
metabolism    O
by    O
spironolactone    O
and    O
consequent    O
changes    O
in    O
sex    O
hormone    O
levels    O
.    O

Because    O
rheumatoid    O
arthritis    O
is    O
more    O
common    O
in    O
women    O
,    O
perhaps    O
sex    B-SteroidHormone114745635
hormones    I-SteroidHormone114745635
may    O
play    O
a    O
role    O
in    O
causing    O
or    O
modulating    O
arthritis    O
.    O

As    O
an    O
adult    O
ages    O
,    O
it    O
is    O
normal    O
for    O
the    O
pituitary    O
to    O
produce    O
diminishing    O
amounts    O
of    O
GH    O
and    O
many    O
other    O
hormones    O
,    O
particularly    O
the    O
sex    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
.    O

The    O
term    O
hypogonadism    O
describes    O
a    O
low    O
level    O
of    O
circulating    O
sex    B-SteroidHormone114745635
hormones    I-SteroidHormone114745635
;    O
testosterone    O
in    O
males    O
and    O
oestrogen    O
and    O
progesterone    O
in    O
females    O
.    O

LH    O
and    O
FSH    O
are    O
essential    O
for    O
stimulating    O
the    O
development    O
of    O
secondary    O
sexual    O
characteristics    O
seen    O
at    O
puberty    O
and    O
for    O
maintaining    O
the    O
normal    O
sexual    O
function    O
of    O
both    O
men    O
and    O
women    O
,    O
including    O
maintaining    O
the    O
correct    O
levels    O
of    O
the    O
sex    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
:    O
testosterone    O
in    O
men    O
and    O
oestrogen    O
and    O
progesterone    O
in    O
women    O
.    O

Although    O
the    O
pharmacological    O
action    O
of    O
catalpol    O
as    O
well    O
as    O
many    O
other    O
iridoids    O
has    O
not    O
been    O
fully    O
established    O
,    O
there    O
is    O
evidence    O
that    O
their    O
primary    O
function    O
is    O
to    O
stimulate    O
the    O
production    O
of    O
adrenal    O
cortical    O
hormones    O
,    O
which    O
increases    O
the    O
production    O
of    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
.    O

Other    O
striking    O
functional    O
dimorphisms    O
are    O
in    O
the    O
behavioral    O
responses    O
to    O
ovarian    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
of    O
the    O
adult    O
.    O

Sex    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
are    O
not    O
the    O
only    O
important    O
influences    O
upon    O
hypothalamic    O
development    O
;    O
in    O
particular    O
,    O
pre    O
-    O
pubertal    O
stress    O
in    O
early    O
life    O
(    O
of    O
rats    O
)    O
determines    O
the    O
capacity    O
of    O
the    O
adult    O
hypothalamus    O
to    O
respond    O
to    O
an    O
acute    O
stressor    O
.    O

Steroids    O
,    O
including    O
gonadal    B-SteroidHormone114745635
steroids    I-SteroidHormone114745635
and    O
corticosteroids    O

This    O
,    O
in    O
turn    O
,    O
results    O
in    O
increased    O
function    O
and    O
maintenance    O
of    O
the    O
gonads    O
and    O
increased    O
gonadal    O
steroidogenesis    O
of    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
such    O
as    O
androgens    O
,    O
estrogens    O
,    O
and    O
progestogens    O
.    O

At    O
puberty    O
,    O
they    O
are    O
virilized    O
by    O
male    B-SteroidHormone114745635
hormones    I-SteroidHormone114745635
,    O
recognized    O
as    O
boys    O
,    O
and    O
raised    O
henceforth    O
as    O
boys    O
.    O

For    O
example    O
,    O
female    B-SteroidHormone114745635
sex    I-SteroidHormone114745635
hormones    I-SteroidHormone114745635
are    O
known    O
immunostimulators    O
of    O
both    O
adaptive    O
and    O
innate    O
immune    O
responses    O
.    O

These    O
include    O
changes    O
in    O
cardiac    O
output    O
,    O
vitamin    O
D    O
,    O
inflammation    O
,    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
activity    O
,    O
lipoprotein    O
lipase    O
activity    O
,    O
and    O
GLUT4    O
activity    O
due    O
to    O
long    O
periods    O
of    O
muscular    O
unloading    O
,    O
among    O
others    O
.    O

An    O
intersex    O
human    O
or    O
other    O
animal    O
is    O
one    O
possessing    O
any    O
of    O
several    O
variations    O
in    O
sex    O
characteristics    O
including    O
chromosomes    O
,    O
gonads    O
,    O
sex    B-SteroidHormone114745635
hormones    I-SteroidHormone114745635
,    O
or    O
genitals    O
that    O
,    O
according    O
to    O
the    O
UN    O
Office    O
of    O
the    O
High    O
Commissioner    O
for    O
Human    O
Rights    O
,    O
"    O
do    O
not    O
fit    O
typical    O
binary    O
notions    O
of    O
male    O
or    O
female    O
bodies    O
"    O
.    O

The    O
development    O
of    O
both    O
is    O
controlled    O
by    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
produced    O
by    O
the    O
body    O
after    O
the    O
initial    O
fetal    O
stage    O
where    O
the    O
presence    O
or    O
absence    O
of    O
the    O
Y    O
-    O
chromosome    O
and/or    O
the    O
SRY    O
gene    O
determine    O
development    O
.    O

When    O
ovulation    O
is    O
about    O
to    O
occur    O
,    O
the    O
sex    B-SteroidHormone114745635
hormones    I-SteroidHormone114745635
activate    O
the    O
fimbriae    O
,    O
causing    O
it    O
to    O
swell    O
with    O
blood    O
and    O
hit    O
the    O
ovary    O
in    O
a    O
gentle    O
,    O
sweeping    O
motion    O
.    O

Sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
(    O
androgens    O
and    O
estrogens    O
)    O

Glucocorticoids    O
are    O
distinguished    O
from    O
mineralocorticoids    O
and    O
sex    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
by    O
their    O
specific    O
receptors    O
,    O
target    O
cells    O
,    O
and    O
effects    O
.    O

Prolactin    O
levels    O
may    O
be    O
checked    O
as    O
part    O
of    O
a    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
workup    O
,    O
as    O
elevated    O
prolactin    O
secretion    O
can    O
suppress    O
the    O
secretion    O
of    O
FSH    O
and    O
GnRH    O
,    O
leading    O
to    O
hypogonadism    O
and    O
sometimes    O
causing    O
erectile    O
dysfunction    O
.    O

In    O
humans    O
,    O
biological    O
sex    O
is    O
determined    O
by    O
five    O
factors    O
present    O
at    O
birth    O
:    O
the    O
presence    O
or    O
absence    O
of    O
a    O
Y    O
chromosome    O
,    O
the    O
type    O
of    O
gonads    O
,    O
the    O
sex    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
,    O
the    O
internal    O
reproductive    O
anatomy    O
(    O
such    O
as    O
the    O
uterus    O
in    O
females    O
)    O
,    O
and    O
the    O
external    O
genitalia    O
.    O

Miss    O
Gay    O
America    O
is    O
unique    O
in    O
that    O
it    O
is    O
the    O
only    O
national    O
pageant    O
that    O
prohibits    O
contestants    O
from    O
using    O
female    B-SteroidHormone114745635
hormones    I-SteroidHormone114745635
or    O
having    O
undergone    O
any    O
feminizing    O
plastic    O
surgery    O
,    O
such    O
as    O
breast    O
implants    O
or    O
liquid    O
-    O
silicone    O
injections    O
below    O
the    O
neck    O
.    O

At    O
the    O
game    O
,    O
bisexual    O
drama    O
teacher    O
Andrew    O
LeGustambos    O
attempts    O
to    O
grab    O
the    O
attention    O
of    O
both    O
Larry    O
and    O
Miracle    O
,    O
but    O
the    O
whole    O
school    O
stands    O
in    O
shock    O
as    O
Stuart    O
arrives    O
with    O
two    O
full    O
and    O
augmented    O
breasts    O
;    O
the    O
pills    O
he    O
had    O
taken    O
were    O
actually    O
librarian    O
Helen    O
Klench    O
's    O
female    B-SteroidHormone114745635
hormone    I-SteroidHormone114745635
replacements    I-SteroidHormone114745635
.    O

Hormones    B-SteroidHormone114745635
and    O
genetic    O
factors    O
are    O
likely    O
to    O
be    O
important    O
in    O
the    O
pathogenesis    O
of    O
the    O
disease    O
.    O

One    O
drug    O
sponsored    O
by    O
Taiho    O
has    O
been    O
TAS-108    B-SteroidHormone114745635
,    O
which    O
is    O
under    O
development    O
by    O
SRI    O
International    O
.    O

The    O
antigonadotropic    O
antiandrogens    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
MPA    O
)    O
,    O
and    O
analogues    O
have    O
all    O
been    O
widely    O
used    O
to    O
treat    O
paraphilias    O
(    O
e.g.    O
,    O
pedophilia    O
)    O
and    O
hypersexuality    O
in    O
men    O
.    O

The    O
Food    O
and    O
Drug    O
Administration    O
approves    O
Depo-Provera    B-SteroidHormone114745635
for    O
use    O
as    O
a    O
contraceptive    O
in    O
the    O
United    O
States    O
.    O

Medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635

Most    O
inhibitors    O
of    O
CYP2C9    O
are    O
competitive    O
inhibitors    O
.    O
Noncompetitive    O
inhibitors    O
of    O
CYP2C9    O
include    O
nifedipine    O
,    O
phenethyl    O
isothiocyanate    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
6-hydroxyflavone    O
.    O

Examples    O
of    O
important    O
progestogen    O
esters    O
include    O
the    O
17α-hydroxyprogesterone    O
derivatives    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
megestrol    O
acetate    O
,    O
cyproterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
hydroxyprogesterone    B-SteroidHormone114745635
caproate    I-SteroidHormone114745635
,    O
the    O
19-norprogesterone    B-SteroidHormone114745635
derivative    O
nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
the    O
19-nortestosterone    O
derivatives    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
norethisterone    O
enanthate    O
.    O

Medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
Provera    O
)    O
entered    O
clinical    O
use    O
and    O
became    O
widely    O
marketed    O
,    O
largely    O
superseding    O
the    O
17α-hydroxyprogesterone    O
esters    O
.    O

Medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
Provera    O
)    O
,    O
the    O
most    O
popular    O
and    O
widely    O
used    O
progestogen    O
ester    O
.    O

In    O
1969    O
,    O
along    O
with    O
a    O
variety    O
of    O
other    O
progestogens    O
including    O
progesterone    O
,    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
megestrol    O
acetate    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
ethynerone    O
,    O
and    O
chloroethynyl    O
norgestrel    O
,    O
anagestone    O
acetate    O
was    O
found    O
to    O
induce    O
the    O
development    O
of    O
mammary    O
gland    O
tumors    O
in    O
Beagle    O
dogs    O
after    O
extensive    O
treatment    O
(    O
2–7    O
years    O
)    O
with    O
very    O
high    O
doses    O
(    O
10–25    O
times    O
the    O
recommended    O
human    O
dose    O
)    O
,    O
though    O
notably    O
not    O
with    O
1–2    O
times    O
the    O
human    O
dosage    O
.    O

Subsequent    O
investigation    O
found    O
that    O
17α-hydroxyprogesterone    O
derivatves    O
included    O
anagestone    O
acetate    O
,    O
chlormadinone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
and    O
megestrol    O
acetate    O
produced    O
similar    O
mammary    O
gland    O
tumors    O
,    O
and    O
that    O
their    O
ability    O
to    O
do    O
so    O
correlated    O
directly    O
with    O
their    O
progestogenic    O
actions    O
.    O

Use    O
of    O
progestin    O
-    O
only    O
contraceptives    O
,    O
such    O
as    O
Depo    B-SteroidHormone114745635
Provera    I-SteroidHormone114745635

A    O
phase-2    O
study    O
involving    O
the    O
administration    O
of    O
antioxidants    O
,    O
pharmaconutritional    O
support    O
,    O
progestin    O
(    O
megestrol    O
acetate    O
and    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
)    O
,    O
and    O
anticyclooxygenase-2    O
drugs    O
,    O
showed    O
efficacy    O
and    O
safety    O
in    O
the    O
treatment    O
of    O
patients    O
with    O
advanced    O
cancer    O
of    O
different    O
sites    O
suffering    O
cachexia    O
.    O

NOMAC    O
is    O
a    O
potent    O
and    O
pure    O
progestogen    O
,    O
acting    O
as    O
a    O
selective    O
,    O
high    O
-    O
affinity    O
full    O
agonist    O
of    O
the    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
PR    O
)    O
(    O
Ki    O
=    O
3    O
nM    O
,    O
67–303%    O
of    O
the    O
of    O
progesterone    O
)    O
,    O
and    O
is    O
said    O
to    O
have    O
higher    O
potency    O
and    O
substantially    O
improved    O
selectivity    O
for    O
the    O
PR    O
relative    O
to    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
(    O
the    O
6-hydrogenated    O
or    O
non-6    O
-    O
7-double    O
bonded    O
analogue    O
of    O
megestrol    O
acetate    O
and    O
the    O
most    O
widely    O
used    O
progestin    O
)    O
.    O

Along    O
with    O
that    O
two    O
contraceptive    O
pills    O
,    O
MPA    O
(    O
Medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
)    O
under    O
Antara    O
program    O
and    O
Chaya    O
(    O
earlier    O
marketed    O
as    O
Saheli    O
)    O
will    O
be    O
made    O
freely    O
available    O
to    O
all    O
government    O
hospitals    O
.    O

,    O
Keith    O
Ablow    O
responded    O
to    O
Kaplan    O
's    O
column    O
,    O
arguing    O
that    O
although    O
he    O
agreed    O
with    O
it    O
on    O
many    O
points    O
,    O
he    O
thought    O
that    O
Kaplan    O
"    O
is    O
wrong    O
to    O
suggest    O
that    O
,    O
merely    O
because    O
something    O
is    O
a    O
known    O
disorder    O
,    O
it    O
should    O
result    O
in    O
protections    O
under    O
the    O
law    O
"    O
and    O
arguing    O
that    O
"    O
If    O
a    O
pedophile    O
wants    O
to    O
not    O
attack    O
children    O
,    O
he    O
can    O
receive    O
confidential    O
psychiatric    O
treatment    O
–    O
including    O
Depo-Provera    B-SteroidHormone114745635
to    O
lower    O
testosterone    O
levels    O
–    O
to    O
make    O
it    O
much    O
less    O
likely    O
.    O
"    O

The    O
people    O
in    O
the    O
program    O
experienced    O
injections    O
of    O
Depro-Provera    B-SteroidHormone114745635
and    O
individual    O
and    O
group    O
therapy    O
aimed    O
at    O
helping    O
priests    O
regain    O
their    O
celibacy    O
;    O
the    O
latter    O
differed    O
from    O
secular    O
treatment    O
,    O
in    O
which    O
the    O
effort    O
was    O
to    O
get    O
the    O
men    O
to    O
transfer    O
their    O
sexual    O
attraction    O
to    O
adults    O
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
)    O
,    O
danazol    B-SteroidHormone114745635
,    O
gestrinone    B-SteroidHormone114745635
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-SteroidHormone114745635
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Non    O
-    O
permanent    O
forms    O
of    O
sterilization    O
were    O
also    O
used    O
including    O
Depo-Provera    B-SteroidHormone114745635
and    O
Norplant    O
.    O

Medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
and    O
medrogestone    B-SteroidHormone114745635
are    O
weak    O
inhibitors    O
of    O
3β-HSD    O
which    O
may    O
substantially    O
inhibit    O
it    O
at    O
high    O
dosages    O
.    O

Drostanolone    B-SteroidHormone114745635
propionate    I-SteroidHormone114745635
(    O
Masteron    O
,    O
Drolban    O
,    O
Masteril    O
,    O
Mastisol    O
,    O
Metormon    O
,    O
Permastril    O
)    O

Masterone    B-SteroidHormone114745635
(    O
Syntex    O
)    O

Altrenogest    B-SteroidHormone114745635

altrenogest    B-SteroidHormone114745635
-    O
used    O
to    O
synchronize    O
estrus    O

Ecdysteroids    B-SteroidHormone114745635
are    O
insect    O
moulting    O
and    O
sex    O
hormones    O
;    O
examples    O
of    O
ecdysteroids    O
include    O
ecdysone    B-SteroidHormone114745635
,    O
ecdysterone    B-SteroidHormone114745635
,    O
turkesterone    O
and    O
20-hydroxyecdysone    B-SteroidHormone114745635
.    O

The    O
skeleton    O
is    O
rich    O
in    O
histidine    O
and    O
contains    O
the    O
unusual    O
ecdysterone    B-SteroidHormone114745635
,    O
ajugasterone    O
-    O
C.    O
The    O
growth    O
rate    O
of    O
the    O
colony    O
is    O
slow    O
and    O
carbon-14    O
dating    O
techniques    O
have    O
given    O
an    O
age    O
of    O
2,700    O
years    O
,    O
giving    O
this    O
zoanthid    O
one    O
of    O
the    O
longest    O
lifespans    O
of    O
any    O
organism    O
on    O
Earth    O
.    O

Future    O
attacks    O
of    O
hereditary    O
angioedema    O
can    O
be    O
prevented    O
by    O
the    O
use    O
of    O
androgens    O
such    O
as    O
danazol    B-SteroidHormone114745635
,    O
oxandrolone    B-SteroidHormone114745635
or    O
methyltestosterone    O
.    O

Danazol    B-SteroidHormone114745635
may    O
also    O
be    O
prescribed    O
to    O
treat    O
this    O
condition    O
and    O
it    O
is    O
usually    O
considered    O
in    O
patients    O
on    O
whom    O
the    O
non    O
-    O
medical    O
treatment    O
fails    O
and    O
the    O
symptoms    O
are    O
intense    O
.    O

Steroid    O
sulfatase    O
(    O
STS    O
)    O
inhibitors    O
such    O
as    O
estradiol    O
sulfamate    O
,    O
estrone    O
sulfamate    O
,    O
irosustat    O
,    O
and    O
danazol    B-SteroidHormone114745635
inhibit    O
the    O
conversion    O
of    O
steroid    O
sulfates    O
such    O
as    O
estrone    B-SteroidHormone114745635
sulfate    I-SteroidHormone114745635
and    O
DHEA    O
sulfate    O
into    O
their    O
hormonally    O
active    O
forms    O
.    O

Danazol    B-SteroidHormone114745635
is    O
a    O
steroid    O
compound    O
that    O
has    O
been    O
labelled    O
as    O
an    O
"    O
Anterior    O
pituitary    O
suppressant    O
"    O
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
)    O
,    O
danazol    B-SteroidHormone114745635
,    O
gestrinone    B-SteroidHormone114745635
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-SteroidHormone114745635
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Treatment(s    O
)    O
with    O
mixed    O
success    O
:    O
omalizumab    O
(    O
anti    O
-    O
IgE    O
therapy    O
)    O
,    O
danazol    B-SteroidHormone114745635
(    O
synthetic    O
androgen    O
)    O
,    O
propranolol    O
(    O
beta    O
blocker    O
)    O
,    O
zileuton    O
(    O
antileukotriene    O
)    O
.    O

Chlormadinone    B-SteroidHormone114745635
acetate    O
was    O
the    O
first    O
oral    O
contraceptive    O
produced    O
by    O
Jenapharm    O
.    O

anabolic    O
to    O
androgenic    O
ratio    O
in    O
pharmacology    O
applications    O
such    O
as    O
methasterone    B-SteroidHormone114745635

Methasterone    B-SteroidHormone114745635
(methyldrostanolone)    I-SteroidHormone114745635

Fluprednisolone    B-SteroidHormone114745635
=    O
6α-fluoro-11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione    O

gestrinone    B-SteroidHormone114745635
(    O
INN    O
)    O

Norsteroid    O
examples    O
include    O
:    O
19-norpregnane    O
(    O
from    O
pregnane    B-SteroidHormone114745635
)    O
,    O
desogestrel    B-SteroidHormone114745635
,    O
ethylestrenol    B-SteroidHormone114745635
,    O
etynodiol    B-SteroidHormone114745635
diacetate    I-SteroidHormone114745635
,    O
ethinylestradiol    O
,    O
gestrinone    B-SteroidHormone114745635
,    O
levonorgestrel    B-SteroidHormone114745635
,    O
norethisterone    B-SteroidHormone114745635
(    O
norethindrone    O
)    O
,    O
norgestrel    O
,    O
norpregnatriene    O
(    O
from    O
pregnatriene    B-SteroidHormone114745635
)    O
,    O
quinestrol    B-SteroidHormone114745635
,    O
19-norprogesterone    B-SteroidHormone114745635
(    O
from    O
a    O
progesterone    O
)    O
,    O
Nomegestrol    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
,    O
19-nortestosterone    O
(    O
from    O
a    O
testosterone    O
)    O
,    O
and    O
norethisterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
.    O

This    O
can    O
also    O
be    O
accomplished    O
with    O
progestational    O
agents    O
(    O
i.e.    O
,    O
medroxyprogesterone    B-SteroidHormone114745635
acetate    I-SteroidHormone114745635
)    O
,    O
danazol    B-SteroidHormone114745635
,    O
gestrinone    B-SteroidHormone114745635
,    O
or    O
gonadotropin    O
-    O
releasing    O
hormone    O
agonists    O
(    O
GnRH    B-SteroidHormone114745635
)    O
,    O
as    O
well    O
as    O
other    O
less    O
well    O
-    O
known    O
agents    O
.    O

Mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
type    O
I    O
)    O
–    O
mineralocorticoids    O
like    O
aldosterone    O

Deactivation    O
of    O
enzymatic    O
activity    O
reduces    O
aldosterone    O
concentrations    O
in    O
plasma    O
and    O
tissues    O
which    O
decreases    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
-    O
dependent    O
and    O
independent    O
effects    O
in    O
cardiac    O
vascular    O
and    O
renal    O
target    O
organs    O
.    O

Mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
MR    O
)    O
antagonist    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
prorenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

In    O
addition    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
mexrenone    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
,    O
and    O
progesterone    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
antagonist    O
(    O
Ki    O
=    O
39    O
nM    O
)    O

This    O
is    O
a    O
critical    O
residue    O
that    O
is    O
completely    O
conserved    O
among    O
species    O
and    O
in    O
the    O
androgen    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
AR    O
)    O
and    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
(    O
MR    O
)    O
.    O

It    O
also    O
binds    O
to    O
the    O
glucocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
,    O
but    O
is    O
only    O
a    O
weak    O
antiglucocorticoid    O
relative    O
to    O
mifepristone    O
,    O
and    O
has    O
no    O
relevant    O
affinity    O
to    O
the    O
estrogen    B-SteroidHormone114745635
,    O
androgen    B-SteroidHormone114745635
and    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
.    O

Mineralocorticoids    O
bind    O
to    O
the    O
mineralocorticoid    B-SteroidHormone114745635
receptor    I-SteroidHormone114745635
in    O
the    O
cell    O
cytosol    O
,    O
and    O
are    O
able    O
to    O
freely    O
cross    O
the    O
lipid    O
bilayer    O
of    O
the    O
cell    O
.    O

Steroid    B-SteroidHormone114745635
atrophy,    I-SteroidHormone114745635
or    O
corticosteroid-induced    B-SteroidHormone114745635
dermal    I-SteroidHormone114745635
atrophy    I-SteroidHormone114745635
,    O
is    O
a    O
side    O
effect    O
of    O
prolonged    O
application    O
of    O
topical    B-SteroidHormone114745635
corticosteroids    I-SteroidHormone114745635
.    O

A    O
mild    O
topical    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
that    O
works    O
on    O
the    O
face    O
may    O
achieve    O
little    O
on    O
the    O
palm    O
.    O

Topical    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635

Misdiagnosis    O
and    O
treatment    O
of    O
ringworm    O
with    O
a    O
topical    B-SteroidHormone114745635
steroid    I-SteroidHormone114745635
,    O
a    O
standard    O
treatment    O
of    O
the    O
superficially    O
similar    O
pityriasis    O
rosea    O
,    O
can    O
result    O
in    O
tinea    O
incognito    O
,    O
a    O
condition    O
where    O
ringworm    O
fungus    O
grows    O
without    O
typical    O
features    O
,    O
such    O
as    O
a    O
distinctive    O
raised    O
border    O
.    O

Notable    O
examples    O
include    O
the    O
non-17α-alkylated    O
trenbolone    B-SteroidHormone114745635
and    O
the    O
17α-alkylated    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
and    O
metribolone    B-SteroidHormone114745635
(    O
R-1881    O
)    O
,    O
as    O
well    O
as    O
the    O
17α-alkylated    O
designer    O
steroids    O
norboletone    B-SteroidHormone114745635
and    O
tetrahydrogestrinone    B-SteroidHormone114745635
(    O
THG    O
)    O
.    O

Tetrahydrogestrinone    B-SteroidHormone114745635
(    O
THG    O
;    O
17α-ethyl-18-methyl-δ9,11    O
-    O
19-NT    O
)    O

The    O
IAAF    O
officially    O
annuls    O
all    O
of    O
Marion    O
Jones    O
'    O
competition    O
results    O
since    O
September    O
2000    O
,    O
including    O
her    O
medals    O
at    O
the    O
2001    O
World    O
Championships    O
,    O
in    O
the    O
wake    O
of    O
her    O
confession    O
to    O
having    O
used    O
steroids    B-SteroidHormone114745635
in    O
2000    O
and    O
2001    O
.    O

Tetrahydrogestrinone    B-SteroidHormone114745635
(THG)    I-SteroidHormone114745635

Derivatives    O
of    O
ethyltestosterone    O
include    O
norethandrolone    O
(    O
ethylnandrolone    O
,    O
ethylestrenolone    O
)    O
,    O
ethylestrenol    B-SteroidHormone114745635
(    O
ethylnandrol    O
)    O
,    O
norboletone    B-SteroidHormone114745635
,    O
ethyldienolone    O
,    O
tetrahydrogestrinone    B-SteroidHormone114745635
,    O
bolenol    B-SteroidHormone114745635
(    O
ethylnorandrostenol    O
)    O
,    O
and    O
propetandrol    B-SteroidHormone114745635
.    O

In    O
2003    O
,    O
it    O
was    O
reported    O
that    O
U.S.    O
authorities    O
found    O
e    O
-    O
mails    O
by    O
Victor    O
Conte    O
addressed    O
to    O
Tzekos    O
while    O
searching    O
BALCO    O
(    O
Bay    O
Area    O
Laboratory    O
Co    O
-    O
operative    O
)    O
,    O
the    O
California    O
company    O
secretly    O
dealing    O
Tetrahydrogestrinone    B-SteroidHormone114745635
,    O
an    O
anabolic    O
steroid    O
specially    O
designed    O
so    O
as    O
to    O
make    O
it    O
undetectable    O
under    O
normal    O
drug    O
testing    O
.    O

In    O
addition    O
,    O
according    O
to    O
the    O
respected    O
French    O
paper    O
"    O
L'Equipe    O
,    O
"    O
Tzekos    O
was    O
directly    O
dealing    O
with    O
the    O
creator    O
of    O
norbolethone    B-SteroidHormone114745635
and    O
THG    O
(    O
tetrahydrogestrinone    B-SteroidHormone114745635
)    O
Patrick    O
Arnold    O
,    O
the    O
father    O
of    O
pro    O
-    O
hormone    O
craze    O
and    O
some    O
undetectable    O
designer    O
steroids    O
.    O

Ciclesonide    B-SteroidHormone114745635
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
aceponate    I-SteroidHormone114745635
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
buteprate    I-SteroidHormone114745635
,    O
hydrocortisone    B-SteroidHormone114745635
butyrate    I-SteroidHormone114745635
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-SteroidHormone114745635
,    O
and    O
tixocortol    B-SteroidHormone114745635
pivalate    I-SteroidHormone114745635
.    O

Ciclesonide    B-SteroidHormone114745635
,    O
cortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
aceponate    I-SteroidHormone114745635
,    O
hydrocortisone    O
acetate    O
,    O
hydrocortisone    B-SteroidHormone114745635
buteprate    I-SteroidHormone114745635
,    O
hydrocortisone    B-SteroidHormone114745635
butyrate    I-SteroidHormone114745635
,    O
hydrocortisone    O
valerate    O
,    O
prednicarbate    B-SteroidHormone114745635
,    O
and    O
tixocortol    B-SteroidHormone114745635
pivalate    I-SteroidHormone114745635
.    O

Corticosteroids    O
:    O
Inhaled    O
corticosteroids    O
(    O
i.e.    O
fluticasone    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
)    O
are    O
typically    O
used    O
when    O
bronchoconstrictive    O
disease    O
has    O
advanced    O
to    O
a    O
persistent    O
inflammatory    O
state    O
,    O
more    O
specifically    O
in    O
persistent    O
or    O
severe    O
asthma    O
and    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
.    O

Fluticasone    B-SteroidHormone114745635

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-SteroidHormone114745635
,    O
fluticasone    B-SteroidHormone114745635
,    O
mometasone    O
and    O
ciclesonide    B-SteroidHormone114745635
.    O

Equol    B-SteroidHormone114745635

Cortivazol    B-SteroidHormone114745635
=    O
6,16α-dimethyl-11β,17α,21-trihydroxy-2'-phenyl[3,2-c]pyrazolopregna-4,6-dien-20-one    O
21-acetate    O

Bolandiol    B-SteroidHormone114745635

Bolandiol    B-SteroidHormone114745635
(    O
19-nor-4-androstenediol    O
)    O

Bolandiol    B-SteroidHormone114745635

Flumetasone    B-SteroidHormone114745635
=    O
6α,9α-difluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione    O

Locorten    B-SteroidHormone114745635

Budesonide    B-SteroidHormone114745635
,    O
by    O
its    O
trade    O
name    O
"    O
Giona    O
"    O

Amcinonide    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
,    O
desonide    B-SteroidHormone114745635
,    O
fluocinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
,    O
fluocinonide    B-SteroidHormone114745635
,    O
halcinonide    B-SteroidHormone114745635
,    O
and    O
triamcinolone    B-SteroidHormone114745635
acetonide    I-SteroidHormone114745635
.    O

Budesonide    B-SteroidHormone114745635

Corticosteroids    O
:    O
Inhaled    O
corticosteroids    O
(    O
i.e.    O
fluticasone    B-SteroidHormone114745635
,    O
budesonide    B-SteroidHormone114745635
)    O
are    O
typically    O
used    O
when    O
bronchoconstrictive    O
disease    O
has    O
advanced    O
to    O
a    O
persistent    O
inflammatory    O
state    O
,    O
more    O
specifically    O
in    O
persistent    O
or    O
severe    O
asthma    O
and    O
chronic    O
obstructive    O
pulmonary    O
disease    O
(    O
COPD    O
)    O
.    O

Budesonide    B-SteroidHormone114745635

In    O
this    O
case    O
,    O
the    O
main    O
compounds    O
used    O
are    O
beclometasone    O
,    O
budesonide    B-SteroidHormone114745635
,    O
fluticasone    B-SteroidHormone114745635
,    O
mometasone    O
and    O
ciclesonide    B-SteroidHormone114745635
.    O

Aromatase    B-SteroidHormone114745635
excess    I-SteroidHormone114745635
syndrome    I-SteroidHormone114745635
,    O
an    O
extremely    O
rare    O
condition    O
characterized    O
by    O
marked    O
hyperestrogenism    B-SteroidHormone114745635
,    O
is    O
associated    O
with    O
precocious    O
breast    O
development    O
and    O
macromastia    O
in    O
females    O
and    O
similarly    O
precocious    O
gynecomastia    O
(    O
women    O
's    O
breasts    O
)    O
in    O
males    O
.    O

The    O
functional    O
opposite    O
of    O
EIS    O
is    O
hyperestrogenism    B-SteroidHormone114745635
,    O
for    O
instance    O
that    O
seen    O
in    O
aromatase    B-SteroidHormone114745635
excess    I-SteroidHormone114745635
syndrome    I-SteroidHormone114745635
.    O

Aromatase    B-SteroidHormone114745635
excess    I-SteroidHormone114745635
syndrome    I-SteroidHormone114745635

Some    O
other    O
examples    O
of    O
putative    O
EDCs    O
are    O
polychlorinated    O
dibenzo    O
-    O
dioxins    O
(    O
PCDDs    O
)    O
and    O
-furans    O
(    O
PCDFs    O
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
PAHs    O
)    O
,    O
phenol    O
derivatives    O
and    O
a    O
number    O
of    O
pesticides    O
(    O
most    O
prominent    O
being    O
organochlorine    O
insecticides    O
like    O
endosulfan    O
,    O
kepone    O
(    O
chlordecone    O
)    O
and    O
DDT    O
and    O
its    O
derivatives    O
,    O
the    O
herbicide    O
atrazine    O
,    O
and    O
the    O
fungicide    O
vinclozolin    O
)    O
,    O
the    O
contraceptive    O
17-alpha    O
ethinylestradiol    O
,    O
as    O
well    O
as    O
naturally    O
occurring    O
phytoestrogens    B-SteroidHormone114745635
such    O
as    O
genistein    B-SteroidHormone114745635
and    O
mycoestrogens    B-SteroidHormone114745635
such    O
as    O
zearalenone    O
.    O

Kudzu    O
contains    O
isoflavones    O
,    O
including    O
puerarin    O
(    O
about    O
60%    O
of    O
the    O
total    O
isoflavones    O
)    O
,    O
daidzein    O
,    O
daidzin    O
(    O
structurally    O
related    O
to    O
genistein    B-SteroidHormone114745635
)    O
,    O
mirificin    O
,    O
and    O
salvianolic    O
acid    O
,    O
among    O
numerous    O
others    O
identified    O
.    O

Phytoestrogen    B-SteroidHormone114745635
,    O
plant    O
compounds    O
with    O
estrogen    O
-    O
like    O
biological    O
activity    O
,    O
such    O
as    O
genistein    B-SteroidHormone114745635
,    O
formononetin    B-SteroidHormone114745635
,    O
biochanin    O
A    O
and    O
daidzein    O
,    O
as    O
well    O
as    O
a    O
mixture    O
of    O
these    O
phytoestrogens    O
were    O
found    O
able    O
to    O
reduce    O
E    O
-    O
selectin    O
as    O
well    O
as    O
VCAM-1    O
and    O
ICAM-1    O
on    O
cell    O
surface    O
and    O
in    O
culture    O
supernatant    O
.    O

The    O
dried    O
flower    O
buds    O
may    O
contain    O
as    O
much    O
as    O
20%    O
rutin    O
with    O
some    O
quercetin    O
.    O
"    O
S.    O
japonicum    O
"    O
dried    O
fruit    O
contain    O
the    O
flavonoid    O
glycosides    O
sophoricoside    O
,    O
genistin    O
and    O
rutin    O
and    O
the    O
flavonoid    O
aglycones    O
genistein    B-SteroidHormone114745635
,    O
quercetin    O
and    O
kaempferol    O
.    O

Although    O
there    O
is    O
only    O
preclinical    O
evidence    O
for    O
a    O
possible    O
mechanism    O
,    O
the    O
meta    O
-    O
analysis    O
report    O
stated    O
that    O
soy    O
phytoestrogens    B-SteroidHormone114745635
–    O
the    O
isoflavones    O
,    O
genistein    B-SteroidHormone114745635
and    O
daidzein    O
–    O
may    O
be    O
involved    O
in    O
reducing    O
serum    O
cholesterol    O
levels    O
.    O

Genistein    B-SteroidHormone114745635

Chemically    O
,    O
amygdalin    O
and    O
prunasin    O
,    O
the    O
derivatives    O
of    O
which    O
produce    O
prussic    O
acid    O
as    O
well    O
as    O
Genistein    B-SteroidHormone114745635
can    O
be    O
extracted    O
from    O
"    O
P.    O
maximowiczii    O
"    O
.    O

Antimicrobial    O
chemicals    O
,    O
including    O
reactive    O
oxygen    O
species    O
such    O
as    O
hydrogen    O
peroxide    O
or    O
peroxynitrite    O
,    O
or    O
more    O
complex    O
phytoalexins    O
such    O
as    O
genistein    B-SteroidHormone114745635
or    O
camalexin    O

Epitiostanol    B-SteroidHormone114745635

Bolasterone    B-SteroidHormone114745635

Bolasterone    B-SteroidHormone114745635

Bolazine    B-SteroidHormone114745635

5-Androstenedione    B-SteroidHormone114745635
is    O
a    O
prohormone    O
of    O
testosterone    O
.    O


